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Abstract  
 
POTENTIAL MODIFICATIONS TO ENZYME REPLACEMENT THERAPY IN 
ANDERSON-FABRY DISEASE 
By 
Mariam F. Meghdari 
 
Advisor: David H. Calhoun, Ph.D. 
Mutations in the GLA gene that encodes the lysosomal enzyme α-galactosidase A (αGal) result 
in the sphingolipidoses named Fabry disease. This enzymatic defect is inherited as an X-linked 
recessive disorder and is associated with a progressive deposition of glycosphingolipids, 
including globotriaosylceramide (GB3), galabioasylceramide, and blood group B substance in 
the cell. In affected males, and in some females, this leads to early death due to occlusive disease 
of the heart, kidney, and brain. This disease is currently treated by infusions of αGal, prolonging 
patients’ lives but producing antibodies against the enzyme reducing the treatment efficacy. 
Treatment also causes numerous and sometimes life threatening infusion related adverse 
reactions, including anaphylactic shock, and even death in rare occasions. Here we propose two 
potential improvements to the current therapeutic practices which would allow for more effective 
enzyme therapies. The first is constructing and analyzing potentially more active carboxyl-
terminal deletions of αGal and the second focuses on targeting of αGal to the very high uptake 
scavenger receptor (SR) for improved transport to the lysosome. 
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Chapter 1 : Introduction 
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Lysosomal storage diseases 
Lysosomal storage diseases (LSDs) are a group of approximately 60 inherited metabolic 
disorders caused by the absence or dysfunction of lysosomal enzymes (Figure 1-1).  
LSD’s lead to a number of clinical manifestations due to the accumulation of intermediate 
substrates of these enzymes in the lysosome. LSDs are individually classified as rare/orphan 
diseases, combined they make up anywhere between 1 in 4000 to 1 in 13,000 live births 
according to various published studies [31] with these numbers potentially being higher 
according to recent with recent newborn screening studies [32, 33].  
 
 
Fabry disease 
Fabry disease is a disorder of glycosphingolipid metabolism due to deficient or absent lysosomal 
of α-galactosidase A (αGal) activity (Figure 1-1) [34]. Numerous gene mutations of the protein 
have been described. Patients with mutations leading to the total absence of αGal suffer the 
classic form of Fabry disease, while those having missense mutations causing residual activity 
(2% to 25%) suffer from the milder forms of the metabolic disorder [35]. In contrast to many 
other LSDs, most patients remain clinically asymptomatic during the very first years of life. The 
first symptoms include chronic pain, skin lesions, myocardial infarction, gastrointestinal 
disorder, and vascular deterioration. Later in life, the complications associated with this disease 
are often life threatening [36, 37]. 
Fabry disease is the second most common LSD after Gaucher disease, initially thought to have a 
worldwide prevalence of approximately 1 in 40,000 to 1 in 117,000 live births for the classic 
form of the disease [38]. However, current newborn screening initiatives have found an 
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unexpectedly high prevalence of the disease, as high as 1 in approximately 3,100 newborns in 
Italy [39] and have identified a surprisingly high frequency of newborn males with Fabry 
disease, approximately 1 in 1,500 in Taiwan [38]. These findings suggest that Fabry disease may 
currently be under recognized, making the need for advancement in treatment more urgent. 
 
 
Figure 1-1: Pathways for the breakdown of GM1(monosialotetrahexosylganglioside) the 
"prototype" ganglioside, globoside and sphingomyeline to ceramide [40].  
Pathway leading to Fabry disease highlighted in red. 
 
 
 
Fabry Disease 
αGal deficiency 
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α-Galactosidase A (αGal) 
The enzyme has a large amino-terminal catalytic domain, a small carboxyl-terminal domain, and 
is present as a head-to-tail homodimer that hydrolyses the terminal alpha-galactosyl moieties 
from glycolipids and glycoproteins [14]. The N-terminal domain is a classic (β/α)8 barrel, and the 
C-terminal domain contains eight antiparallel β strands packed into a β sandwich (Figure 1-2) 
[14]. The authors of this structure conclude that the carboxyl-terminal amino acids are most 
likely not in contact with the catalytic site being “at least 45 Å from each active site and on the 
 
 
Figure 1-2: Crystal structure of human αGal. 
The α-galactosidase A polypeptide trace is shown with a rainbow from blue at the 
N-terminus to red at the C-terminus. N-linked carbohydrates are shown as bonds, 
and the galactose ligand is shown as spheres, marking the active site in the first 
domain [14]. 
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opposite face of the molecule” and therefore most likely do not play a role in enzyme activity 
[10]. 
Each monomer contains three N-linked carbohydrate sites (Asn-139, Asn-192 and Asn-215) and 
five disulfide bonds. Elimination of any two glycosylation sites lead to an unstable enzyme and 
premature degradation, while Asn-215 was shown to be essential for protein solubility [41]. 
There are a large number of known mutations (over half of the residues) in the GLA gene which 
encode αGal causing Fabry disease. Most of these mutations lead to disruption of the 
hydrophobic core of the protein making Fabry disease primarily a disease of protein-folding [42]. 
Available therapies 
The FDA has approved treatment of Fabry disease through intravenous administration of 
recombinant αGal known as enzyme replacement therapy (ERT) [3]. Two different forms of 
ERT are available for the treatment of Fabry disease; both are administered by intravenous 
infusion every other week and have been compared [3]. The first is genetically engineered in a 
human cell line by gene activation (agalsidase alfa, Replagal®, Shire Human Genetic Therapies, 
Inc., Cambridge, MA), the second produced in a Chinese hamster ovary cell line by recombinant 
techniques (agalsidase beta, Fabrazyme ®, Genzyme Corporation, Cambridge, MA). The 
recombinant enzymes contain mannose-6-phosphate (M6P) residues that are recognized by the 
M6P receptor on the cell surface and incorporated into the cell [43]. However, the importance of 
the M6P uptake system as the sole mechanism of uptake for αGal has recently been questioned 
[15]. Uptake of αGal is mainly mediated by the high molecular weight endocytic receptor 
megalin in proximal tubule cells [44] . The sortilin receptor has also been identified as an αGal 
binding protein important in human glomerular endothelial cells [15]. The endocytic receptors 
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M6P, sortilin, and megalin have been identified to play a role in αGal cellular internalization in 
podocytes [45]. 
The clinical efficacy of ERT for Fabry disease has been shown through several clinical trials [3, 
46-49]. Therapy was initially undertaken for males with the classic form of the disease (no 
detectable αGal activity) [36, 50, 51],  but is now also underway for symptomatic heterozygous 
females [43, 52]. Treatment is also under consideration for adults and children with atypical (low 
levels of enzyme) Fabry disease. More than 80% of Fabry patients treated with agalsidase-beta 
and 56 % treated with agalsidase-alfa developed an immune response [50, 51]. The antibodies 
are primarily of the IgG class, in addition, a fraction of the antibodies appear to exhibit 
neutralizing properties, which has been associated with an increase in urinary 
globotriaosylceramide (GB3) levels due to the uptake of immune-enzyme complexes by 
granulocytes in the bloodstream and macrophages in the tissues [53-55].  
Fabry disease patients with adverse reactions to the infusions are currently treated with 
antihistamines and antipyretics and the initial immune response is typically manageable [56]. It 
can be anticipated however, that life-long treatment required for these patients will lead to 
unacceptable levels of neutralizing antibodies. The drug cost of ERT is very high, running 
between $75,000 and $350,000 per patient-year, depending on the body weight of the patient as 
opposed to a generally accepted threshold for a new drug of $50,000–$150,000 [57]. The 
limitations of current approaches for ERT for Fabry disease and the need for improved 
techniques have been discussed [58, 59]. In addition, the effects of gene therapy [60-67] and 
pharmacological chaperones [68] are under investigation for the treatment of Fabry disease. 
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The recombinant enzymes prescribed for ERT are produced in mammalian cells (human or CHO 
cells). Producing adequate amounts of protein for ERT from mammalian cells is expensive. 
Mammalian cell culture is highly susceptible to viral infections, compromising the constant 
supply needed by patients. In 2009, a contamination in one of Genzyme’s plants forced a halt to 
the manufacturing of Fabrazyme, used to treat for Fabry patients, and Imiglucerase 
(Cerezyme®), for Gaucher patients. This caused a shortage in the United States and lasted until 
2012, when the production was moved to a new plant [69]. These cells are used in part because 
the glycan structure is similar to that of native enzyme, allowing for the necessary M6P exposure 
and decreasing potential antigen production [43].   
Alternative expression systems have been used for the production of αGal. Tobacco cell cultures 
[70] and the moss (Physcomitrella patens) [1] have both been successfully used to produce 
active forms of human αGal. Both of these systems have been engineered to perform human-like 
glycosylation. Recombinant αGal has also been produced in a modified yeast strains where 
Saccharomyces cerevisiae  was manipulated to synthesize glycoprotein that lacks the outer chain 
of N-glycan, a structure that is specific to yeast but not humans [71]. αGal purified by that group 
was introduced into Fabry patient fibroblasts and a Fabry mouse model and successfully 
hydrolyzed accumulating substrates [71].  This study supports the use of yeast as a host for 
recombinant αGal production for ERT. These alternative systems could help lower the cost of 
treatments, increase manufacturing safety, and improve availability of ERT therapeutic options 
for patients decreasing the probability of shortages in the future. 
In this work, we use the methylotrophic yeast Pichia pastoris.  P. pastoris is the most highly 
developed of a small group of alternative yeast species chosen for their advantages over S. 
cerevisiae as expression hosts.  This is due in part to the existence of well-established 
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fermentation methods and the presence of a tightly regulated methanol-inducible promoter 
PAOX1.  Alcohol oxidase (AOX) expression is undetectable in cells cultured on carbon sources 
such as glycerol, but constitutes up to 30% of total soluble protein in methanol-grown cells.  
Therefore, genes under the control of the PAOX1 promoter can be maintained in an expression-off 
mode on a non-methanolic carbon source to minimize selection for non-expressing mutant 
strains during cell growth, and then efficiently switched on by shifting to methanol. We propose 
two new and innovative approaches allowing for more effective enzyme therapies and potentially 
circumventing adverse reactions.  
Scope of work 
Aim 1: Carboxyl-Terminal Deletions of αGal. Based on a previous report [2] indicating a 
possible correlation between C-terminal deletions of human αGal and enzyme activity; the first 
major goal of this research was to explore the effects of C-terminal deletions of the human αGal 
on enzyme activity. According to work done by Miyamura’s group, carboxyl-terminal deletions 
of the human αGal protein led to an increase of activity using a transient expression system [2]. 
This data was semi-quantitative and relied on comparison of the amounts of RNA present in 
northern blots of mRNA for αGal compared to β-actin (Figure 1-3). We constructed a set of even 
(2, 4, 6, 8, 10 amino acids) carboxyl-terminal deletion mutants, and characterized the Km, and 
Vmax of these mutants. 
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Aim 2: Targeting of αGal to mannose and scavenger receptors of endothelial cells. The 
scavenger receptors (SRs) bind acetylated or oxidized low-density lipoprotein and 
macromolecules with negative charge, leading to subsequent degradation in the lysosome [72].  
We hypothesized that αGal transported by way of functionalized liposomes or coupled to 
scavenger ligands would be delivered to lysosomes to degrade accumulated substrates in Fabry 
disease patients. We also hypothesized that mannose terminated αGal expressed in yeast would 
target the mannose receptors (MR) present on endothelial cells improving uptake in these cells. 
 
 
 
Figure 1-3: Relative enzyme activity of C-terminal deletions of human αGal [2]. 
A) Mutant cDNAs with premature stop codons yielding deletions were obtained by site-
directed mutagenesis. Amino acid sequence of the C-terminal residues are shown in the 
right. αGal activities obtained from cell lysates in transfections with these plasmids are 
shown in the left. αGal activity was adjusted by subtraction of activity seen after mock-
transfection, and normalization by the ratio of the αGal mRNA to the β-actin mRNA in the 
Northern blot. Values are shown as % control (WT=100), representing mean for n=2-3. B) 
Northern blot, representative autoradiogram is shown. 
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These strategies have the potential to significantly reduce the number of infusions needed for the 
desired therapeutic effect. Currently there are more than 50 LSDs [50, 73] including Fabry 
disease that could potentially be treated through ERTs, making the possible contribution of this 
work to the field vast. 
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Abstract  
Fabry disease is an X-linked inborn error of glycolipid metabolism caused by deficiency of the 
human lysosomal enzyme, αGal, leading to strokes, myocardial infarctions, and terminal renal 
failure, often leading to death in the fourth or fifth decade of life. The enzyme is responsible for 
the hydrolysis of terminal α-galactoside linkages in various glycolipids. ERT has been approved 
for the treatment of Fabry disease, but adverse reactions, including immune reactions, make it 
desirable to generate improved methods for ERT. One approach to circumvent these adverse 
reactions is the development of derivatives of the enzyme with more activity per mg. It was 
previously reported that carboxyl-terminal deletions of 2 to 10 amino acids led to increased 
activity of about 2 to 6-fold. However, this data was qualitative or semi-quantitative and relied 
on comparison of the amounts of mRNA present in Northern blots with αGal enzyme activity 
using a transient expression system in COS-1 cells. Here we follow up on this report by 
constructing and purifying mutant enzymes with deletions of 2, 4, 6, 8, and 10 C-terminal amino 
acids (Δ2, Δ4, Δ6, Δ8, Δ10) for unambiguous quantitative enzyme assays. The results reported 
here show that the kcat/Km approximately doubles with deletions of 2, 4, 6 and 10 amino acids 
(0.8 to 1.7-fold effect) while a deletion of 8 amino acids decreases the kcat/Km (7.2-fold effect). 
These results indicate that the mutated enzymes with increased activity constructed here would 
be expected to have a greater therapeutic effect on a per mg basis, and could therefore reduce the 
likelihood of adverse infusion related reactions in Fabry patients receiving ERT treatment. These 
results also illustrate the principle that in vitro mutagenesis can be used to generate αGal 
derivatives with improved enzyme activity.  
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Introduction  
Mutations in the αGal gene result in the sphingolipidosis named Fabry disease [74]. The 
enzymatic defect is inherited as an X-linked disorder and is associated with a progressive 
deposition of the glycosphingolipids, including globotriaosylceramide, galabioasylceramide, and 
blood group B substance. In affected males, this leads to early death due to occlusive disease of 
the heart, kidney, and brain.  
De Duve [75] first suggested that ERT might be a successful approach to the treatment of 
lysosomal storage defects such as Gaucher’s and Fabry disease. For Gaucher’s disease, ERT 
produced unequivocal clinical responses [76, 77] that were subsequently confirmed by others 
[78-80]. Classical Fabry disease patients lack detectable levels of αGal [74] so it should not be 
surprising that more than 80% of Fabry patients treated with agalsidase-beta [50] and more than 
50% treated with agalsidase-alfa [51] developed an immune response. The antibodies produced 
are primarily of the IgG class and a fraction of the antibodies appear to exhibit neutralizing 
properties. These antibodies have been associated with an increase in urinary 
globotriaosylceramide levels due to the uptake of immune-enzyme complexes by granulocytes in 
the bloodstream and macrophages in the tissues [53-55]. 
ERT for Fabry disease patients was initially undertaken for males with the classic form of the 
disease (no detectable αGal activity) in a variety of clinical trials [34, 36, 37, 50, 51, 81], but 
therapy is now also underway for heterozygous females with Fabry disease [43, 46, 82] and is 
under consideration for children [48, 83, 84] and adults with atypical (low levels of enzyme) 
Fabry disease [85]. The two products used for ERT in Fabry disease patients have been 
compared [3]. The pattern of glycosylation on αGal has been analyzed [86] and its importance 
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for activity [41] and uptake by cells has been established [71, 87]. The limitations of current 
approaches for ERT for Fabry disease and the need for improved techniques have been discussed 
[55, 88, 89]. Efforts for gene therapy for Fabry disease are underway [60-65, 67, 90] and 
molecular chaperones are under investigation for specific alleles[91-93]. Substrate reduction 
therapy as an augmentation to ERT has been evaluated [94]. There are several reviews on the 
general topic of ERT for lysosomal storage diseases [95-99].  
Expression of the human αGal has been reported in Escherichia coli [12], baculovirus [8, 9] 
Chinese hamster ovary cells [100] and human foreskin fibroblasts [101].The highest levels of 
heterologous αGal expression was observed in P. pastoris [7]. Recombinant αGal has also been 
produced in a modified strain of S. cerevisiae that synthesized glycoprotein lacking the outer 
chain of N-glycan, a structure that is specific to yeast but not humans[71, 102]. When this αGal 
was introduced into Fabry patient fibroblasts or a Fabry mouse model, there was hydrolysis of 
accumulated substrates [71, 102]. 
The methylotrophic yeast P. pastoris is the most highly developed of a small group of alternative 
yeast species chosen for their advantages over S. cerevisiae as expression hosts [103, 104]. Two 
attributes critical in its selection are the existence of well-established fermentation methods and 
the presence of the tightly regulated methanol-inducible promoter. AOX expression is 
undetectable by enzyme assay or mRNA production in cells cultured on carbon sources such as 
glycerol, but constitutes up to 30% of total soluble protein in methanol-grown cells. 
Heterologous genes under the control of the PAOX1 promoter can be maintained in an expression-
off mode on a non-methanolic carbon source in order to minimize expression of potentially toxic 
heterologous proteins during cell growth. The P. pastoris expression system has now been 
successfully used to produce a number of heterologous proteins at commercially useful 
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concentrations [105].  
Lysosomal enzymes such as αGal are glycoproteins that are modified in the Golgi to contain N 
or O-linked carbohydrate structures [106]. The human αGal is glycosylated at Asp residues 139, 
193, and 215 [41] with branched carbohydrate structures that vary in composition and sequence 
depending upon the host species and tissue type [86]. For example, the enzyme purified from 
humans contains variable amounts (5–15%) of asparagine linked complex and high mannose 
oligosaccharide chains [74]. Consequently, multiple forms are present in SDS gels and in 
isoelectric focusing experiments that correspond to the plasma and various tissue forms. The 
recombinant human αGal preparations used therapeutically are produced in human and CHO 
cells and these have distinct glycosylation patterns and differ in levels of sialic acid and M6P [3]. 
The recombinant αGal produced in insect cells [8, 9] and in P. pastoris [7] contain variable 
levels of mostly complex and high mannose side chains, respectively. Glycoproteins produced in 
P. pastoris typically contain from 6 to 14 mannose units (Man6GlcNac2 to Man14GlcNac2) that 
sometimes produces a Gaussian-like distribution of oligomannosides that may center near 
Man12GlcNac2 to Man13GlcNac2 [107].  
These carbohydrate moieties serve a structural and functional role. For example, it has been 
demonstrated that glycosylation, particularly at Asn-215, is required for enzyme solubility [41]. 
Also, uptake of the enzyme by cells in vivo is affected by terminal M6P residues on the enzyme 
[87], and the 10–12 sialic acid residues on the plasma form of the enzyme accounts for the 
prolonged circulatory half-life of the enzyme compared to the tissue form with only one or two 
sialic acid residues [25]. The identification of these multiple forms as derivatives of the same 
protein in purified enzyme preparations can conveniently be monitored by treatment with 
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specific N-glycosidases or by Western blots.  
Fabry disease patients with adverse reactions to the infusions are currently treated with 
antihistamines and antipyretics and the initial immune response has been manageable to date [56, 
108], but it can be anticipated that life-long treatment required for these patients will lead to 
unacceptable levels of neutralizing antibodies. In this context, it is reasonable to devise 
approaches to circumvent these adverse reactions and the development of derivatives of the 
enzyme with more activity per mg is a logical approach. Miyamura and coworkers [2] reported 
that carboxyl-terminal deletions of 2 to 10 amino acids of αGal led to an increase in activity of 
about 4 to 6-fold as compared to wild type (WT). However, this data was qualitative or semi-
quantitative. αGal activity was measured in cell lysates during transient infection of COS-1 cells 
using the artificial substrate MUG with a mock-transfection being used as a blank background 
subtraction. These results were then normalized by using the ratio of αGal to actin mRNA 
present in Northern blots. Here we use a P. pastoris expression system for the construction and 
purification of mutant enzymes with C-terminal deletions. The quantitative results reported here 
with purified enzymes reveal that C-terminal deletions results in an increase (Δ2, Δ4, Δ6, and 
Δ10) or decrease (Δ8) in enzyme activity.  
Materials and Methods  
Cell strains and plasmids  
The P. pastoris host strain X-33 (No. K1740-01), E. coli strains TOP10 (No. C4040-50) and 
TOP10F′  (No. C665-11), plasmid pPICZαA (No. K1740-01), and TOPO
1 XL PCR cloning kit 
(No. K4700-10) were purchased from Invitrogen.  
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Bioreactor expression of recombinant αGal in P. pastoris  
High-cell-density fermentation was carried out as previously described [7] with a modified 
growth medium utilizing non-precipitating sodium hexametaphosphate as a phosphate source 
[109]and modified for a 7 L Applikon bioreactor. Fermentation medium of 3.5 L (0.93 g/l 
CaSO4, 18.2 g/l K2SO4, 14.9 g/l MgSO4.7 H2O, 9 g/l (NH4)2SO4, 40.0 g/l glycerol) was 
autoclaved at 121°C for 20 min in the vessel. After cooling to room temperature, filter sterilized 
sodium hexametaphosphate (25 g/l of fermentation basal salt medium dissolved in 500 ml of 
deionized water) and 0.435% PTM1 trace elements (CuSO4.5 H2O 6.0 g, NaI 0.08 g, MgSO4. 
H2O 3.0 g, Na2MoO4.2 H2O 0.2 g, H3BO3 0.02 g, CoCl2 0.5 g, ZnCl2 20.0 g, FeSO4.7 H2O 
65.0 g, biotin 0.2 g, 5.0 ml H2SO4 per liter) were added to complete the fermentation medium. 
The pH was adjusted to 6.0 using ammonium hydroxide (28%).  
Four frozen MGY cultures of 4 ml each were used to inoculate four 100 ml MGY cultures in 1-
liter baffled flasks and grown at 250 rpm and 30°C until the OD600 reached 2 to 6. The 
cultivation was divided into three phases, the glycerol batch, glycerol-fed batch, and methanol 
fed batch. The glycerol batch phase was initiated with 400 ml of inoculum shake-flask culture 
added to 4 L of the fermentation medium containing 4% glycerol and an initial value of 100% 
dissolved oxygen until a spike was observed indicating complete consumption of glycerol. Next, 
the glycerol-fed batch phase was initiated and a 50% w/v glycerol feed rate of 18.15 ml/h/ liter 
initial fermentation volume and maintained until a cell yield of 180 to 220 g/liter wet cells was 
achieved. At this point the glycerol feed was terminated manually and a methanol-fed batch 
phase was initiated by starting a 100% methanol feed containing 12 ml PTM1 trace salts per 
liter. Methanol was initially fed at 3.6 ml/h/liter of initial fermentation volume, then increased to 
7.3 ml/h/liter and finally increased to 10.9 ml/h/liter of initial fermentation volume for the 
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remainder of the fermentation. Dissolved oxygen spikes were used during the glycerol fed batch 
phase and methanol-fed batch phase and to monitor substrate levels. A dissolved oxygen level of 
40%, pH of 6, and temperature of 25 °C were maintained by an ADI 1030 regulator. Sampling 
was performed at the end of each phase and at least twice daily and analyzed for cell wet weight 
and increased αGal activity over time. Cultivation was terminated once a plateau in αGal activity 
was observed.  
Construction of strains  
Plasmid pMS118 [12] contains the αGal cDNA cloned as an EcoRI fragment to the EcoRI site of 
plasmid pUC9. PCR primers (Figure. 2-1, 2-2) were used with plasmid pMS118 DNA and the 
PCR system (Roche, No. 11732641001) according to the vendor’s instructions. This generated 
cDNAs with a 5¢ extension containing an XhoI site, Kex2 and Ste13 yeast signal cleavage sites, a 
3¢ end with an XbaI site, and a deletion of C-terminal amino acids to generate Δ2 to Δ10 mutants 
(Figure 2-1, 2-2). The PCR products were ligated to pCR-XL-TOPO to generate Δ2 to Δ10 
plasmids (Table 2-1). These plasmids were used for electroporation [7] into E. coli strain TOP10 
or TOP10F¢ (Table 2-1).  
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Figure 2-1: Introduction of a C-terminal deletion of 2 amino acids into αGal.  
The strategy shown here for the Δ2 mutant was used to generate all five deletion mutations (Figure 2-
2). Plasmid pMS118 [12] contains the αGal cDNA cloned as an EcoRI fragment to the EcoRI site of 
plasmid pUC9. Primers AAF and AARD2 (Figure 2-2) were used as PCR primers for plasmid pMS118 
DNA to generate cDNAs with a 5′ extension containing an XhoI site, Kex2 and Ste13 yeast signal 
cleavage sites, a 3′ end with an introduced XbaI site, and a deletion of C-terminal amino acids to 
generate the Δ2 mutant. Primer AAF anneals to the cDNA at the sequences encoding the N-terminal 
sequences of αGal and primer AARD2 anneals to the C-terminal sequences of αGal. Primer AARD2 
anneals 12 nucleotides from the 3′ end of the cDNA and introduces a stop codon (UAA) after the 
aspartate codon three amino acids from the C-terminal end of the coding sequences of αGal resulting in 
a deletion of the two C-terminal amino acids (Leu-Leu) of the human enzyme (right panel). Cloning to 
the XhoI and XbaI sites of plasmid pPICZαA generates a protein fusion with the yeast signal peptide 
coding sequences in the vector. This signal peptide is removed by the Kex2 and Ste13 yeast signal 
peptidases through cleavage immediately upstream of the leucine corresponding the first amino acid of 
the mature form of αGal (left panel). This strategy was generalized to create the other deletion mutants 
using the primers in (Figure 2-2). In the left panel, the N-terminal peptide LDNGLAR was identified in 
mass spectrometric analysis while EALDNGLAR was not (Figure 2-5). 
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DNA sequence analysis using the universal M13 primers (Table 2-2) confirmed the expected 
insert for these pCR-XL-TOPO derivatives. The modified cDNAs were excised from pCR-
XLTOPO plasmids using XhoI and XbaI endonucleases and ligated into expression plasmid 
pPICZαA treated with the same two restriction enzymes to generate expression plasmids (Table 
2-1) that were subsequently used for electroporation [7] into strain TOP10 or TOP10F′ (Table 2-
1). The nucleotide sequence of mutant cDNAs in pPICZαA derivatives was analyzed (Genewiz) 
using 5′ AOX, 3′  AOX and α-factor sequencing primers (Table 2-2). These pPICZαA 
derivatives were used for electroporation of P. pastoris strain X-33 to generate yeast expression 
strains (Table 2-1).  
 
Table 2-1: Starins and Plasmids 
Strain Species Plasmid Description 
CC878 E. coli pCC248 pCR-XL-TOPO derivative plasmid a modified cDNA using primers AAF and AARD4 to generate C-terminal deletion of 4 amino acids (Δ4) 
CC892 E. coli pCC262 pPICZαA derivative plasmid with Δ4 cDNA insert 
CC970 E. coli pCC278 pCR-XL-TOPO derivative plasmid a modified cDNA using primers AAF and AARD6 to generate C-terminal deletion of 6 amino acids (Δ6) 
CC973 E. coli pCC281 pCR-XL-TOPO derivative plasmid a modified cDNA using primers AAF and AARD10 to generate C-terminal deletion of 10 amino acids (Δ10) 
CC983 E. coli pCC291 pPICZαA derivative plasmid with Δ6 cDNA insert 
CC990 E. coli pCC298 pPICZαA derivative plasmid with Δ10 cDNA insert 
CC993 E. coli pCC301 pCR-XL-TOPO derivative plasmid a modified cDNA using primers AAF and AARD2 to generate C-terminal deletion of 2 amino acids (Δ2) 
CC994 E. coli pCC302 pCR-XL-TOPO derivative plasmid a modified cDNA using primers AAF and AARD8 to generate C-terminal deletion of 8 amino acids (Δ8) 
CC995 E. coli pCC303 pPICZαA derivative plasmid with Δ2 cDNA insert 
CC997 E. coli pCC305 pPICZαA derivative plasmid with Δ8 cDNA insert 
PC626 P. pastoris pCC106 Integrated pPICZαA derivative with WT cDNA insert [7] 
PC897 P. pastoris pCC262 Integrated pPICZαA derivative with Δ4 cDNA insert 
PC958 P. pastoris pCC291 Integrated pPICZαA derivative with Δ6 cDNA insert 
PC960 P. pastoris pCC298 Integrated pPICZαA derivative with Δ10 cDNA insert 
PC971 P. pastoris pCC303 Integrated pPICZαA derivative with Δ2 cDNA insert 
PC973 P. pastoris pCC305 Integrated pPICZαA derivative with Δ8 cDNA insert 
TOP10 E. coli None E. coli host for modified Δ2, Δ6, Δ8, Δ10 cDNA plasmids 
TOP10F′ E. coli None E. coli host for pCC106 and modified Δ4 cDNA plasmid 
X-33 P. pastoris None Expression host for αGal expression 
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Purification of αGal using double affinity chromatography  
Purification was as described [7, 110] with minor modifications (below). Bioreactor supernatant 
was passed through a 0.2 µm hollow fiber filter (Spectrum Labs, No. M22M-300-01N) and 
subjected to diafiltration using a 50 kDa pore size hollow fiber filter (Spectrum Labs, No. M25S-
300-01N) against wash buffer (0.1 M sodium acetate buffer, pH 6.0, 0.1 M NaCl, 1 mM MgCl2, 
1 mM CaCl2, 1 mM MnCl2). The resulting supernatant was applied to a Con A Sepharose 4B 
(GE Healthcare No. 17-0440-01) column, pre-equilibrated with wash buffer, and washed with 5 
column volumes of wash buffer. It was observed that near-saturating sugar eluent concentrations 
do not improve glycoprotein recovery as compared to lower concentrations and that elution 
 Table 2-2: Primers Used for DNA Sequence Analysis. 
Primer Sequence Function 
5′ AOX 5′ GACTGGTTCCAATTGACAAGC 
3′ 
DNA sequencing primer for pPICZαA 
3′ AOX 5′ GCAAATGGCATTCTGACATCC 
3′ 
DNA sequencing primer for pPICZαA 
α-factor 5′ TACTATTGCCAGCATTGCTGC 3′ DNA sequencing primer for pPICZαA 
M13: 
forward 
5′ GTAAAACGACGGCCAG 3′ DNA sequencing primer for pCR-XL-
TOPO 
M13: reverse 5′ CAGGAAACAGCTATGAC 3′ DNA sequencing primer for pCR-XL-
TOPO 
 
Note. Primers were HPLC purified, 50 nmoles from Invitrogen 
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phase pauses improve recovery [111]. In accordance with these findings, elution of αGal was 
carried out using modified elution buffer I (0.5 M methyl-α-D-mannopyranoside, 0.25 M methyl-
α-D-glucopyranoside in wash buffer) over 1.5 column volume blocks separated by 12-hour 
interval soaks. Elution was discontinued when the absorbance at 280 nm and enzyme assays 
showed negligible presence of protein and αGal activity. No substantial difference in recovered 
enzyme was observed between purifications carried out with modified elution buffer I versus 
sugar saturated elution buffer I (data not shown). The Con A pool was subjected to diafiltration 
using a 50 kDa pore size hollow fiber filter (Spectrum Labs, No. M25S-30001N) against binding 
buffer (25 mM citrate-phosphate buffer, pH 4.8 containing 0.1 M NaCl).  
The Con A pool was applied to an immobilized-D-galactose gel column (Thio-Gal, Pierce No. 
20372) pre-equilibrated with binding buffer. The column was washed with 5 column volumes of 
binding buffer and αGal was eluted with elution buffer II (25 mM citrate-phosphate buffer, pH 
5.5, 0.1 M NaCl, 0.1 M D-galactose) over 1.5 column volume blocks separated by 12 hour soaks. 
Fractions were assayed for enzyme activity and protein concentration and a peak tube with high 
specific activity was chosen as the sample to be used in a substrate saturation curve.  
Electrophoresis analysis  
Samples (8 µg) were mixed with an equal volume of reducing sample buffer (Bio-Rad Laemmli 
sample buffer with 5% β-mercaptoethanol) and heated for 5 minutes at 95 °C before loading on a 
Mini-Protean TGX Precast Gel 4–20% (w/v) (Bio-Rad No. 456-1094). Bands were visualized by 
Coomassie blue staining via the modified Fairbanks protocol [112].  
Western blot analysis  
Western blot analysis was performed using an anti-αGal polyclonal antibody produced in 
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chicken (Pierce/ThermoSci #PA1-9528) and horseradish peroxidase-conjugated anti-Chicken 
IgY antibody (Sigma #A9046). After SDS-PAGE (2 µg of samples loaded), the gel was 
incubated with a nitrocellulose membrane (Whatman, No. 10402594) for 15 minutes at room 
temperature in Transfer Buffer (48 mM Tris, 39 mM glycine, 20% MeOH, pH 9.2) and the 
proteins were then transferred to the nitrocellulose membrane using a Bio-Rad Trans Blot SD 
Semi-Dry Transfer Cell. The membrane was blocked with 8% (w/v) non-fat dried milk in PBST 
[10 mM Na2HPO4, 1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl and 0.2% Tween 20 (pH 
7.4)] at room temperature for 20 minutes. The membrane was then treated with primary antibody 
diluted in a milk/blot solution [1% (w/v) non-fat dried PBST] for 2 h at room temperature with 
mild shaking. After rinsing with PBST solution, the membrane was treated for 1 h at room 
temperature with secondary antibody diluted in the milk/blot solution. Protein bands were 
visualized on Kodak BioMax XAR film (VWR #lB1651454) with a Konica SRX-101A 
processor.  
Enzyme and protein assays  
Activity of αGal was assayed using the synthetic substrate, 4-methylumbelliferyl-α-D-
galactopyranoside (MUG) as described [7] with modifications to a microtiter plate format 
(below). Enzyme activity is measured in units/ml where one unit is defined as the amount of 
enzyme required to convert 1 nmole of MUG to 4-methylumbelliferone in one hour at 37 °C. An 
aliquot of 3 µl was added to 27 µl of enzyme assay buffer (5 mM MUG in 40 mM sodium 
acetate buffer, pH 4.5). This mixture was incubated at 37 °C and 10 µl aliquots were taken at two 
time points and added to 290 µl of 0.1 M diethylamine in a microtiter plate to stop the reaction. 
Typically, time points were chosen as 1–4 minutes and values that were proportional to time 
were considered valid. The fluorescence of each sample was measured at an excitation 
M a r i a m 	 M e g h d a r i 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
25	
wavelength of 365 nm and an emission wavelength of 450 nm using a Tecan Infinite F200 
microtiter plate reader. A standard curve of 10 µl of 0 – 0.5 nmol 4-methylumbelliferone 
dissolved in MeOH in 290 µl of 0.1 M diethylamine was used to quantitate MUG cleavage at 
specific time intervals. Analysis of the effects of MeOH indicated no effect on the 4-
methylumbelliferone standard curve.  
For samples containing higher protein concentrations, the BioRad DC Protein Assay (No. 500-
0116) with a standard curve of (0.2 – 1.5) mg/ml was used according to the manufacturer’s 
specifications. For dilute samples of purified αGal, a more sensitive fluorescence-based 
fluorescamine assay [113] with a standard curve containing lower protein concentrations of (4.0–
160) µg/ml was used. Briefly, 150 µl of 0.05 M sodium phosphate buffer and 50 µl of 1.08 mM 
fluorescamine dissolved in acetone were added to an aliquot of 50 µl of the sample and 
standards, mixed and incubated for 12 minutes. The fluorescence of each sample was measured 
at an excitation wavelength of 400 nm and an emission wavelength of 460 nm. Bovine serum 
albumin (Bio-Rad No. 500-0112) was used as the standard in both assays. Absorbance and 
fluorescence measurements were conducted on a Tecan Infinite F200 microplate reader using 96-
well plates.  
Mass spectrometry of a purified mutant enzyme  
The Δ6 mutant was selected for mass spectrometry analysis conducted at the Rockefeller 
University Proteomics Resource Center in collaboration with M.T. Mark. SDS-PAGE gel slices 
were washed, de-stained, reduced using 10 mM dithiothreitol, alkylated using 100 mM 
iodoacetamide, and digested using trypsin. Peptides were then extracted from the gel two times, 
dried, and re-suspended in a 5% acetonitrile and 2% formic acid mixture. One third of each 
sample was loaded onto a C18 PepMap1000 micro-precolumn (300 µm I.D., 5 mm length, 5 µm 
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beads, Thermo Scientific) at a flow-rate of 5 µl/min, and subsequently onto an analytical C18 
column (75 µm I.D., 3 µm beads, Nikkyo Technos Co.) at a flow rate of 300 nl/min. The gradient 
was 40 min long in the range 5 to 45% B (buffer A was 0.1% formic acid in water, and buffer B 
was 0.1% formic acid in acetonitrile). Eluted peptides were applied by electrospray directly into 
the LTQ-Orbitrap XL mass spectrometer from Thermo Scientific, operating in a 300 to 1800 m/z 
mass range. Tandem mass spectrometry was performed by collision induced dissociation using 
nitrogen as a collision gas. The resulting spectra were analyzed using Mascot and Proteome 
Discoverer 1.3 (Thermo Scientific) to identify the peptides in the sample.  
Thermostability and pH optimum of WT and mutant αGal  
Purified enzyme samples were diluted in 25 mM citrate-phosphate buffer, pH 5.5, 0.1 M NaCl, 
0.01 M D-galactose. Samples of 50 µl were incubated in triplicate at 50 °C, 30 °C and 40 °C. 
Aliquots of 3 µl were removed for enzyme assays every 15 minutes for two hours. Samples were 
assayed in 0.02 M citrate buffer, pH 3.0-pH 6.5, containing 2 mM MUG.  
Characterization of kinetic properties  
Substrate saturation curves for αGal have been reported using MUG at concentrations up to 2 
mM, 5 mM, and 10 mM (in the presence of 0.1% BSA and 0.67% EtOH [3]). We noted that 
under our experimental conditions MUG is fully soluble at 2 mM, partially soluble at 5 mM, and 
chemically oversaturated at higher concentrations. Other investigators reported the use of 
sonication or detergent treatment to increase the solubility of MUG (e.g., [26]) but we avoided 
this approach in order to avoid potential artifacts due to the use of these techniques. Substrate 
saturation curves using 2 mM and 5 mM MUG as the highest concentrations were carried out 
and the kinetic parameters for αGal were calculated separately obtaining similar values. The 
values reported here (Table 2-3A) were obtained using a substrate saturation curve of 0.3 to 2 
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mM MUG since this is the highest concentration that is fully soluble under our experimental 
conditions. The Km and Vmax values were calculated using Lineweaver-Burk and non-linear 
regression through the program Sigma-Plot (Systat Software, San Jose, CA).  
Kinetic parameters were also determined using the colorimetric substrate, para-nitrophenyl-α-D-
galactopyranoside (PNPαGal) (Table 2-3B). [114] Purified enzymes were diluted to 
approximately 20,000 units/mL as determined by fluorescent MUG assay. These diluted samples 
were then added at a proportion of 1:9 citrate-phosphate buffer (0.1 M) containing 7 - 50 mM 
PNPαGal. Aliquots of 20 µl of the enzymatic reaction were removed at 15 minute intervals to 
terminate the reaction over the course of an hour and added to 320 µl of borate buffer (pH 9.8) in 
Table 2-3: Values of Km, Vmax, kcat and and the specificity constant (kcat/Km) for WT and C-Terminal 
Deletion Mutants of αGal. 
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a microplate. Product formation was monitored by absorbance at 400 nm. Linear reaction 
velocities were observed for all measurements. A standard curve of 0–150 µM p-nitrophenylate 
in borate buffer (pH 9.8) [115] was used to quantitate product formation. Km and Vmax 
parameters were determined through non-linear regression using Sigma-Plot (Systat Software, 
San Jose, CA).  
Protein structure analysis  
The crystal structure of αGal (PDB 1R47) was viewed and analyzed in PyMOL (Delano 
Scientific). The MSLDKLL and QMSLKDLL peptides corresponding to the last 7 or 8 C-
terminal amino acids of αGal were built in PyRosetta [116] and visualized in PyMOL [117]. 
Interatomic distances were measured using the PyMOL wizard distance command.  
A homology model of the coffee bean α-galactosidase was generated on the Phyre2 server [118]. 
The primary sequence of coffee bean α-galactosidase (GenBank No. AAA33022.1) was set as 
the query. The crystal structure of rice α-galactosidase (73% sequence identity to coffee α-
galactosidase, PDB# 1UAS) was set as the template. Superposition of the coffee homolog and 
human crystal structure of αGal (PDB# 1R47) was conducted in PyMOL [117]. Primary 
sequence alignments were carried out in ClustalOmega (EMBL-EBI).  
Results  
Purification of WT and mutant αGal  
The WT and mutant enzymes were obtained from a 7 L bioreactor and purified (Table 2-
4, Figure 2-3) using Con A and Thio-Gal tandem affinity chromatography. This two-column 
purification is simpler and faster than our previous purification methods that used three [9] or 
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four [7, 8] columns and the yield, degree of purity, and final specific activities were similar for 
all three methods.  
The non-glycosylated form of αGal (41.8 kDa) is isolated from cells as multiple glycosylated 
species with a predominant band of about 50 kDa and multiple higher molecular weight forms 
that differ in extent of glycosylation (Figure 2-3; See Introduction). We have previously 
demonstrated that high molecular weight glycoforms produced in insect cells and P. pastoris can 
be identified as derivatives of αGal rather than contaminants and these glycoforms are converted 
to a single band on SDS gels of about 41.8 kDa with endoglycosidase treatment [7-9], In this 
report we also use a Western blot (Figure 2-4) to confirm that the high molecular weight forms 
seen on SDS gels for the WT and deletion mutants are all glycoforms of αGal. In some cases, 
lower molecular weight species present in purified enzyme preparations can be identified as αGal 
fragments in Western blots (e.g., Figure 2-4, lane 2). We quantitated the distribution of 
glycoforms in (Figure 2-3, S1 Fig, online supplement) and there is no obvious correlation 
between the glycosylation pattern and catalytic activity. It is well established that glycosylation 
affects enzyme stability and enzyme uptake (above) but to our knowledge there is no evidence 
that the glycosylation pattern affects the catalytic properties of this enzyme.  
 
Table 2-4: Purification Table for WT αGal Expressed in P. pastoris. 
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Figure 2-3: SDS-PAGE for purification of αGal. 
Purified samples were run on a 4–20% polyacrylamide gel, under reducing conditions, and stained 
with Coomassie Brilliant Blue. The contents of the lanes are as follows: molecular weight marker 
(lane 1 and 8), WT(PC626) (lane 2), Δ2 (PC995) (lane 3), Δ4 (PC897) (lane 4), Δ6 (PC958) (lane 
5), Δ8 (PC973) (lane 6), Δ10 (PC960) (lane 7). The minor bands present in the purified fraction are 
consistent with high molecular weight glycoforms seen previously when WT enzyme was purified 
from the same P. pastoris expression system [7]. 
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Figure 2-4: Western Blot of purified WT and mutant αGal. 
Purified WT and mutant enzymes were subjected to Western blotting using a polyclonal 
antibody raised against residues 55–64 and 396–407 of αGal. (a) Blot at shorter and (b) 
longer exposure. 
 
 
M a r i a m 	 M e g h d a r i 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
32	
Mass spectrometry of a purified mutant enzyme  
Two possible amino terminal amino acids, glutamate or leucine, could be produced in P. pastoris 
depending upon the selection of the signal peptidase, Kex2 or Ste13 (Figure 2-1). Due to the fact 
that potential improper amino terminal processing may have an effect on kinetics, we selected 
one of the purified mutant enzymes (Δ6) for mass spectrometry analysis in order to identify the 
amino terminal sequence of this enzyme. This analysis also made it possible to provide 
independent verification of the expected changes in the C-terminal amino acid sequence 
predicted by in vitro mutagenesis (Figure 2-1, 2-2).  
The mature form of the enzyme (signal peptide removed; [119]) produced in humans begins with 
a leucine codon (Figure  2-1, 2-2). Therefore, tandem mass spectrometry following tryptic 
digestion of the Δ6 αGal purified from P. pastoris could produce tryptic peptides EALDNGLAR 
or LDNGLAR, depending upon the use of the Kex2 or Ste13 protease sites (Figure 2-1, 2-2). A 
putative LDNGLAR peak was identified in the MS spectra with an m/z of 379.71, consistent 
with the (M+2H)2+ state of this peptide, while no peaks consistent with an EALDNGLAR 
peptide were found. We cannot eliminate what we consider to be the less likely possibility that 
the failure to detect the EALDNGLAR peptide may be due to the failure of the peptide to ionize 
in this MS experiment. Further fragmentation of the m/z = 379.71 associated peptide peak 
produced an MS/MS spectrum containing 4 of 7 possible y-ions and 4 of 7 possible b-ions from 
the expected fragmentation pattern of a hypothetical LDNGLAR peptide (Figure 1-5a). This 
result indicates that the Ste13 signal peptidase of P. pastoris generates an enzyme with an amino 
terminus identical to the enzyme produced in humans.  
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A search for a Δ6 C-terminal tryptic peptide of SHINPTGTVLLQLENTMQM (Figure 1-2) 
yielded a matching MS m/z = 1064.03 peak consistent with its (M+2H)2+ state. Further 
fragmentation also produced an MS/MS spectrum containing 4 of 19 possible y-ions and 9 of 19 
possible b-ions consistent with the anticipated sequence (Figure 1-5b). This result confirms the 
predicted C-terminal deletion of 6 amino acids and confirms the efficacy of the mutagenesis 
protocol used to produce this mutant enzyme.  
Thus, the purified Δ6 αGal mutant possesses an N-terminal sequence corresponding to the 
mature form of αGal and a C-terminal sequence truncated by six amino acids.  
 
 
Figure 2-5: Mass spectrometry of purified Δ6 αGal 
MS/MS spectra obtained from parental MS ions (a) m/z = 379.71 and (b) m/z = 1064.03 corresponding 
to a C-terminal and N-terminal peptide, respectively. Product ion peaks are annotated according to their 
predicted [M+H]+ forms. Annotations in red and blue correspond to b-series and y-series ion fragments, 
respectively.  
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Thermostability and pH optima of WT and deletion mutants of αGal  
 
 
Figure 2-6: Thermostability profiles of WT and mutant αGal. 
Stability of recombinant WT and Δ2 to Δ10 mutant αGal at 30°C (a), 40°C (b), 
and 50°C (c) at pH 5.5 as monitored by fluorescent enzyme assay. Initial 
activities ranged from approximately 300 to 1,900 units/mL for all enzymes 
assayed. % Activity is normalized against activity at t = 0 mins. Data points for 
(a) and (c) are the mean of a triplicate measurement with error bars equivalent to 
± 1 standard deviation. Data points for (b) are the results of a single 
measurement. MUG was used as the substrate for enzyme assay.  
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Preparations of purified WT and mutant αGal show similar thermostability profiles at 30°C, 
40°C, and 50°C, with activity half-lives of 30, 25 and 17 minutes, respectively (Figure 2-6). The 
general trend of these profiles agrees with previous results [120]. All enzymes show optimal 
activity near pH 4.5 (Figure 2-7) in accord with previous reports for WT αGal [16, 114, 121, 
122], and there is no significant difference in the activity optima of purified WT and mutant 
αGal.  
 
 
Figure 2-7: pH activity curves of WT and mutant αGal. 
pH activity curves for WT and Δ2 to Δ10 mutant αGal. % Activity is normalized 
against each enzyme’s peak activity. Data points are the mean of a triplicate 
measurement and error bars are ± 1 standard deviation. MUG was used as the 
substrate for enzyme assay. 
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Kinetic analysis of WT and C-terminal deletion mutants 
The values for Km and Vmax for WT enzyme (Table 2-3a) are in accord with published values 
(Table 2-5). The range of Km and Vmax values for the enzymes purified from several sources in 
various laboratories over a period of more than 30 years (Table 2-5) are in good agreement and 
the observed subtle variations are in the range expected. However, more precision is expected for 
measurements recorded for enzymes purified from the same source in a single laboratory at one 
given time (Table 2-3a). Substrate saturation curves (Figure 2-8a) and the calculated values for 
Km, Vmax, kcat, and kcat/Km using the MUG substrate (Table 2-3a) reveal differences in the 
enzyme activity of the mutants compared to WT. Deletions of 2, 4, 6 and 10 amino acids 
approximately double the kcat/Km (0.8 to 1.7-fold effect; 29/34.4 = 0.8 and 58.3/34.4 = 1.7) 
while a deletion of 8 amino acids decreases the kcat/Km (7.2-fold effect; 34.4/4.78 = 7.2). There 
are corresponding changes in the Vmax values and deletions of 2, 4, 6 and 10 amino acids 
approximately double the Vmax (1.5 to 2.2-fold effect; 4.89/3.36 = 1.5 and 7.29/3.36 = 2.2) 
while a deletion of 8 amino acids decreases the Vmax (4.5-fold effect; 3.36/0.742 = 4.5). There 
are also smaller differences in the Km values of the C-terminal deletion mutants compared to the 
WT (Table 2-3a). The Vmax data presented for the Δ8 (0.742 ± 0.21) and WT (3.36 ± 0.29) are 
derived from multiple assays from three and two independent enzyme samples, respectively, and 
this indicates the reliability of this data and adds strength to the interpretations of the data from 
the single enzyme preparations used for the other deletion mutants.  
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Table 2-5: Literature Values for Km and Vmax for the WT Human αGal. 
Km (mM) Vmax (mmole/hr/mg) Source Reference year 
1.6 NA Placenta [13] 1978 
2.9 1.7 Liver [16, 17] 1979 
1.9 NA Plasma [25] 1979 
2.5 NA Spleen [25] 1979 
2.0 2.8 Spleen [26] 1981 
2.3 2.3 Sf9 insect cells [27] 2000 
2.0 4.8 Replagal [3] 2003 
2.0 4.8 Fabrazyme [3] 2003 
4.0 3.3 Fabrazyme [28] 2009 
2.8 2.6 COS-7 cells [29] 2007 
4.5 3.3 COS-7 cells [30] 2011 
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The effects of the C-terminal deletions on the kinetic properties of the enzyme using the artificial 
substrate MUG (Table 2-3a) could be due to alterations in the inherent catalytic mechanism of 
the enzyme [21]. Alternatively, the altered kinetic properties could be due to changes in the 
 
 
Figure 2-8: Substrate saturation curves of WT and mutant αGal. 
Purified WT, Δ2, Δ4, Δ6, Δ8and Δ10 αGal were enzyme assayed in 0.3 to 2.0 mM 
MUG (Figure 2-8a) and in 7 mM to 50 mM PNPαGal (Figure 2-8b) to measure initial 
velocities (mmol product per hr/mg enzyme). Km and Vmax parameters were extracted 
and compiled in Table 2-3. The figure indicates fits of Michaelis-Menten hyperbolas to 
experimental data indicated as mean ± one standard deviation. 
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affinity of the enzyme for specific structural components of the artificial substrate, MUG. In this 
context, it is of interest to measure these kinetic parameters with an alternative substrate such as 
PNPαGal. The results (Table 2-3b, Figure 2-8b) indicate that there are similar changes in kinetic 
parameters using PNPαGal as the substrate, including increases (2.2-fold effect; 9.18/4.18 = 2.2) 
and decreases (3.2-fold effect; 4.18/1.31 = 3.2) in the kcat/Km for the specific C-terminal 
deletion mutants (Δ10 and Δ8, respectively). Taken together, these results suggest that the C-
terminal deletions likely affect some aspect of the inherent catalytic mechanism of the enzyme.  
Discussion  
This is the first report to establish in a quantitative manner that the C-terminal residues of αGal 
act as a modulator of catalytic activity. Our results confirm the general results of Miyamura et al. 
[2] that C-terminal deletions of 2, 4, 6 and 10 amino acids increase the kcat/Km compared to 
WT. However, our results differ in that we find that a deletion of 8 amino acids results in a 
decrease of kcat/Km. It should be noted that there are numerous experimental differences 
between these two reports. For example, our analysis used purified enzymes expressed in P. 
pastoris and their experiments measured αGal enzyme activity during transient infection of 
COS-1 cells. There could be differences in αGal mRNA or protein stability between P. pastoris 
and COS-1 cells, and other proteins in the cytoplasm of P. pastoris or COS-1 cells could interact 
directly or indirectly with the αGal protein to affect its catalytic activity.  
It is of interest that the two recombinant protein therapeutics, Fabrazyme (agalsidase-beta) and 
Replagal (agalsidase-alfa) contain C-terminal heterogeneity with truncated species lacking either 
one or two C-terminal residues [3]. Fabrazyme contains 69.7% full length protein with 7.6% Δ1 
and 22.8% Δ2, while Replagal contains only 5.7% full length, with 73.2% Δ1 and 21.1% Δ2. 
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These authors attribute the C-terminal heterogeneity to in vivo proteolytic processing of an 
undefined nature. These commercial enzymes do not differ significantly from the WT in Km and 
Vmax (Table 2-5) in spite of this degree of protein heterogeneity [3]. The significantly increased 
Vmax of some of the mutants with C-terminal deletions suggests the basis for an improved 
treatment for Fabry disease.  
These results also illustrate the principle that in vitro mutagenesis can be used to generate αGal 
derivatives with improved enzyme activity. The potential for improved catalytic activity for this 
enzyme is illustrated by the existence of closely related enzymes with 3-fold to 250-fold higher 
activity (Table 2-6). A direct comparison of relevant amino acid residues between the human and 
related enzymes suggests the basis for rational in vitro mutagenesis to improve catalytic activity 
of the WT human enzyme. In this context, it is likely that mutants which show altered catalysis 
against the MUG substrate used here also have a correspondingly higher rate of catalysis against 
the natural substrate, but this possibility needs to be tested directly.  
Clinical trials for ERT show seroconversion frequencies of more than 50% for males treated with 
0.2 mg/kg agalsidase-alfa [51] and 88% for 1.0 mg/kg agalsidase-beta [50, 123]. Increasing the 
dose of administered enzyme in seroconverted patients raised antibody titers in some patients 
[123, 124]. IgG antibody status shows a strong association with serious infusion associated 
adverse reactions [124]. IgG positive serum from Fabry patients exhibits in vitro neutralization 
of enzyme activity [125]and lessens targeting to key disease organs in a Fabry mouse model 
[126]. The disease marker of urinary globotriaosylceramide levels is increased in seropositive 
patients as compared to seronegative patients [123, 125]. It has been proposed that higher doses 
of administered enzyme could overcome the inhibitory effect of antibodies on treatment 
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effectiveness [123]. By using an enzyme that is more active on a per mg basis, a therapeutic 
effect equivalent to WT is achievable through administration of a lower dose. The ability to 
administer a lower dose of the enzyme will intern decrease the amount of harmful antibodies 
produced in patients making this a better alternative to the current therapy. Future studies should 
include examination of these mutant enzymes relative to WT in cultured cells [15] and in mouse 
models [127, 128].  
The specificity constant (kcat/Km) has a maximum possible value determined by the frequency 
at which enzyme and substrate molecules collide in solution [129] If every collision results in 
formation of an enzyme-substrate complex, diffusion theory predicts that kcat/Km will attain a 
value of 108 – 109M−1s−1 [129]. The kcat/Km of WT human αGal is approximately 5.49 × 
103M−1s−1 (Table 2-6) suggesting the possibility that altered forms of the human enzyme may 
exist that have higher catalytic activity. A BLAST analysis [10] identified the 33 sequences most 
closely related to αGal and kinetic parameters have been reported for 6 of these enzymes (Table 
2-6). These enzymes share a high degree of sequence and structural similarities and are all in the 
same family 27 of glycosyl hydrolases [10]. There is a broad range in the values reported (Table 
1.6) for Km, kcat and kcat/Km. Thus, a detailed structural comparison of these enzymes may 
permit the identification of key amino acid residues that influence these kinetic parameters.  
Truncation of the C-terminus of the coffee bean α-galactosidase (Figure  2-9) showed that 
deletion of one or two amino acids decreases activity and deleting 3 or more residues abolished 
activity completely [130]The results with the coffee bean enzyme contrast those presented here 
for the human enzyme. Both results however demonstrate that the C-terminus of αGal is critical 
for enzyme function.  
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We examined a superposition between the crystal structure of the human enzyme and a 
homology model of the coffee bean enzyme (see Methods) to explore a structural basis for this 
biochemical dissimilarity. The N-terminal catalytic (α/β)8 domain superimposes very well 
(RMSD of 0.729 Å over 1126 total atoms) while the C-terminal antiparallel β-domain 
superimposes poorly (RMSD of 2.494 Å over 342 total atoms). A primary sequence alignment 
shows a comparable trend; the catalytic domain shows high sequence conservation while the C-
terminal domain does not. An alignment of the C-terminal ends of the human and coffee bean 
enzymes is presented (Figure 2-9) indicating secondary structure alignment (left) and primary 
 
 
Figure 2-9 : The C-termini of human and coffee αgalactosidase.  
The crystal structure of human αGal and a predicted model of the coffee homolog were 
superimposed. Underlined terminal residues, (MSLKDLL) in humans and (Q) in the coffee 
bean enzyme, indicate amino acids that could not be modeled due to conformational disorder. 
The terminal amino acid of the coffee enzyme (glutamine, Q) aligns with (threonine, T) in the 
human enzyme and is located 9 amino acids (MQMSLKDLL) from the C-terminus of the 
human enzyme. 
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sequence alignment (right). If the C-terminal domain governs a conserved mechanism of 
enzymatic regulation across the human and coffee homologs, then the deleterious effect of 
removing C-terminal amino acids from the coffee enzyme is consistent with observations made 
by Miyamura et al. [2] on the human enzyme.  
Because of the low sequence homology observed in the C-terminal residues it can be 
hypothesized that the effect on the catalytic activity due to C-terminus deletions in both the 
human and coffee bean α-galactosidase is due to disruption of the enzyme’s three-dimensional 
structure. This disruption could have an effect on enzyme dimerization, the ability to bind 
substrate, or potential interactions with other molecules in the cell.  
The most straightforward expectation of a series of C-terminal deletions is a direct correlation 
between the extent of the deletion and the effect on enzyme activity. In this sense, the reduced 
activity of the Δ8 mutant relative to the other C-terminal deletion mutants (Table 2-3) is 
unanticipated. However, we note that similar effects have been reported by others who carried 
out C-terminal deletion studies, including the IN269 mutation for the integrase of HIV [131], the 
Δ8 and Δ9 mutants of the thymidine kinase of Epstein-Barr virus [132], and the D5 and D10 
mutants of the plant vacullar H (+)-pyrophosphatase [133] Differential proteolysis may also 
explain why the Δ8 construct does not follow the same trend as the other mutants.  
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The crystal structure of αGal [10]revealed that the last visible residue of the C-terminus is 
separated by approximately 45 Å from the active site on the opposite monomer and is too far to 
have a direct effect on catalysis. However, within the same crystal structure (PDB 1R47) we 
measured C-terminal end to be only 20–25 Å away from a second ligand-binding site for β-
Dgalactopyranose [21], demarcated by Tyr329 (Figure  2-10). Directly visualizing a putative 
interaction between the C-terminus and the second binding site is not possible because C-
terminal disorder limits resolution to the 7th or 8th amino acid from the full-length C-terminal 
end. If these 7 or 8 amino acids were to adopt a fully-extended conformation, they would span a 
 
 
Figure 2-10: C-terminal Distance from Secondary Binding Site and Opposite Active Site.  
The homodimeric crystal structure of αGal (PDB ID 1R47) solved by [10] is displayed in two 
different perspectives. Distance relationships relative to one out of the two possible C-termini are 
discussed. The carbon backbone is rendered in a ribbon format. The C-terminus on monomer A is 
separated by 20 Å to 25 Å from a secondary binding site for β-D-galactopyranose on the same 
monomer [21] which is marked by Tyr 329 rendered as spheres. The C-terminus on monomer A is 
also separated by 45 Å to 50 Å from the active site of monomer B which is marked by the α-D-
galactopyranoside ligand also rendered as spheres. 
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distance of 22–26 Å (see Methods), bringing the C-terminus within potential contact distance of 
the secondary binding site. A crucial missing detail is the functional significance of the 
secondary site. It may serve as a site for small molecule chaperoning [21]. It also might 
participate allosterically in a manner similar to phosphofructokinase-1, that is allosterically 
activated by ADP [134, 135], a product of the enzyme’s ATPase function. The ligand that binds 
the secondary site on αGal is β-D-galactopyranose [21], which is the mutarotated product of the 
enzyme’s glycoside hydrolase function. A dynamic interplay may exist between the C-terminus, 
the secondary site and its ligand to affect the catalytic activity of αGal through allostery or 
structural stability of the protein. Further mechanistic studies will be needed to work out the 
exact relationships between these putative components and their relevance to in vitro catalysis.  
Due to the lack of direct contact between the carboxyl-terminal amino acids and the catalytic site 
of αGal, the explanation for the effect of the deletions of the carboxyl-terminal amino acids is not 
obvious. Another hypothesis to be tested is that αGal is in a class of enzymes like the E. coli 
dihydrofolate reductase [136-140], in which tunneling and coupled motion accounts for the 
effects of mutations distal from the catalytic site on enzyme function.  
Conclusions  
C-terminal truncation mutants of αGal were constructed, expressed and purified from P. pastoris 
using Con A and Thio-Gal affinity column chromatography. Michaelis-Menten parameters were 
measured on the purified mutants. Deletion of 2, 4, 6 and 10 amino acids approximately doubles 
kcat/Km relative to WT (0.8-1.7-fold effect) while deleting 8 amino acids decreases kcat/Km 
(7.2-fold effect). Mutants with increased activity are proposed as an improved alternative therapy 
over WT enzyme for Fabry disease patients. These results also illustrate the principle that in vitro 
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mutagenesis can be used to generate αGal derivatives with improved enzyme activit
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Chapter 3 : Uptake of α-Galactosidase A by the Scavenger 
and Mannose Pathways 
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Abstract 
ERT for Fabry disease has so far proved only partially successful in preventing adverse 
outcomes, presumably due to the lack of efficient delivery of therapeutic αGal to many affected 
tissues. ERT improves patient symptoms but fatal outcomes persist and storage of the toxic 
enzyme substrate, GB3, remains in many of the affected organs. Our approach is the 
development of derivatives of the enzyme with improved uptake properties targeting disease 
affected tissues such as the brain and in particularly endothelial cells, a major site of 
accumulation of GB3. A relatively unexplored possibility is to target therapeutic enzyme to the 
ubiquitous SR uptake system. SRs are abundant on endothelial cells that are not effectively 
targeted by current ERT mediated by the M6P uptake system used for treatment of LSDs such as 
Fabry disease.  In addition, these treatments do not pass the blood-brain barrier (BBB). The 
scavenger receptors SR-A3, SR-A5, and SR-BI are expressed in brain capillary endothelial cells 
and promote receptor-mediated endocytosis and transcytosis for delivery of drugs across the 
BBB. Production of αGal in Pichia results in mannose terminated recombinant enzyme. This 
enzyme is hypothesized to target the MR that is known to be expressed in many cell types 
including endothelial, smooth muscle, and kidney mesangial cells. 
We introduced negative charges on HSA and the recombinant human αGal by treatment with cis-
aconitic anhydride to generate terminal carboxyl groups (Aco-αGal).  We tested the uptake of 
αGal using Fabry fibroblasts and endothelial cells. Targeting to the SR was tested by monitoring 
uptake in cells overexpressing the murine scavenger receptor A (U2OS-SRA).  Enzyme uptake 
in cells in culture was monitored by direct enzyme assay and by confocal microscopy using 
Alexa-tagged-αGal (Alexa-αGal) using fixed cells and a live-cell assay for continuous uptake 
analysis.  Our preliminary results indicate targeting of αGal produced in Pichia to both the SR 
M a r i a m 	 M e g h d a r i 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
49	
and MR uptake pathways with enhanced uptake of aconitylated αGal after short incubation times 
(30 min) in Fabry endothelial cells. The ability to target αGal to the MR and SR pathways would 
permit enhanced effectiveness of the currently available M6P-dependent ERT. These results may 
lead to improved approaches for ERT for Fabry disease patients and for other LSD patients 
including targeting accumulated substrate in endothelial and neurological tissues dependent upon 
transit of the BBB. 
 
Introduction 
The relative tissue and cellular distribution of agalsidase alfa (Replagal™, therapeutic produced 
in a cultured human cells), was shown to be heterogeneous following a single intravenous 
injection in a mouse knockout model of Fabry disease [141]. Therefore, in addition to antibody 
formation, enzyme access to certain sites of tissue substrate storage may be another limiting 
factor of ERT. Currently approved ERT for Fabry disease [97, 142] was assumed to depend upon  
the M6P receptor for uptake of αGal. However, the M6P receptor is present on some but not all 
cell types that are affected in Fabry disease.  Endothelial cells, a major site of GB3 accumulation 
(Figure 3-1), lack M6P receptors [15, 143]. Despite recent studies suggesting uptake of 
phosphorylated enzyme by the M6P receptor at the BBB in newborn mice [144], or in adult mice 
using epinephrine as an inducer [145] or in the presense of much higher doses that used in ERT 
[146] in the LSD Mucopolysaccharidosis type IIIA (MPS IIIA). This uptake however was shown 
to be very low[147], in addition maintaining high plasma levels of the lysosomal enzyme used in 
ERT to achieve this uptake would most likely result in a severe immune response. As is the M6P 
pathway is known to not operate substantially at the BBB [58, 148, 149].  It was suggested that 
M6P mediated uptake of αGal is not representative of the mechanism of uptake of the enzyme in 
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cells that are a focus of storage and injury in Fabry disease [15].  Recombinant human αGal 
produced in plants removes accumulated GB3 even though these enzymes lack terminal M6P 
residues [1, 70], indicating that M6P receptors are not essential for enzyme uptake.  Patients with 
I-cell disease lack M6P groups on lysosomal enzymes but still transport some enzymes to the 
lysosome, including αGal, using other uptake pathway(s) [150, 151]. 
SRs were first defined in 1979 by Brown and Goldstein as macrophage receptors that mediate 
endocytosis of modified low density lipoprotein (LDL) such as acetylated LDL (Ac-LDL) and 
oxidized LDL leading to foam cell formation and were shown to play a role in the pathogenesis 
of atherosclerosis. Currently this definition has been broadened such that SRs are now 
categorized as a family of molecules sharing the ability to bind polyanionic ligands. Structurally 
diverse, including both membrane bound and soluble proteins, they are involved in the 
recognition and/or endocytosis of negatively charged molecules [152]. SRs are grouped into 
eight different classes (Class A-H) based on shared structural domains (Figure 3-1)[153]. Despite 
these structural differences, mutagenesis studies have shown that the ligand-binding domain of 
many of these receptors contains arginine or lysine clusters mediating electrostatic interactions 
with the negatively charged ligands [154]. Ligand-binding can activate signaling cascades 
leading to diverse cellular functions or the SR/ligand complexes can undergo endocytosis leading 
to degradation or accumulation of the ligand in the endosome-lysosome system[154]. 
The ligands for the SRs involve negatively charged proteins, such as aconitylated, maleylated 
and succinylated albumins, modified low-density lipoproteins, and polynucleotides [155]. 
Negatively charged albumins can participate as drug carriers for delivery to SRs [156].  
Successful receptor-mediated delivery to macrophages in vitro used low-molecular-weight 
antitumor agents conjugated with maleylated albumin [157-159].  Maleylated albumin was used 
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as a targeting carrier for a photosensitizer [160] and a macrophage activating peptide [161, 162] 
using SRs. In addition, direct succinylation targeted delivery of catalase to liver nonparenchymal 
cells [156].   
The delivery of an enzyme by way of the SR for the therapy of LSDs builds on previous 
techniques for specific delivery of molecules to cells.  For example, sterically stabilized 
liposomes derivatized with polyethylene glycol were used to deliver doxorubicin to squamous 
cell lung carcinoma cells by means of specific antibodies attached to the liposome surface [163]. 
In addition, others have demonstrated massive targeting of liposomes that are surface modified 
with anionized albumins, one of the techniques we propose here as a future study, to hepatic 
endothelial cells [164]. This group also demonstrated the successful targeting to the SR of 
formaldehyde treated HSA [165] and oxidized human LDL [166]. In addition, efficient hepatic 
uptake of negatively charged proteins and uptake of soluble antigens by dendritic cells through 
targeting to the SR has been shown [4, 167].  
The SR family of uptake systems are highly active on several tissue types including 
macrophages, monocytes, platelets, endothelial, smooth muscle, and epithelial cells (Figure 3-
1)[154]. An important site of accumulation of αGal substrates, including GB3 and other related 
compounds, is in endothelial cells. In a study of the effect of these SRs, the delivery of acetylated 
HSA to endothelial cells was described as “massive”, with complete clearance from the blood in 
30 minutes, while in the control 80% was still in the blood [164]. 
SR-AI and SR-BI are expressed at brain capillary endothelial cells and they have been shown to 
have a very important role at the BBB [17, 24]. The current ERT is prevented from accessing the 
central nervous system because of the BBB.  The SR-BI receptor has been shown to play a role 
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in the transport of cholesteryl esters at the BBB. This makes these receptors suitable for targeting 
ERT in Fabry disease to the brain [168]. 
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Figure 3-1: Domain architecture of the different classes of scavenger receptors [22]. Their ligands, and 
expression profiles [23, 24]. 
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Aconitylation was hypothesized to be a good means 
of adding negative charge and targeting to the SR for 
several reasons. Firstly, with aconitylation a net 
negative charge of three is added for each surface 
lysine, which is modified; maximizing the potential 
of adding negative charge to our enzyme (Figure 3-
2). Secondly, aconitylation is shown to be reversible 
at acidic pH (Figure 3-3) and this will generate a 
normal and fully active αGal at the low pH of the 
lysosome after ERT in Fabry disease patients. 
Chloroquine, an inhibitor of lysosomal acidification, blocked deacylation of aconitylated 
ovalbumin after lysosomal uptake in vivo [4]. Lastly, saturating SRs with aconitylated human 
serum albumin (Aco-HSA), in vivo, produces no immune response (Figure 3-4)[6].  
 
 
Figure 3-2: Reaction of surface Lys 
with cis-aconitic anhydride. 
Cis-aconitic anhydride coupling to Lys 
residues introduces a net three negative 
charges for each Lys residue. 
 
 
 
Figure 3-3: Aconitylation is reversible at the acidic pH of the 
lysosome [4].   
Treatment of succinylated (Suc-Ova), maleylated (Mal-Ova), and 
aconitylated (Aco-Ova) ovalbumin (OVA) at 37° in phosphate 
buffered saline at pH 5.0 (a) or 7.4 (b)[4].  Reversal of aconitylation 
will generate a normal and fully active αGal at the low pH of the 
lysosome after ERT. 
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A SR system present in the mononuclear phagocytic system on endothelial and Kupffer cells 
(Figure 3-4) is responsible for the uptake and clearance of Aco-HSA [6].  High plasma 
concentrations (up to 1 mg/ml) of 125I-Aco-HSA did not affect blood coagulation or lymphocyte 
proliferation, and showed no acute or sub-acute toxicity [6].  The lack of an immune response to 
Aco-HSA (Figure 3-4) was indicated by sensitive lymphocyte proliferation assays showing that 
lymphocyte functions were not significantly altered following immunization of rats with 
complete Freund's adjuvant (an immunopotentiator) for a four-week period [6].  Liver and spleen 
uptake of 125I-Aco-HSA was selectively blocked by the specific SR inhibitors polyinosinic acid 
(PolyI) or formaldehyde-treated human serum albumin [6].  These results demonstrate the 
presence of high levels of Aco-HSA distributed throughout the body.   
 
 
Figure 3-4: Saturation of scavenger receptors in liver, spleen, kidney, and blood 
endothelium [6]. 
Tissue distribution of 125I-Aco-human serum albumin 10 min after intravenous injection 
to male rats in the absence (control) and presence of the scavenger receptor inhibitors 
Poly-I or formaldehyde-treated human serum albumin (Form-HSA) [6].  There was no 
detectable immune response to Aco-HSA following immunization of rats for four 
weeks using complete Freund's adjuvant. 
M a r i a m 	 M e g h d a r i 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
56	
Aco-αGal can potentially target diverse sites of accumulation of GB3 substrate in Fabry disease 
patients (Figure 3-1), including kidneys, lungs, cardiomyocytes [169, 170], virtually all 
microvascular endothelial cells, and potentially the brain.  Development of an efficient and 
widespread delivery system for αGal can minimize ERT dose and frequency and this could 
reduce the immune response to αGal [34, 37, 50, 51, 53-55, 81, 99, 171-173]. 
Because of the amount of genetic, clinical, and structural information available for Fabry disease, 
it can serve as model for the entire family of LSDs [14]. Therefore, if successful, these 
approaches could be applied to enzyme therapy for other LSDs. While ERT can be expected to 
extend life spans, most patients suffer from ill-defined infusion-associated reactions. Therefore, 
any improvement in treatment that leads to more effective therapeutic effects or less frequent 
infusions would markedly improve the lives of Fabry disease patients and other patients 
receiving ERT for LSDs. 
 
Methods and Research Design  
Purification of recombinant αGal 
High-cell-density fermentation was carried out as previously described using a 7L bioreactor 
[20]. Bioreactor supernatant was passed through a 0.2 µm hollow fiber filter (Spectrum Labs, 
No. M22M-300-01N) and subjected to diafiltration using a 50 kDa pore size hollow fiber filter 
(Spectrum Labs, No. M25S-300-01N) against Buffer A (10 mM NaHPO4, pH 6.5, 0.02% NaN3, 
and 0.05 mM PMSF). The resulting supernatant was applied to a DEAE Sepharose Fast Flow 
(GE Healthcare, No.17-0709-01) column, pre-equilibrated with 5 column volumes Buffer A. 
Elution of αGal was carried out using a 0 to 1M NaCl gradient in Buffer A. Elution was 
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discontinued when the absorbance at 280 nm and enzyme assays showed negligible presence of 
protein and αGal activity. The DEAE elution tubes with sufficient αGal activity were pooled and 
subjected to diafiltration using the previously described 50 kDa pore size hollow fiber filter 
(Spectrum Labs, No. M25S-30001N) against binding buffer (25 mM citrate-phosphate buffer, 
pH 4.8 containing 0.1 M NaCl). The diafiltrated product was applied to an immobilized-D-
galactose gel column (Thio-Gal, Pierce No. 20372) pre-equilibrated with binding buffer. The 
column was washed with 5 column volumes of binding buffer and αGal was eluted with elution 
buffer II (25 mM citrate-phosphate buffer, pH 5.5, 0.1 M NaCl, 0.1 M D-galactose) over 1.5 
column volume blocks separated by 12-hour soaks. Fractions were assayed for enzyme activity 
and protein concentration and pooled, this pool was chosen as the sample to be used in uptake 
studies. This two-column purification is simpler and faster than our previous purification 
methods that used two [20] three [9] or four [7, 8] columns and the yield, degree of purity, and 
final specific activities were similar for all three methods.  
Enzyme assay 
Activity of αGal was assayed using the synthetic substrate MUG as described [7] with 
modifications to a microtiter plate format (below). Enzyme activity is measured in units/ml 
where one unit is defined as the amount of enzyme required to convert 1 nmole of MUG to 4-
methylumbelliferone in one hour at 37°C. An aliquot of 3 µl was added to 27 µl of enzyme assay 
buffer (5 mM MUG in 40 mM sodium acetate buffer, pH 4.5). This mixture was incubated at 
37°C and 10 µl aliquots were taken at two time points and added to 290 µl of 0.1 M diethylamine 
in a microtiter plate to stop the reaction. The fluorescence of each sample was measured at an 
excitation wavelength of 365 nm and an emission wavelength of 450 nm using a Tecan Infinite 
F200 microtiter plate reader. A standard curve of 10 µl of 0 – 50 nM 4-methylumbelliferone 
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dissolved in MeOH in 290 µl of 0.1 M diethylamine was used to quantitate MUG cleavage at 
specific time intervals. Analysis of the effects of MeOH indicated no effect on the 4-
methylumbelliferone standard curve. 
Protein assay  
Absorbance at 280nm on A NanoDropTM 2000/2000c was used to quantify purified recombinant 
protein. An Extinction coefficient of 117,475 M-1 cm-1 was calculated for αGal [174] and used 
for A280 measurements with a molecular weight of the monomer, 45 kDa.  A standard Bradford 
protein assay was also used to confirm results. In short, 10 µl of the.  A standard Bradford 
protein assay was also used to confirm results. In short, 10 µl of the sample/standard was 
combined with filtered 4X diluted Coomassie dye and incubated for 5 minutes. The absorbance 
was measured at 595 nm using a Tecan Infinite F200 microtiter plate reader. A standard curve of 
0 - 400 µg/ml BSA was used. 
Electrophoresis analysis  
Samples were mixed with an equal volume of reducing sample buffer (Bio-Rad Laemmli sample 
buffer with 5% β-mercaptoethanol) and heated for 5 minutes at 95°C before loading on a Mini-
Protean TGX Precast Gel 4–20% (w/v) (Bio-Rad No. 456-1094). Bands were visualized by 
Coomassie blue staining via the modified Fairbanks protocol [112].  
Cell culture 
FFB (GM2775, Coriell Institute for Medical Research, Camden, NJ) and healthy non-fetal tissue 
fibroblasts (NFB) (GM04390, Coriell Institute for Medical Research, Camden, NJ) used as a 
control were grown to confluency in MEM, GlutaMAX™ (Gibco) supplemented with 10% FBS, 
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Antibiotic-Antimycotic, and MEM nonessential amino acid solution (ThermoFisher) in T-75 
flasks at 37 °C and 5% CO2.  
Human Dermal Microvascular Endothelial Cells (HMVEC, Lonza, Walkersville, MD) and the 
immortalized Fabry endothelial cell line-1 (IMFE-1) cells [175] were generously donated by 
Prof. R. Schiffmann (Baylor Research Institute), and were plated into T-75 flasks and grown to 
confluency in the EGM-2MV kit (Lonza, Walkersville, MD) at 37 °C and 5% CO2 as per that 
labs recommendation before the experiment. 
Human osteosarcoma U2OS (HTB-96TM) cells from ATCC were grown in McCoy’s 5A 
medium with 1% Pen-Strep and10% FBS in tissue culture treated T-75 flasks. U2OS-SRA cells 
(human U2OS osteosarcoma cells over-expressing the murine scavenger receptor A) were 
generously donated by Professor F. Maxfield (Weill Cornell Medical College) and grown in 
McCoy’s 5A medium with 1% Pen-Strep, 1 mg/ml G418 and 10% FBS on non-tissue culture 
treated petri plates at 37 °C and 5% CO2. 
Evaluation of uptake using enzyme assay   
Fibroblast and endothelial cells were grown till 80-90% confluence on 6-well plates. The 
medium was removed and 2ml of culture medium containing BSA (5 mg/ml) and appropriate 
concentration of the purified recombinant αGal was added. plates were then incubated at 37˚C 
and 5% CO2 for indicated times. Following this incubation, the medium was removed, followed 
by three washes with PBS. Cells were then harvested using trypsin/EDTA and precipitated by 
centrifugation. Each cell pellet was re-suspended in 50 µl of 1X Buffer A. Cells were then 
ruptured by freeze-thawing three times and protein and enzyme assays done on the cell extracts. 
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[7, 9, 166], [15] Uptake of human αGal was measured by enzyme assay using the synthetic 
substrate MUG. 
Evaluation of uptake using confocal microscopy 
Recombinant αGal was labeled with Alexa Fluor 488 according to the instructions of the 
manufacturer (Molecular Probes). Alexa tagging was done in Modified Buffer A at a pH of 7.5. 
Degree of Labeling (DOL = moles dye / moles protein) of the sample was determined based on 
obtaining the protein concentration by absorbance at 280 nm and at 494 nm in a NanoDropTM 
2000/2000c. 
FFB, IMFE1 and U2OS-SRA cells were grown to near confluence on an 8-well Nunc™ Lab-
Tek™ II Chambered Coverglass (Thermo Fisher Scientific, Catalog# 155409) incubated at 37°C 
and 5% CO2 with Alexa Fluor 488-labeled αGal (5 µg/ml) for variable time lengths with or 
without inhibitors in the presence of 5 mg/ml BSA to increase enzyme stability. Cells were 
washed with PBS and fixed with 4% paraformaldehyde for 10 min at room temperature. Cells 
were then washed with PBS 3 times and covered with the ProLong® Diamond Antifade 
Mountant with the nuclear stain DAPI (4',6-diamidino-2-phenylindole) before imaging in a Zeiss 
Confocal LSM 710. Cells were counterstained with LysoTracker Red DND-99 (L-7528; 
Molecular Probes) for 2 hours before fixation for co-localization analysis. Uptake was quantified 
using ImageJ. 
Live cell imaging  
Live cell imaging was performed using a ZEISS LSM 880 Super-Resolution confocal laser-
scanning microscope with Airyscan and CO2 incubator was used. Cells were incubated with 
Alexa488 tagged enzyme in FluoroBrite™ DMEM and Prolong Live Antifade Reagent 
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(Invitrogen) in the presence of 5 mg/ml BSA to increase enzyme stability. Images were acquired 
every 10 minutes. ImageJ was also used to quantify live cell images. Cells were incubated with 
LysoTracker Deep Red to visualize lysosomes and evaluate uptake of enzyme to lysosomes (co-
localization). 
Quantification of uptake in confocal images 
ImageJ was used to quantify the fluorescence intensity of enzyme and lysosomes and to 
determine colocalization. Images were loaded on the ImageJ software and the channels 
separated. Particle analysis was performed on both the green and red channel images (Figure 
3.6). Co-localization of the LysoTracker Red and αGal particle images was visualized using the 
co-localization highlighter plugin. (Figure 3-9) Particle analysis was performed on the co-
localized image generated as well as the Alexa and LysoTracker channels (Figure 3-10). 
Aconitylation  
Aconitylation was carried out as per published methods with minor changes to accommodate 
αGal instability at high pH (Figure 3-19) [165, 167, 176]. The surface lysine residues of samples 
in buffer at a pH of 7.5 were reacted with excess cis-aconitic anhydride and stirred at 4°C for 
1hr. The degree of modification of lysine residues was assessed by estimating the loss of free 
amino groups as measured by trinitrobenzenesulphonic acid assay (TNBS) [18]  or 
fluorescamine [177] assay post removal of excess anhydride and using a glycine standard curve. 
In addition, the pre-and post aconitylated samples were analyzed using native PAGE and 2D 
protein electrophoresis, where the first dimension is an isoelectric focusing gel (IEF) and the 
second dimension is an SDS-PAGE. IEF gels can be used to detect minor changes in the protein 
charge.  
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Quantification of modification by TNBS and fluorescamine assay 
The TNBS component reacts readily with primary amino groups of amino acids in aqueous 
format at basic pH to form yellow adducts which can be monitored at 345 nm. Assay samples 
were dialyzed in 0.1 M sodium bicarbonate buffer (pH 8.5). The supplied 5% TNBS solution 
(Thermo Fisher Scientific Inc.) was diluted 500-fold in 0.1 M sodium bicarbonate buffer (pH 
8.5). 0.5 mL of the diluted TNBS solution was added to 1mL of protein solution (approximately 
1 mg), mixed and incubate at 37 °C for 2 hours. 0.5 mL of 10 % SDS and 0.25 mL of 1 N HCl 
was added to each sample/standard to stop and stabilize the reaction. Absorbance of the solution 
was measured using a Tecan infinite F200 at 335nm.  
Fluorescamine also reacts with primary amino groups of amino acids [177]. 150 µl of 0.05 M 
sodium phosphate buffer pH 8.5 and 50 µl of 1.08 mM fluorescamine dissolved in acetone were 
added to an aliquot of 50 µl of the sample and standards, mixed and incubated at room 
temperature for 12 minutes. The fluorescence of each sample was measured at an excitation 
wavelength of 400 nm and an emission wavelength of 460 nm. 
2D electrophoresis  
Samples were loaded on isoelectric focusing gels (pH 3.0 to 10.0) (Novex, San Diego, CA). The 
gels were run at 100 V for 1 hour and then at 200 V for 1 hour and 500 V for 30 minutes in an 
XCM II Mini-Cell per company instructions (Novex, San Diego, CA). The gel was washed with 
distilled water for 30 seconds and fixed and stained with Crocein Scarlet 7B (Sigma) and 
Coomassie brilliant blue R-250 (Sigma) to determine the isoelectric point (pI) via the modified 
Fairbanks protocol [112] with minor modification to incorporate fixation by Crocein Scarlet 7B. 
Briefly, the proteins separated on IEF Gels were subjected to 2D electrophoresis using 
M a r i a m 	 M e g h d a r i 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
63	
NuPAGE® 4-12% Bis-Tris Protein Gels with a 2D-well to separate focused proteins by mass 
according to manufacturer specifications. The IEF gel was incubated in 100 mL 20% ethanol for 
10 minutes, the desired lane cut out and incubated for 3-5 minutes in 1) 2 mL 2X SDS sample 
buffer and 0.5 mL ethanol, 2) 0.25% 2-Mercaptoethanol βME in 1X sample buffer, and 3) 125 
mM Alkylating Solution consisting of iodoacetamide in 1X sample buffer. Each incubation step 
was followed by rinsing with 1X NuPAGE® MES SDS Running Buffer. The IEF gel strip was 
transferred into the 2D well of the NuPAGE gel and run at 200V. A pre-stained low MW marker 
(Bio-Rad 161-0305) was used.  
 
Results: 
Purification of recombinant human αGal in P. pastoris 
αGal was obtained from a 7 L bioreactor (Figure 3-5) and purified (Table 3-1, Figure 3-6) using 
the DEAE and Thio-Gal columns. Due to the high concentration and volume of enzyme needed 
for the uptake studies planned, the more efficient DEAE column was substituted for the Con A 
Sepharose 4B (GE Healthcare No. 17-0440-01) column used in earlier experiments. The ConA 
column required lengthy soaks which caused a loss of enzyme. The DEAE column however, has 
much greater efficiency, being much quicker, and results in over 80% recovery of sample. Side-
by-side comparison of the two procedures showed they both result in  pure enzyme being 
produced, observed in specific activity and on SDS-PAGE. 
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The non-glycosylated monomeric form of αGal is 41.8 kDa. However, the form isolated from 
cells contains multiple glycosylated species with a predominant band of about 50 kDa and 
multiple higher molecular weight forms that differ in extent of glycosylation (Figure 3-6). We 
have previously demonstrated that high molecular weight glycoforms produced in insect cells 
and P. pastoris can be identified as derivatives of αGal rather than contaminants and these 
glycoforms are converted to a single band on SDS gels of about 41.8 kDa with endoglycosidase 
treatment [7-9, 20] and all appear in a western blot [20]. 
 
Figure 3-5: Fermentation profile of the bioreactor expression of recombinant 
human αGal in pichia following a methanol-limited strategy.  
The fermentation process is divided in 3 major stages. The initial glycerol batch and 
fed-batch, are intended to achieve a high cell concentration. Once the desired cell 
concentration is achieved (approximately hour 48), the methanol fed-batch phase 
starts triggering αGal production. During the whole process, enough aeration is 
guaranteed to maintain a dissolved oxygen set-point above 40%, keeping glycerol and 
then methanol as the limiting nutrients. Bioreactor run terminated when a drop in 
enzyme activity is observed. 
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Figure 3-6: αGal was purified as a single 
band on an SDS-PAGE gel.  
Purified samples were run on a 4–20% 
polyacrylamide gel, under reducing conditions, 
and stained with Coomassie Brilliant Blue. The 
contents of the lanes are as follows: Bio-Rad 
unstained low molecular weight ladder (lane 1), 
Supernatant (lane 2), DEAE pool (lane 3), and 
Thiogal pool (lane 4). The minor bands present 
in the purified fraction are consistent with high 
molecular weight glycoforms seen previously 
when WT enzyme was purified from the 
same P. pastoris expression system. [7] [20] 
 
 
Table 3-1: Purification Table for αGal Expressed in P. pastoris 
Step 
Total Protein 
(mg) 
Total Activity 
(Units ´ 106 ) 
Specific Activity 
(Units/mg ´ 103 ) 
Purification 
(Fold) 
Yield 
(%) 
Supernatant 55,550 208 3.7 1.0 100 
DEAE Pool 653 137 211 56.2 66.0 
Thio-Gal Pool 9.92 25.0 2,504 668 11.9 
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Uptake of αGal using confocal microscopy 
 
Confocal microscopy was used as a reliable and sensitive method of monitoring uptake of αGal 
(Figure 3-7, 3-8, 3-12). The recombinant αGal was tagged with Alexa 488 according to 
manufacturer specifications. Initial experiments showed that uptake could be accurately 
monitored in both IMFE1 and FFB cells after fixation for short time periods as well as overnight 
(Figure 3-7, 3-8, 3-13). Untagged recombinant αGal was used as a negative control to account 
for auto-fluorescence. In these experiments, LysoTracker Red DND-99 was used to identify 
lysosomes allowing for monitoring uptake as well as co-localization/ targeting to the lysosomes 
of αGal (Figure 3-7, 3-8, 3-12). The nuclear stain DAPI was also used to visualize the nucleus.  
In addition to 2D confocal images (Figure 3-8), 3D images using z-stacks were generated in a 
Zeiss LSM 710 Confocal microscope to better visualize co-localization of αGal with the 
lysosomes (Figure 3-7). 
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Figure 3-7: Uptake of αGal-Alexa using 3D confocal microscopy.  
Laser-scanning microscope 3D images of uptake of αGal-Alexa in normal fibroblast cells. 
Cells are labeled with LysoTracker Red (red) to identify lysosomes, DAPI nuclear stain 
(blue) and αGal with AlexaFluor488 fluorescent tag (green; yellow represents co-
localization) from a LSM 710 Super-Resolution confocal laser-scanning microscope. 
 ALEXA  LysoTracker Red DAPI Co-localization 
 αGal  
(no Alexa) 
(- Control) 
    
αGal-
Alexa 
    
 
Figure 3-8: Uptake of αGal-Alexa in fixed cells using normal fibroblast (NFB) cells (2hr incubation).  
αGal-Alexa (5 ug/ml) was added to wells containing NFB cells and incubated for 2-hour at 37˚C and 5% CO2. 
Cells were fixed post incubation with Alexa tagged αGal and counterstained with LysoTracker Red DND-99 for 
co-localization analysis. Post fixation the cells were covered with the ProLong® Diamond Antifade Mountant 
with DAPI before imaging on a LSM 710 confocal laser-scanning microscope.  
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Live cell imaging  
Live cell imaging provides for continuous monitoring of uptake compared to images acquired in 
fixed cell confocal experiments. We carried out live cell imaging over an 80-minute time period 
(Figure 3-9). For this live cell assay a ZEISS LSM 880 Super-Resolution confocal laser-scanning 
microscope with Airyscan and live cell temperature and CO2 incubator attachment was used. 
Cells were incubated with αGal-Alexa in FluoroBrite™ DMEM and Prolong Live Antifade 
Reagent in the presence of 5 mg/ml BSA to increase enzyme stability. By monitoring uptake in 
one cell over a period of time we hoped to be able to draw conclusions as to the dynamics of 
uptake in that cell and could potentially use this as a means to compare uptake of our sample pre-
and post aconitylation.  
We initially observed excessive bleed through of LysoTracker Red into the green Alexa 
(490/525) channel during preliminary live cell experiments, which made accurate quantification 
of the green channel impossible. To resolve this issue LysoTracker Deep Red (647 ⁄ 668) was 
substituted for the more commonly used LysoTracker Red (577⁄590) marker to identify 
lysosomes. We also observed bleed through of the live cell nuclear stain, Hoechst 33342 
(360⁄460) into the green Alexa (490/525) channel. We were unable to resolve this issue and 
therefore omitted the nuclear dye from our live cell experiments to maintain the integrity of the 
quantification of the green channel (Figure 3-9).   
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Figure 3-9: Uptake of αGal-Alexa using live cells. 
αGal-Alexa (5ug/ml) was incubated in Fabry fibroblast in the live cell attachment of a ZEISS 
LSM 880 confocal microscope at 37˚C and 5% CO2. Images were acquired every 10 minutes. 
30 min 40 min 
60 min 
70 min 80 min 
50 min 
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ImageJ was used to quantify the uptake of the Alexa tagged enzyme in confocal studies as 
described in the methods (Figures 3-10). N=5 cells were initially chosen at random (more cells 
would need to be imaged to draw substantial conclusions in future studies) and the images from 
this live experiment were analyzed and uptake quantified with ImageJ (Figure 3-11). ImageJ 
allows quantification of an otherwise subjective data set. It also identifies the existence of the 
cell-to-cell variability consistent with variations seen when measuring uptake by fixed cell 
confocal microscopy. 
 
 
Figure 3-10: Quantification procedure of confocal images with ImageJ.  
a) Particle analysis of the LysoTracker (red) channel in ImageJ identifies lysosome particles, b) 
Particle analysis of the Alexa-488 (green) channel in ImageJ identifies enzyme particles c) Co-
localized image generated by ImageJ. d) zoomed in view showing co-localized particles e) zoomed in 
view showing co-localization in original confocal image. f) Particle analysis in ImageJ on co-
localized image identified co-localized particles. g) Zoomed in view showing numbered co-localized 
particles.  
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Quantification of uptake in n = 5 cells (Figure 3-11), highlights the dramatic cell to cell 
variability initially observed in fixed cell experiments but allows us to still observe the general 
trend in the increase of uptake of Alexa tagged αGal over the 80-minute incubation period. In 
future studies flow cytometry can be used to address this cell to cell variability. By using flow 
cytometry to monitor the presence of the Alexa tagged enzyme we would be able to analyze 
millions of cells and therefore draw more concreate conclusions as to the trends observed. The 
dip in uptake observed at 80 minutes is due to a shift in focus of the LSM 880 lens from the 
optimal position do to repeated plate movements necessary to visualize all selected cells. 
 
 
 
Figure 3-11: Particle analysis of live cell uptake of αGal-Alexa in Fabry fibroblast (FFB) 
cells. 
αGal-Alexa (5ug/ml) was incubated in FFB cells in the live cell attachment of a LSM880 
confocal microscope. Distinct fields/cells (n=5) were chosen for continued analysis and confocal 
images of these fields were acquired every 10 minutes. Uptake was quantified using ImageJ.  
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Time course confocal microscopy in fixed cells using IMFE1 endothelial cells 
Uptake of αGal was monitored in IMFE1 immortalized endothelial cells over different time 
periods; 0, 0.5, 2 and 19 hours (Figure 3-12). Cells were incubated with enzyme for the indicated 
time periods and then fixed before imaging in a confocal microscope. An average of 15 cells was 
imaged in each instance and the images analyzed using ImageJ (Figure 3-13). These results 
indicated an increase in both uptake of αGal-Alexa as well as co-localization of the enzyme with 
the lysosomes over time. Untagged recombinant αGal was used as a negative control to account 
for auto-fluorescence. 
This time course analysis (Figure 3-13) indicates that αGal is initially taken up at a higher rate (t 
<3hrs) and that uptake plateaus with longer incubation times (19 hours). These trends were 
confirmed in uptake studies done where enzyme assay was used to quantify uptake in both FFB 
and IMFE1 cells (Figure 3-17). 
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Figure 3-12: Time course uptake of αGal-Alexa in IMFE1 cells. 
αGal-Alexa (5 ug/ml) in IMFE cells post 0.5, 2, and 19-hour incubation at 37˚C and 5% CO2. Cells were 
incubated with Alexa tagged αGal and counterstained with LysoTracker Red DND-99 for 2 hours before 
fixation for co-localization analysis. Post fixation the cells were covered with the ProLong® Diamond Antifade 
Mountant with DAPI before imaging on a LSM 710 confocal laser-scanning microscope. 
 
M a r i a m 	 M e g h d a r i 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
74	
 
 
 
 
 
 
 
 
     
 
 
Figure 3-13: Particle analysis of uptake of αGal-Alexa in IMFE1 cells from (Figure 3-12). 
Quantification with ImageJ of uptake and co-localization with lysosomes of αGal-Alexa (5 ug/ml) 
in IMFE1 cells post 0.5, 2, and 19-hour incubation at 37˚C and 5% CO2. (mean and standard 
deviation from n=15 cells) 
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Uptake of αGal is dose dependent  
It has been previously reported that FFB in cell culture take up the recombinant human αGal 
produced in insect cells and P. pastoris in a dose dependent manor as measured using direct 
enzyme assays (Figure 3-14) [7-9].   
Uptake of the recombinant human αGal produced in the 7L bioreactor and purified using the 
DEAE and Thio-Gal columns was measured by direct enzyme assay in FFB and IMFE1 cells in 
replicates and was confirmed to be dose dependent in an overnight incubation with enzyme 
(Figure 3-15). 
 
 
Figure 3-14: Purified recombinant αGal produced in insect 
cells and P. pastoris is taken up by FFB (GM2775) in cell 
culture [7-9]. 
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Figure 3-15: Dose dependent uptake of αGal in Fabry fibroblast (FFB) and Fabry 
endothelial (IMFE1) cells.  
Cells were incubated with indicated doses of αGal overnight (19 hours) in replicates, then 
lysed and uptake was quantified using enzyme assay with the artificial substrate MUG as 
described in the methods. 
Normal Enzyme Level 
Normal Enzyme Level 
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Recombinant αGal produced in Pichia is taken up in higher levels in Fabry 
endothelial cells (IMFE1) compared to Fabry fibroblasts (FFB) 
In a recent study analyzing the lysosomal delivery of the available therapeutic αGal in 
cell models of Fabry disease, it was shown that total endothelial uptake was less than fibroblast 
uptake at concentrations relevant to the therapeutic situation (≤ 3 µg/ml) (Figure 3-16B) [15]. 
This is in accord with the currently approved ERT being mediated by the M6P receptors which 
are generally absent from endothelial cells, a major site of GB3 accumulation in Fabry disease. 
A) Recombinant Pichia αGal               B) Therapeutic 
           (Meghdari, unpublished)                    (Replagal or Fabrazyme) [15] 
                    
 
Figure 3-16: Comparison of uptake trends of αGal produced in pichia and mammalian cells in 
fibroblast and endothelial cells.  
A) Recombinant αGal produced in Pichia was incubated with FFB and IMFE1 overnight at varying 
concentrations. Uptake was quantified using direct enzyme assay. B) Uptake of αGal in normal 
fibroblasts and blood outgrowth endothelial cells. Uptake after 3-hour incubation at varying enzyme 
concentration of Replagal (Shire Human Genetic Therapies) or agalsidase beta - Fabrazyme (Genzyme 
Corporation – a Sanofi subsidiary) [15]. 
M a r i a m 	 M e g h d a r i 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
78	
In order to investigate these results, the recombinant αGal was incubated overnight at varying 
concentrations in Fabry fibroblast and endothelial cells (Figure 3-16A). Published results (Figure 
3-16B) [15] indicate the current M6P terminated therapeutic is taken up in greater abundance in 
FFB as opposed to endothelial cells.  Our mannose terminated enzyme, rectifies this issue with 
observed increased uptake in disease-relevant IMFE1 as opposed to FFB (Figure 3-16A). Our 
Mannose terminated recombinant αGal was taken up at much higher levels in endothelial cells, a 
major disease-relevant cell type in Fabry disease.  
 
Uptake of αGal in IMFE1 cells reaches a plateau after 3 hours 
 
To compare uptake rates in a dynamic phase, IMFE1 and FFB cells were incubated with 
recombinant αGal overnight (19 hours) and for a shorter time period of 3 hours and uptake 
quantified by enzyme assay (Figure 3-17). Uptake in IMFE1 cells was substantially higher than 
FFB at both time points with maximum uptake being reached after 3-hours of incubation with 
αGal. We hypothesize that this plateau is most likely due to saturation of uptake by the MR, in 
 
 
Figure 3-17: Comparison of time course uptake of αGal in FFB and IMFE1 cells. 
αGal was incubated with FFB and IMFE1 cells overnight and at 3hours at a concentration 
of 6 µg/ml. Uptake was quantified using enzyme assay. 
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which all accessible MR have bound enzyme. These results agree with trends observed in 
Confocal studies (Figure 3-13) and indicate the need to monitor uptake at lower time points in 
IMFE1 cells in order to study kinetics of uptake. 
Preliminary control experiments to demonstrate aconitylation of HSA 
HSA was aconitylated as per published methods with minor changes to accommodate αGal 
instability at high pH (Figure 3-18) [165, 167, 176].  We synthesized Aco-HSA by reacting the 
surface lysine residues of HSA in buffer at a pH of 7.5 with excess cis-aconitic anhydride and 
stirring at 4°C for 1hr. The degree of modification of lysines was assessed by estimating the loss 
of free amino groups as measured by TNBS [18] or fluorescamine [177] assay post removal of 
excess anhydride and using a glycine standard curve (Table 3-2). In addition, the pre-and post 
aconitylated samples were analyzed using native PAGE, isoelectric focusing (IEF), and 2D 
isoelectric focusing to measure aconitylation. (Figure 3-19, 3-20).   
 
 
Figure 3-18: Analysis of stability of αGal over high pH range. 
Conjugation with cis-aconitic anhydride is recommended under basic 
conditions (pH 8.5) [18]. In preliminary experiments, we measured the 
stability of αGal at pH 6.5 to 8.5 at incubations times of 15, 30, and 60 
min. The results indicated that conjugation at a pH of 7.5 for 30 or 60 min 
was optimal to prepare Aco-αGal.   
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Table 3-2: Overview of HSA/BSA aconitylation samples 
Sample conc. Anhydride added 
% Aconitylation 
Fluorescamine 
Aco-HSA 
1X 56 
1X 43 
0.5X 52 
2X 61 
2X 52 
Aco-BSA 
1X 36 
2X 42 
 
 
 
 
 
 
A)  native PAGE                              B)  Isoelectric focusing gel 
 
                      
 
Figure 3-19: Analysis of charge of HSA pre-and post aconitylation. 
A) Native PAGE separates HSA/Aco-HSA samples based on size to charge ratio 
and B) IEF gel separates HSA/Aco-HSA samples solely based on their charge. 
The more negatively charged Aco-HSA samples migrates farther on both gels 
confirming aconitylation of the sample. 
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Aconitylation promotes uptake of HSA  
It was reported in the literature that the introduction of negative charges on the surface of 
proteins by chemical modifications such as acetylation or aconitylation targets proteins for 
uptake by the scavenger receptor family of integral membrane proteins [4, 167]. Specifically, 
aconitylation of HSA was reported to result in massive uptake in vivo and in vitro to the 
lysosomes of endothelial cells [164, 178].  An essential step in enzyme therapy for Fabry disease 
and other lysosomal storage diseases depends upon enzyme uptake and lysosomal transport by 
multiple cell types and using several uptake pathways. HSA has a circulating half-life of 20 days 
due to its size and protection from intracellular degradation in the lysosome, making it a good 
A) HSA                                                                                     B) Aco-HSA 
 
Figure 3-20: 2D electrophoresis of HSA and Aco-HSA samples. 
Appropriate lanes were cut out of IEF gels and after preparation (see methods) loaded on the 2D well 
of an SDS-PAGE gel. 
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control for the aconitylation experiments with αGal. In preliminary experiments, we modified 
HSA by aconitylation and tagged it with the fluorescent dye Alexa488 and monitored uptake into 
normal human fibroblast cells using confocal microscopy (Figure 3-21).   
 
No detectable fluorescence of Alexa488 (green fluorescence) was detected in a control 
experiment for lysosomes (labeled with LysoTracker Red) with unmodified and unlabeled HSA 
(Figure 3-21A, Frames 1, 2) and very low levels of uptake were detected with unmodified HSA-
Alexa488 (Figure 3-21B, Frames 1,2).  In contrast, significant accumulation of Aco-HSA-
Alexa488 was detected in lysosomes as indicated by co-localization of LysoTracker Red (red 
fluorescence) with Alexa488 (green fluorescence) in the formation of yellow lysosomal 
compartments (Figure 3-21C, Frames 1,2,3,4). These results confirm literature reports that Aco-
HSA is successfully targeted to the lysosome and demonstrate the efficacy of our aconitylation 
protocol.  
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        (A)     (B)        (C) 
	
(D) 
      
(E) 
  
         
 
Figure 3-21: Uptake of HSA-Alexa compared to Aco-HSA-Alexa in NFB. 
Cells were labeled with LysoTracker (red) to identify lysosomes, DAPI nuclear stain (blue) 
Cells were incubated for 3 hours with A) HSA (Control) B) HSA and C) Aco-HSA with 
AlexaFluor488 fluorescent tag (Green); yellow represents co-localization) from a LSM 710 
Super-Resolution confocal laser-scanning microscope. Multiple frames shown for 
clarification. D) Individual channels of Frame 1, cells incubated with HSA-Alexa E) 
Individual channels of Frame 1, cells incubated with Aco-HSA-Alexa. 
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Aconitylation of HSA targets the enzyme to the scavenger receptor uptake 
pathway   
U2OS-SRA cells are human U2OS osteosarcoma cells over-expressing the murine scavenger 
receptor A. Because of the dramatic increase of scavenger receptors present in these cells in 
contrast to their control (U2OS cells) they are used as a tool for identifying uptake to the 
scavenger receptor uptake pathway [179].  
Confocal uptake studies were done with Aco-HSA in U2OS cells as well as U2OS-SRA cells 
overexpressing scavenger receptor type A. Aco-HSA was taken up more readily in U2OS-SRA 
cells than in U2OS cells after a short incubation time of 2 hours. This difference practically 
disappears after overnight incubation with the fluorescently labeled Aco-HSA when uptake 
seems to plateau in both cells types (Figure 3-22). 
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A) 2hr incubation 
 
Cells Aco-HSA-Alexa LysoTracker Red DAPI Co-localization 
U2OS 
    
U2OS-SRA 
    
 
 
B) Overnight incubation 
 
Cells Aco-HSA-Alexa LysoTracker Red DAPI Co-localization 
U2OS 
    
U2OS-SRA 
    
 
Figure 3-22: Uptake of Aco-HSA-Alexa in U2OS and U2OS-SRA cells. 
Aco-HSA-Alexa (5 ug/ml) in U2OS and U2OS-SRA cells A) post 2-hour incubation and B) post overnight 
incubation at 37˚C and 5% CO2. Cells were incubated with Alexa tagged αGal and counterstained with 
LysoTracker Red DND-99 for 2 hours before fixation for co-localization analysis. Post fixation the cells were 
covered with the ProLong® Diamond Antifade Mountant with DAPI before imaging on a LSM 710 confocal 
laser-scanning microscope. 
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Aconitylation of αGal 
The first step in forming SR-targeted αGal is to construct aconitylated and fluorescently-labeled 
αGal.  αGal has 33 lysines per subunit; the programs ASA-View [180] and GetArea[181] were 
used to visualize and analyze the relative surface accessibility of residues of the Protein data 
bank (PDB) structure of human αGal (1R46)[10]. Relative solvent accessibility was determined 
by dividing the accessible surface area of a residue for the maximum exposed surface of the 
same residue type in a Gly–X–Gly oligopeptide, residues with relative solvent accessibility of 
more than 50 % are considered to be solvent exposed. Using this calculation αGal contains 
approximately 20 surface lysines in the monomer, which will be used for aconitylation and 
fluorescent labeling (Figure 3-23). Cis-aconitic anhydride coupling to lysine residues introduces 
a net three negative charges for each lysine residue (Figure 3-2). 
 
 
 
 
Figure 3-23: Surface Lys residues of 
αGal. 
The surface structure of the αGal dimer 
contains about 20 well-exposed Lys 
residues (red).  Aconitylation of ε-NH2 
groups (Figure 3-2) introduces a net three 
negative charges for each Lys residue. 
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Aconitylation of αGal targets the enzyme to the scavenger receptor uptake 
pathway in U2OS-SRA cells  
Uptake of αGal and Aco-αGal was analyzed in U2OS cells (human bone osteosarcoma) as well 
as U2OS-SRA cells (overexpressing murine scavenger receptor type A). Aco-αGal was more 
readily taken up in U2OS-SRA cells with an average of 100 ± 74 particles of Aco-αGal-Alexa 
per field than in U2OS cells with an average of 12 ± 9 particles of Aco-αGal-Alexa per field 
after an incubation time of 2 hours with enzyme (Figure 3-24, 3-25, Table 3-3). This is similar to 
the trend seen in the control with Aco-HSA (Figure 3-22). This is in contrast to the trend in 
uptake of non-Aco-αGal in which uptake is similar in both cell types with slightly more uptake 
being observed in U2OS-SRA cells indicating that non-Aco-αGal may also be slightly targeted 
to the SR uptake pathway (159 ± 104 in U2OS vs 192 ± 20 in U2OS-SRA). 
It is important to note that the overall uptake of non-Aco-αGal is higher than Aco-αGal in both 
of these cells types. This is most likely due to the loss of approximately 44% in specific activity 
of the enzyme during the aconitylation procedure. We also hypothesis that aconitylation may be 
blocking another uptake pathway of non-Aco-αGal in U2OS cells but this hypothesis needs to be 
tested further.  
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Cells  αGal-Alexa LysoTracker Red DAPI Co-localization 
U2OS 
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SRA 
    
Cells Aco- αGal -Alexa LysoTracker Red DAPI Co-localization 
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Figure 3-24:Uptake of αGal-Alexa and Aco-αGal-Alexa in U2OS and U2OS-SRA cells. 
U2OS and U2OS-SRA cells were incubated with Alexa tagged αGal-Alexa and Aco-αGal-Alexa at 37˚C and 
5% CO2 for 2 hours. Cells were counterstained with LysoTracker Red DND-99 for 2 hours before fixation for 
co-localization analysis. Post fixation the cells were covered with the ProLong® Diamond Antifade Mountant 
with DAPI before imaging on a LSM 710 confocal laser-scanning microscope. 
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A) Average particles per field for cells incubated with αGal-Alexa 
 
      
 
B) Average particles per field for cells incubated with Aco-αGal-Alexa 
 
 
 
Figure 3-25: Quantification of uptake of αGal-Alexa and Aco-αGal-Alexa in U2OS and U2OS-
SRA cells from Figure 3-24. 
Confocal images were analyzed using ImageJ. A) cells incubated with αGal-Alexa, B) cells incubated 
with Aco-αGal-Alexa. Values included in table are average particles per Field for n = 20 cells 
imaged.  
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Table 3-3: ImageJ particle analysis of Aco (+, -) αGal in U2OS and U2OS-SRA cells from 
Figure 3-24. 
Average # of particles per filed 
Aco  + - 
Cells U2OS U2OS-SRA U2OS U2OS-SRA 
Alexa 12 ± 9 100 ± 74 159 ± 159 192  ±20 
LysoTracker 159 ± 104 192 ± 20 217 ± 96 185 ± 31 
Co-localized 8 ± 7 45 ± 14 66 ± 52 109 ± 18 
Note. Values included in table are average particles per Field (n = 20 cells imaged).  
 
 
 
In order to confirm targeting of Aco-αGal to the SR in U2OS-SRA cells, uptake was analyzed in 
the presence and absence of the SR inhibitor PolyI (Figure 3-26). This experiment showed that 
addition of PolyI completely inhibited uptake of Aco-αGal-Alexa in U2OS-SRA cells with no 
green fluorescence being detectable in the presence of the inhibitor after a 2-hour incubation 
(Figure 3-26B). This inhibition indicates that the primary pathway of uptake of Aco-αGal-Alexa 
in these cells is through the scavenger receptor uptake pathway. 
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A) Confocal Image of representative field 
 
Inhibitor Aco-αGal-Alexa LysoTracker Red DAPI Co-localization 
- PolyI 
    
+PolyI 
    
 
B) ImageJ particle analysis of all fields 
 
 Alexa LysoTracker Co-localized 
PolyI - + - + - + 
Average 
Per Field 30 ± 26 0 172  ± 72 89 ± 26 22 ± 23 0 
 
Figure 3-26: Uptake of Aco-αGal-Alexa in U2OS-SRA cells (+, -) PolyI inhibition. 
Aco-αGal-Alexa was incubated in U2OS-SRA cells for 2 hour with and without 100 µg/ml PolyI at 37˚C and 
5% CO2. Cells were counterstained with LysoTracker Red DND-99 for 2 hours before fixation for co-
localization analysis. A) Representative image taken with a ZEISS LSM 880 confocal laser-scanning 
microscope B) ImageJ particle analysis of all fields, mean and Standard deviation for n = 30-35 cells. 
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αGal is targeted to the scavenger receptor uptake pathway in U2OS-SRA cells 
Uptake of Alexa488 tagged recombinant αGal was monitored in U2OS-SRA cells as a control. 
U2OS-SRA cells are human U2OS osteosarcoma cells over-expressing the murine scavenger 
receptor, making them an ideal candidate for analyzing targeting to the scavenger receptors. 
αGal-Alexa was incubated for two hours with cells with and without the scavenger receptor 
inhibitor PolyI. Images were acquired of approximately 20 cells per well and analyzed. (Figure 
3-27) Interestingly the addition of PolyI to the wells seems to have completely inhibited uptake 
of the recombinant αGal in this cell type. This suggests that the enzyme produced in P. pastoris 
may already be targeting to the scavenger receptor to some extent.  
Inhibitor αGal-Alexa LysoTracker Red DAPI Co-localization 
-PolyI 
    
+PolyI 
    
 
Figure 3-27:Uptake of αGal-Alexa in U2OS-SRA cells: Representative images. 
Uptake of αGal-Alexa (5 ug/ml) in U2OS-SRA cells post 2 hour incubation at 37˚C and 5% CO2. Cells were 
incubated with Alexa tagged αGal and counterstained with LysoTracker Red DND-99 for 2 hours before 
fixation for co-localization analysis. Post fixation the cells were covered with the ProLong® Diamond 
Antifade Mountant with DAPI before imaging on a LSM 710 confocal laser-scanning microscope. 
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Aconitylation improves targeting of αGal to lysosomes in IMFE1 endothelial 
cells  
In order to compare the uptake and targeting to the lysosomes of aconitylated and non 
aconitylated αGal in IMFE1 endothelial cells, a time course uptake study was done using Aco-
αGal-Alexa (Figure 3-28) to mimic what was done with non-Aco-αGal (Figure 3-12).  
 
Incubation Aco-αGal-Alexa  LysoTracker Red DAPI Co-localization 
0.5 hr 
    
2hr 
    
19hr 
    
 
Figure 3-28: Time course uptake of Aco-αGal-Alexa in IMFE1 cells. 
Aco-αGal-Alexa (5 ug/ml) in IMFE1 cells post 0.5, 2, and 19-hour incubation at 37˚C and 5% CO2. Cells were 
counterstained with LysoTracker Red DND-99 for 2 hours before fixation for co-localization analysis and 
images taken on a LSM 710 confocal laser-scanning microscope. 
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Table 3-4: ImageJ particle analysis of Aco (+, -) αGal time course uptake in IMFE1 cells. 
Average # of particles per filed 
Aco + - 
Incubation 
(hr) 0.5 2 19 0.5 2 19 
Alexa 18 ± 3 24 ± 29 96 ± 45 10 ± 10 73 ± 27 110 ± 35 
Co-localized 4 ± 5 10 ± 20 50 ± 30 6 ± 8 17 ± 19 42 ± 13 
% Co-localized* 22 ± 27 36 ± 32 50 ± 18 58 ± 43 24 ± 23 41 ± 13 
 Note. Values included in table are average particles per field (n = 15-20 cells imaged).  
*% Co-localized = "#$%#&'%()*+,%*-' 	×	100  
 
Initial time course analysis with αGal (Figure 3-13, 3-29A) indicates that αGal is initially taken 
up at a higher rate (t <3hrs) and that uptake plateaus with longer incubation times (19-hours) in 
IMFE1 cells. In the case of Aco-αGal however this relationship seems to be more linear with 
uptake increasing steadily over time (Figure 3-29B). Compression of the uptake of aconitylated 
and non-aconitylated αGal shows that at t = 0.5 hours, Aco-αGal is taken up better (18 ± 3 Alexa 
particles) than non-Aco-αGal (10 ± 10 Alexa particles) in IMFE1cells with the difference being 
close to 4-fold once the ~50% loss in specific activity of the aconitylated sample is taken into 
account.  
Comparing the amount of Aco (+, -) αGal co-localized with the lysosomes, we see that a higher 
percentage of internalized enzyme are targeted to the lysosomes (% co-localized) in the case of 
Aco-αGal with this percentage steadily increasing with the increase of overall uptake over the 
three time points measured (22% ® 36% ® 50%). In contrast, the growth of % co-localization 
seems to be much slower in non-Aco-αGal (58% ® 24% ® 41%) (Table 3-4). 
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A) Uptake of αGal-Alexa in IMFE1 cells 
 
 
 
B) Uptake of Aco-αGal-Alexa in IMFE1 cells 
     	  
 
Figure 3-29: Particle analysis of time course uptake of Aco-αGal-Alexa in IMFE1 cells from 
Figure (3-13, 3-28). 
A) αGal-Alexa (5 ug/ml) B) Aco-αGal-Alexa (5 ug/ml) in IMFE1 cells post 0.5, 2, and 19-hour 
incubation at 37˚C and 5% CO2. Uptake was quantified using ImageJ as described in methods. 
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αGal produced in Pichia is targeted to the mannose receptor 
To further investigate potential receptors involved in the uptake of the aconitylated and non-
aconitylated αGal produced in yeast, uptake of these enzymes was monitored in the presence of 
M6P and Mannan and scavenger receptor inhibitors PolyI, Aco-HSA, and Ac-LDL in an 
overnight uptake experiment (Figure 3-30A, 3-31A) by enzyme assay and with a combination of 
Mannon and PolyI during a 2-hour incubation (Figure 3-30B, 3-31B) using confocal microscopy. 
Our results indicated a reduction of approximately 80% in uptake overnight and approximately 
40% after 2 hours when the MR is inhibited indicating that in IMFE1 cells this is the major 
pathway for uptake of non-Aco-αGal (Figure 3-30). 
SR inhibitors PolyI, Aco-HSA, and Ac-LDL had no effect on uptake of non-aconitylatd αGal in 
IMFE1 cells (Figure 3-30). Therefore, despite our previouse results indicating αGal ability to 
target to scavenger receptors (Figure 3-27), the scavenger receptor does not contribute very much 
to the overall uptake of αGal uptake in IMFE1 cells. Unexpectedly, these inhibitors increased 
uptake in the case of Aco-αGal both in overnight studies measured with enzyme assay (Figure 3-
31A) as well as confocal studies where uptake was analyzed using imageJ (Figure 3-31B). The 
reason for this increase in uptake when the scavenger receptor is inhibited is unknown but one 
reason may be due to competition between the mannose and scavenger receptors for Aco-αGal. 
This is further demonstrated when both receptors are inhibited (Figure 3-31B). In this case, the 
uptake of Aco-αGal is decreased more than with mannan alone indicating both receptors are 
playing a role in the uptake of Aco-αGal. 
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A) Overnight (19 hours) incubation 
 
 
 
B) 2-hour incubation 
 
 
 
Average # of particles of Alexa per field 
Inhibitor No Inhibitor Mannan PolyI 
Non-Aco-αGal 78 ± 27 46 ± 55 86 ± 41 
 
Figure 3-30: Effect of inhibitors on uptake of non-Aco-αGal in IMFE1 cells. 
A) αGal (6 µg/ml) were incubated overnight (19 hours) at 37˚C and 5% CO2 in IMFE1 
cells post. The effect of 5mM M6P, 2 mg/ml Mannan, 10 µg/ml Aco-HSA, and 100 µg/ml 
Poly(I) were tested in duplicate. Uptake was quantified using enzyme assay, B) Uptake of 
αGal-Alexa (5 ug/ml) in IMFE1 cells post 2-hour incubation at 37˚C and 5% CO2. The 
effect of 2 mg/ml Mannan and 100 µg/ml Poly(I) were tested. Uptake analyzed by confocal 
microscopy. Results are displayed as % of control (No Inhibitor = 100%). 
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A) Overnight (19 hours) incubation 
 
 
 
B) 2-hour incubation 
 
 
 
Average # of particles of Alexa per field 
Inhibitor(s) No Inhibitor Mannan PolyI PolyI + Mannan 
Aco-αGal 56 ± 68 41 ± 69 69 ± 55 20 ± 22 
 
Figure 3-31: Effect of inhibitors on uptake of Aco-αGal in IMFE1 cells. 
A) Aco-αGal (6 µg/ml) were incubated overnight (19 hours) at 37˚C and 5% CO2 in IMFE1 
cells post. The effect of 5mM M6P, 2 mg/ml Mannan, 10 µg/ml Aco-HSA, and 100 µg/ml 
Poly(I) were tested in duplicate. Uptake was quantified using enzyme assay, B) Uptake of 
Aco-αGal-Alexa (5 ug/ml) in IMFE1 cells post 2-hour incubation at 37˚C and 5% CO2. 
The effect of 2 mg/ml Mannan and 100 µg/ml Poly(I) were tested. Uptake analyzed by 
confocal microscopy. Results are displayed as % of control (No Inhibitor = 100%). 
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Measurement of the degree of aconitylation of αGal  
We synthesized Aconitylated αGal by reacting the ε-NH2  group of lysine residues of 
approximately 1 mg/ml of purified αGal in Buffer A at a pH of 7.5 with excess cis-aconitic 
anhydride (SIGMA) as preformed with the positive control HSA and described in literature [165, 
167, 176]. The pH of the reaction mixture was adjusted to 7.5 post anhydride addition with 1M 
NaOH and was then stirred at 4˚C for approximately 1.5 hours. Either dialysis or a Sephadex G-
25 column were used to remove excess anhydride.  
The degree of modification of lysines was assessed by estimating the loss of free amino groups 
and using a glycine standard curve as measured by TNBS assay [182] and the more sensitive 
fluorescamine assay [113] post removal of excess anhydride. In addition, 2D electrophoresis was 
done on the pre-and post aconitylated samples as described in the previous section for HSA 
(Figure 3-19, 3-20).  
Table 3-5: Overview of αGal aconitylation samples 
Aco-αGal sample 
Conc. 
Anhydride 
added 
% Aconitylation 
Fluorescamine 
% Aconitylation 
TNBS 
MMII112 1X NA 47 
63.61 1X -6 NA 
63.66 1X -5 NA 
63.71 5X -53 -183 
63.73 2X -15 NA 
63.74 2X -35 -378 
63.83 2X 11 -32 
60.28 2X -20 NA 
40.22 (Δ4) 2X -16 NA 
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Aconitylation was performed on multiple preparations of recombinant αGal. Initially it was 
observed by TNBS assay that the αGal sample was successfully aconitylated (Table 3-5). These 
aconitylated samples were tagged with Alexa488 and confocal studies were subsequently 
performed. Upon further testing with the TNBS assay it was observed that there is large 
variability between replicates in this assay with the signal being very low above background. 
Therefore, the more sensitive fluorescamine assay was used to confirm aconitylation of samples. 
This assay indicated that no aconitylation had taken place in either of the preparations (Table 3-
5). Because of the puzzling nature of this result IEF was done on all aconitylated and non-
aconitylated samples to clarify the issue.  
IEF gels were run as described earlier, in all gels except for one, non-aconitylated αGal presented 
as a broad band as opposed to a sharp band as we had anticipated indicating our recombinant 
sample is present as a mixture containing varying negative charge (Figure 3-32A). There was no 
difference observed in the native PAGE (3-32B) and IEF gels (Figure 3-32A) for aconitylated 
and non-aconitylated αGal. When these bands were run on the second dimension SDS-PAGE it 
further confirmed that this method could not be used to confirm aconitylation of our samples 
(Figure 3-32C, 3-32D). This inability to confirm aconitylation using TNBS assay, fluorescamine 
assay, and IEF gels conflicts with the results we see in confocal uptake studies with aconitylated 
and non-aconitylated αGal. 
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 (A) Isoelectric focusing gel               (B) native PAGE 
                                                              
 
   (C)            (D)  
 
 
 
Figure 3-32: Gel electrophoresis of representative αGal and Aco- αGal samples. 
A) IEF and B) Native PAGE were performed under non-denaturing conditions on 
αGal and Aco-αGal samples. Lanes containing C) αGal and D) Aco-αGal were cut out 
of the IEF gel and run on a NuPAGE® 4-12% Bis-Tris Protein Gels with a 2D-well to 
separate focused proteins by mass according to manufacturer specifications. 
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Discussion: 
Our findings suggest that the recombinant αGal produced in P. pastoris is taken up by the MR 
and by the SR uptake pathways and that aconitylation of αGal increases the uptake by the SR 
resulting in better delivery of enzyme to lysosomes in Fabry endothelial cells. Our results also 
confirm that aconitylation of HSA improves uptake and delivery to the lysosomes. 
The two therapeutics currently available for ERT are expressed in Chinese Hamster Ovary 
(CHO) cells used by Genzyme and HT1080 (fibroblasts derived from fibrosarcoma) used by 
Shire. The use of these mammalian cell lines is due in part to their ability to perform human-like 
glycosylation containing M6P, promoting uptake of the therapeutic by the M6P pathway. It was 
initially assumed that targeting to the M6P pathway is necessary for ERT therapy in LSD such as 
Fabry disease. However, more recent results indicate that mannose terminated forms of human 
αGal produced in moss (moss-αGal) [1] as well as tobacco cells [70] (PRX-102, chemically 
modified, resulting in a cross-linked dimer of PEGylated subunits increasing enzyme stability) 
are taken up by different cells types and are successful in clearing substrate in both in-vitro and 
in-vivo studies. Although the mechanism of uptake for PRX-102 is unknown, the mannose 
terminated moss-αGal is shown to be taken up by the MR (Figure 3-33). Shen et. al. suggested 
that mannose-terminated enzymes can be more effective than M6P terminated enzymes in the 
treatment of Fabry disease, and that M6P residues may not always be a prerequisite for ERT as 
previously assumed. These newly developed recombinant enzymes are among 122 other Fabry 
disease therapies currently in clinical trials (ClinicalTrials.gov). 
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Unlike mammalian glycosylation patterns which are phosphorylated and composed of sugars 
terminated with sialic acid residues, enzymes produced in P. pastoris contain a simpler form of 
glycan known as high mannose (Figure 3 34).  These glycans are composed of two core N-
acetylglucosamine residues and ramified mannoses (Figure 3-34) The MR has been shown to be 
present on endothelial cells [1] a major site of accumulation of GB3 in Fabry disease. Our results 
show that our recombinant high mannose αGal produced in P. pastoris is mainly targeting the 
MR as indicated by a reduction of approximately 80% in uptake overnight and approximately 
40% after 2 hours of incubation in the presence of mannan (Figure 3-29). We also show that 
αGal expressed in P. pastoris is taken up more readily in immortalized Fabry endothelial cells 
(IMFE1) than in Fabry fibroblast cells (Figure 3-16A) which contain low levels of MR[1]. 
Published results indict the therapeutic αGal with M6P regulated uptake is more efficient in 
A)      B) 
 
        
 
Figure 3-33: Uptake of moss αGal [1]. 
A) Uptake rates of different enzymes in IMFE1 cells. Cells were harvested at indicated 
time points and intracellular activities were measured. ***P < 0.001, moss-αGal vs. high 
mannose (high-mann) moss-αGal or agalsidase alfa (current therapeutic). B) Intracellular 
αGal activities of IMFE1 cells after overnight incubation with different enzymes in the 
presence or absence of M6P or mannan.  
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fibroblast than endothelial cells (Figure 3-16B). This better delivery to endothelial cells could 
prove to be tremendously advantageous in ERT in both Fabry disease and other LSDs.  
 
SRs are a diverse group comprised of membrane proteins and soluble secreted extracellular 
domain isoforms with the ability to recognize common ligands such as poly-ionic ligands 
including lipoproteins, apoptotic cells, cholesterol esters, phospholipids, proteoglycans, ferritin, 
and carbohydrates. SRs are grouped into subclasses with little to no primary sequence similarity 
between each class. HSA was aconitylated and the change in charge of the protein was 
confirmed by TNBS Assay as well as isoelectric focusing gels (Figure 3-19, 3-20). This 
negatively charged Aco-HSA was fluorescently tagged with Alexa 488 and was shown to target 
more readily than non-Aco-HSA to the lysosomes in NFB cells, using confocal microscopy 
(Figure 3-21). In addition, confocal studies in U2OS as well as U2OS-SRA cells showed that 
 
 
Figure 3-34: Types of N-glycans. 
The three different types (High Mannose, Complex and Hybrid) share a common core 
structure including the first two N-acetylglucosamine residues and the first three mannose 
residues.[11] 
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aconitylated HSA is taken up more readily in U2OS-SRA cells than in U2OS cells after a short 
incubation time of 2 hours. This difference is narrowed after overnight incubation where uptake 
seems to plateau in both cells types (Figure 3-22). U2OS cells contain low levels of the type A 
scavenger receptor SRABA5 [183], this may be the reason we are able to see uptake of Aco-
HSA in U2OS cells overnight.  
Mimicking trends seen in the HSA control, aconitylation of αGal also resulted in targeting of the 
enzyme to the scavenger receptor as demonstrated by complete inhibition of uptake in U2OS-
SRA cells post incubation with the scavenger receptor inhibitor PolyI (Figure 3-26). 
Interestingly, non-Aco-αGal was also shown to have the potential to target to the scavenger 
receptor uptake pathway (Figure 3-27). αGal is a negatively charged enzyme (Figure 3-35) 
which is most likely why it is targeted to the scavenger receptors in this cell type. This is 
however not the major uptake pathway in the more therapeutically relevant IMFE1 cells. 
Inhibition studies done overnight and analyzed using enzyme assay as well as with 2-hour 
 
                 
Figure 3-35: Surface potential of αGal.  
 Image generated in Chimera. 
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incubation (analyzed using confocal microscopy) in IMFE1 cells, revealed that Poly I had no 
major effect on uptake of non-Aco-αGal in these cells (Figure 3-30). In contrast, addition of SR 
inhibitors such as PolyI, Aco-HSA, and Ac-LDL cause an increase in uptake of Aco-αGal in 
IMFE1 cells (Figure 3-31). Our results indicate that in the case of Aco-αGal the mannose and 
scavenger receptor uptake pathways compete for internalization of Aco-αGal with the MR 
resulting in more efficient internalization into the cell while the SR results in faster targeting to 
the lysosomes.  
Further analysis with our αGal sample using confocal uptake studies done on live cells (Figure 3-
9, 3-11) and time course studies in fixed cells (Figure 3-12, 3-13, 3-17) indicate that uptake in 
IMFE1 cells is initially rapid at t < 3 hours and plateaus with a longer incubation time of 19 
hours (Figure 3-13, 3-17). This is in contrast to general trends observed with Aco-αGal in which 
overall uptake as well as percentage of internalized enzyme targeted to the lysosomes (% co-
localized) increases steadily over a period of 19 hours (Figure 3-28B) (Table 3-4). This steady 
increase indicates the potential of Aco-αGal as an 
improved form of therapy and should therefore be 
further analyzed in longer experiments in vitro as well 
as in vivo. 
In contrast to HSA we were unable to confirm 
successful aconitylation of our recombinant αGal. 
TNBS and fluorescamine assays had varying results 
with variable preparations and were consistently 
inconclusive with the number of free surface lysines 
being identified post aconitylation being higher than 
 
 
Figure 3-36: Isoelectric focusing gel 
of Fabrazyme and Replagal. [3] 
Lane 1, Pharmacia IEF standards, pH 
2.5±6.5; lane 2, 10 m g Fabrazyme; 
lane 3, 10 m g Replagal.  
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pre aconitylation. In addition, IEF gels showed no difference between the aconitylated and non-
Aco-αGal samples (Figure 3-32A). Both of these samples appeared as a broad band or as a set of 
bands in the pH range of 4-5. This result poses questions of its own as one would expect the non-
aconitylated αGal sample to appear as a single band on an IEF gel. The therapeutics currently 
being produced in mammalian cells appear to be similar on an IEF gel to the gels performed in 
this lab (Figure 3-32A) [3]. This is consistent with αGal being produced in mammalian cells 
containing negatively charged carbohydrates with M6P and sialic acid components accounting 
for the lower pH range and the variability in charge seen on published IEF gels (Figure 3-36, 3-
37) [19]. Further studies with our recombinant αGal are needed to analyze the reason for the 
pattern we see on our IEF gels. It is unclear how high mannose glycans would have any effect on 
the recombinant protein charge. Another explanation for the multiple charged proteins observed 
could be protein deamidation which may occur during the purification process. 
 
 
Figure 3-37: Comparison of the sizes and charges of 
agalsidase beta [19]. 
(A) Sizes of agalsidase beta (Fbz; Fabrazyme) were 
compared in SDS-PAGE before and after 
deglycosylation using PNGase F digestion. Here, M 
represents the molecular weight marker. (B) Isoelectric 
patterns were analyzed in IEF gel with/without a 
sialidase treatment.  
M a r i a m 	 M e g h d a r i 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
108	
The inability to show aconitylation αGal could also be due to the fact that αGal contains only 
approximately 20 exposed surface lysines while HSA contains about 60 lysines with most of 
them having well-exposed lysine –NH groups making it possible to produce strongly negatively 
charged poly-anionic molecules by reaction with cis aconitic anhydride.  
The argument can therefore be made that the current available therapeutic for ERT, which due to 
the presence of M6P and sialic acid residues is more negatively charged than the recombinant 
αGal produced here, may also be targeted to the scavenger receptor uptake pathway to some 
 
 
Figure 3-38: Comparison of the association of M6P-HSA liposomes and 
AcoHSA liposomes [5]. 
Liver endothelial cells were incubated with	[3H]cholesteryloleyl ether (3H-COE) 
labelled M6P-HSA liposomes (closed bars) and AcoHSA liposomes (open bars) in 
the absence or presence of 0.1 mg/ml M6P-HSA, AcoHSA or 10 mg/ml 
polyinosinic acid. The association of M6P-HSA liposomes and AcoHSA 
liposomes without treatment was taken as 100%. mean±SEM of 3–4 experiments. 
**P<0.001 versus M6P-HSA liposomes without treatment, #P<0.05, ##P<0.001 
versus AcoHSA liposomes without treatment.  
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extent. These results corroborate published data suggesting that coupling M6P-HSA to liposomes 
targets them to both the M6P and scavenger receptor uptake pathways in hepatic stellate and 
endothelial cells (Figure 3-38) [5]. Therefore, enhancing the negative charge on αGal should 
increase this targeting and result in a more efficient enzyme for ERT.  
Conclusions: 
Our overall results indicate the potential for the development of a therapeutic produced in Pichia 
allowing for targeting to the MR with an increase in negative charge resulting in better 
internalization to the lysosomes by targeting to the SRs. The aconitylation procedure results in 
the loss of approximately 50 % in specific activity of αGal and therefore is not ideal for the 
addition of negative charge. One possible solution to adding more negative charge to αGal is to 
construct multi-arm–PEG-αGal-Aco-HSA conjugates, and liposomes encapsulating αGal with 
surface Aco-HSA-targeting (Figure 3-39) Further studies involving construction of these 
conjugates and multi-molecular assemblies composed of recombinant human αGal and 
aconitylated HSA should be evaluated for targeting αGal to the SR uptake system without the 
loss in specific activity seen with aconitylation, offering the potential for a better enzyme for 
ERT. 
 
Figure 3-39: Proposed α-Gal A Conjugates.	
M a r i a m 	 M e g h d a r i 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
110	
Literature Cited: 
 
1.	 Shen	JS,	Busch	A,	Day	TS,	Meng	XL,	Yu	CI,	Dabrowska-Schlepp	P,	et	al.	Mannose	receptor-
mediated	delivery	of	moss-made	alpha-galactosidase	A	efficiently	corrects	enzyme	deficiency	in	Fabry	
mice.	J	Inherit	Metab	Dis.	2016;39(2):293-303.	doi:	10.1007/s10545-015-9886-9.	PubMed	PMID:	
26310963;	PubMed	Central	PMCID:	PMCPMC4754329.	
2.	 Miyamura	N,	Araki	E,	Matsuda	K,	Yoshimura	R,	Furukawa	N,	Tsuruzoe	K,	et	al.	A	carboxy-
terminal	truncation	of	human	alpha-galactosidase	A	in	a	heterozygous	female	with	Fabry	disease	and	
modification	of	the	enzymatic	activity	by	the	carboxy-terminal	domain.	Increased,	reduced,	or	absent	
enzyme	activity	depending	on	number	of	amino	acid	residues	deleted.	J	Clin	Invest.	1996;98(8):1809-17.	
doi:	10.1172/JCI118981.	PubMed	PMID:	8878432;	PubMed	Central	PMCID:	PMCPMC507620.	
3.	 Lee	K,	Jin	X,	Zhang	K,	Copertino	L,	Andrews	L,	Baker-Malcolm	J,	et	al.	A	biochemical	and	
pharmacological	comparison	of	enzyme	replacement	therapies	for	the	glycolipid	storage	disorder	Fabry	
disease.	Glycobiology.	2003;13(4):305-13.	Epub	2003/03/11.	doi:	10.1093/glycob/cwg034.	PubMed	
PMID:	12626384.	
4.	 Shakushiro	K,	Yamasaki	Y,	Nishikawa	M,	Takakura	Y.	Efficient	scavenger	receptor-mediated	
uptake	and	cross-presentation	of	negatively	charged	soluble	antigens	by	dendritic	cells.	Immunology.	
2004;112(2):211-8.	Epub	2004/05/19.	doi:	10.1111/j.1365-2567.2004.01871.x.	PubMed	PMID:	
15147564;	PubMed	Central	PMCID:	PMC1782477.	
5.	 Adrian	JE,	Poelstra	K,	Scherphof	GL,	Molema	G,	Meijer	DK,	Reker-Smit	C,	et	al.	Interaction	of	
targeted	liposomes	with	primary	cultured	hepatic	stellate	cells:	Involvement	of	multiple	receptor	
systems.	J	Hepatol.	2006;44(3):560-7.	doi:	10.1016/j.jhep.2005.08.027.	PubMed	PMID:	16368158.	
6.	 Swart	PJ,	Beljaars	E,	Smit	C,	Pasma	A,	Schuitemaker	H,	Meijer	DK.	Comparative	pharmacokinetic,	
immunologic	and	hematologic	studies	on	the	anti-HIV-1/2	compounds	aconitylated	and	succinylated	
HSA.	J	Drug	Target.	1996;4(2):109-16.	doi:	10.3109/10611869609046269.	PubMed	PMID:	8894971.	
7.	 Chen	Y,	Jin	M,	Egborge	T,	Coppola	G,	Andre	J,	Calhoun	DH.	Expression	and	characterization	of	
glycosylated	and	catalytically	active	recombinant	human	alpha-galactosidase	A	produced	in	Pichia	
pastoris.	Protein	Expr	Purif.	2000;20(3):472-84.	Epub	2000/11/23.	doi:	10.1006/prep.2000.1325	
S1046-5928(00)91325-1	[pii].	PubMed	PMID:	11087687.	
8.	 Chen	Y,	Jin	M,	Goodrich	L,	Smith	G,	Coppola	G,	Calhoun	DH.	Purification	and	characterization	of	
human	alpha-galactosidase	A	expressed	in	insect	cells	using	a	baculovirus	vector.	Protein	Expr	Purif.	
2000;20(2):228-36.	PubMed	PMID:	11049747.	
9.	 Coppola	G,	Yan	Y,	Hantzopoulos	P,	Segura	E,	Stroh	JG,	Calhoun	DH.	Characterization	of	
glycosylated	and	catalytically	active	recombinant	human	alpha-galactosidase	A	using	a	baculovirus	
vector.	Gene.	1994;144(2):197-203.	Epub	1994/07/08.	PubMed	PMID:	8039705.	
10.	 Garman	SC,	Garboczi	DN.	The	molecular	defect	leading	to	Fabry	disease:	structure	of	human	
alpha-galactosidase.	J	Mol	Biol.	2004;337(2):319-35.	Epub	2004/03/09.	doi:	10.1016/j.jmb.2004.01.035.	
PubMed	PMID:	15003450.	
11.	 Higel	F,	Seidl	A,	Sorgel	F,	Friess	W.	N-glycosylation	heterogeneity	and	the	influence	on	structure,	
function	and	pharmacokinetics	of	monoclonal	antibodies	and	Fc	fusion	proteins.	European	journal	of	
pharmaceutics	and	biopharmaceutics	:	official	journal	of	Arbeitsgemeinschaft	fur	Pharmazeutische	
Verfahrenstechnik	eV.	2016;100:94-100.	Epub	2016/01/18.	doi:	10.1016/j.ejpb.2016.01.005.	PubMed	
PMID:	26775146.	
12.	 Hantzopoulos	PA,	Calhoun	DH.	Expression	of	the	human	alpha-galactosidase	A	in	Escherichia	coli	
K-12.	Gene.	1987;57(2-3):159-69.	PubMed	PMID:	2826294.	
M a r i a m 	 M e g h d a r i 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
111	
13.	 Kusiak	JW,	Quirk	JM,	Brady	RO.	Purification	and	properties	of	the	two	major	isozymes	of	alpha-
galactosidase	from	human	placenta.	J	Biol	Chem.	1978;253(1):184-90.	PubMed	PMID:	201618.	
14.	 Guce	A,	Garman	S.	The	Structure	of	Human	α-Galactosidase	A	and	Implications	for	Fabry	
Disease.	In:	Elstein	D,	Altarescu	G,	Beck	M,	editors.	Fabry	Disease:	Springer	Netherlands;	2010.	p.	21-38.	
15.	 Marchesan	D,	Cox	TM,	Deegan	PB.	Lysosomal	delivery	of	therapeutic	enzymes	in	cell	models	of	
Fabry	disease.	J	Inherit	Metab	Dis.	2012;35(6):1107-17.	Epub	2012/03/28.	doi:	10.1007/s10545-012-
9472-3.	PubMed	PMID:	22450713.	
16.	 Dean	KJ,	Sweeley	CC.	Studies	on	human	liver	alpha-galactosidases.	I.	Purification	of	alpha-
galactosidase	A	and	its	enzymatic	properties	with	glycolipid	and	oligosaccharide	substrates.	J	Biol	Chem.	
1979;254(20):9994-10000.	PubMed	PMID:	39940.	
17.	 de	Boer	AG,	van	der	Sandt	IC,	Gaillard	PJ.	The	role	of	drug	transporters	at	the	blood-brain	
barrier.	Annu	Rev	Pharmacol	Toxicol.	2003;43:629-56.	doi:	
10.1146/annurev.pharmtox.43.100901.140204.	PubMed	PMID:	12415123.	
18.	 Habeeb	AF.	Determination	of	free	amino	groups	in	proteins	by	trinitrobenzenesulfonic	acid.	Anal	
Biochem.	1966;14(3):328-36.	Epub	1966/03/01.	PubMed	PMID:	4161471.	
19.	 Sohn	Y,	Lee	JM,	Park	HR,	Jung	SC,	Park	TH,	Oh	DB.	Enhanced	sialylation	and	in	vivo	efficacy	of	
recombinant	human	alpha-galactosidase	through	in	vitro	glycosylation.	BMB	Rep.	2013;46(3):157-62.	
PubMed	PMID:	23527859;	PubMed	Central	PMCID:	PMCPMC4133871.	
20.	 Meghdari	M,	Gao	N,	Abdullahi	A,	Stokes	E,	Calhoun	DH.	Carboxyl-terminal	truncations	alter	the	
activity	of	the	human	alpha-galactosidase	A.	PLoS	One.	2015;10(2):e0118341.	doi:	
10.1371/journal.pone.0118341.	PubMed	PMID:	25719393;	PubMed	Central	PMCID:	PMCPMC4342250.	
21.	 Guce	AI,	Clark	NE,	Salgado	EN,	Ivanen	DR,	Kulminskaya	AA,	Brumer	H,	3rd,	et	al.	Catalytic	
mechanism	of	human	alpha-galactosidase.	J	Biol	Chem.	2010;285(6):3625-32.	doi:	
10.1074/jbc.M109.060145.	PubMed	PMID:	19940122;	PubMed	Central	PMCID:	PMCPMC2823503.	
22.	 Pluddemann	A,	Neyen	C,	Gordon	S.	Macrophage	scavenger	receptors	and	host-derived	ligands.	
Methods.	2007;43(3):207-17.	Epub	2007/10/09.	doi:	10.1016/j.ymeth.2007.06.004.	PubMed	PMID:	
17920517.	
23.	 Schiffmann	R,	Waldek	S,	Benigni	A,	Auray-Blais	C.	Biomarkers	of	Fabry	disease	nephropathy.	Clin	
J	Am	Soc	Nephrol.	2010;5(2):360-4.	doi:	10.2215/CJN.06090809.	PubMed	PMID:	19965549.	
24.	 Srimanee	A,	Regberg	J,	Hallbrink	M,	Vajragupta	O,	Langel	U.	Role	of	scavenger	receptors	in	
peptide-based	delivery	of	plasmid	DNA	across	a	blood-brain	barrier	model.	Int	J	Pharm.	2016;500(1-
2):128-35.	doi:	10.1016/j.ijpharm.2016.01.014.	PubMed	PMID:	26773601.	
25.	 Desnick	RJ,	Dean	KJ,	Grabowski	G,	Bishop	DF,	Sweeley	CC.	Enzyme	therapy	in	Fabry	disease:	
differential	in	vivo	plasma	clearance	and	metabolic	effectiveness	of	plasma	and	splenic	alpha-
galactosidase	A	isozymes.	Proc	Natl	Acad	Sci	U	S	A.	1979;76(10):5326-30.	PubMed	PMID:	228284;	
PubMed	Central	PMCID:	PMCPMC413135.	
26.	 Bishop	DF,	Desnick	RJ.	Affinity	purification	of	alpha-galactosidase	A	from	human	spleen,	
placenta,	and	plasma	with	elimination	of	pyrogen	contamination.	Properties	of	the	purified	splenic	
enzyme	compared	to	other	forms.	J	Biol	Chem.	1981;256(3):1307-16.	PubMed	PMID:	6256390.	
27.	 Ishii	S,	Suzuki	Y,	Fan	JQ.	Role	of	Ser-65	in	the	activity	of	alpha-galactosidase	A:	characterization	
of	a	point	mutation	(S65T)	detected	in	a	patient	with	Fabry	disease.	Arch	Biochem	Biophys.	
2000;377(2):228-33.	doi:	10.1006/abbi.2000.1743.	PubMed	PMID:	10845698.	
28.	 Sugawara	K,	Tajima	Y,	Kawashima	I,	Tsukimura	T,	Saito	S,	Ohno	K,	et	al.	Molecular	interaction	of	
imino	sugars	with	human	alpha-galactosidase:	Insight	into	the	mechanism	of	complex	formation	and	
pharmacological	chaperone	action	in	Fabry	disease.	Mol	Genet	Metab.	2009;96(4):233-8.	Epub	
2009/02/03.	doi:	10.1016/j.ymgme.2008.12.017.	PubMed	PMID:	19181556.	
29.	 Ishii	S,	Chang	HH,	Kawasaki	K,	Yasuda	K,	Wu	HL,	Garman	SC,	et	al.	Mutant	alpha-galactosidase	A	
enzymes	identified	in	Fabry	disease	patients	with	residual	enzyme	activity:	biochemical	characterization	
M a r i a m 	 M e g h d a r i 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
112	
and	restoration	of	normal	intracellular	processing	by	1-deoxygalactonojirimycin.	Biochem	J.	
2007;406(2):285-95.	doi:	10.1042/BJ20070479.	PubMed	PMID:	17555407;	PubMed	Central	PMCID:	
PMCPMC1948963.	
30.	 Tsukimura	T,	Chiba	Y,	Ohno	K,	Saito	S,	Tajima	Y,	Sakuraba	H.	Molecular	mechanism	for	
stabilization	of	a	mutant	alpha-galactosidase	A	involving	M51I	amino	acid	substitution	by	imino	sugars.	
Mol	Genet	Metab.	2011;103(1):26-32.	Epub	2011/03/01.	doi:	10.1016/j.ymgme.2011.01.013.	PubMed	
PMID:	21353612.	
31.	 Vairo	FP,	Boczek	NJ,	Cousin	MA,	Kaiwar	C,	Blackburn	PR,	Conboy	E,	et	al.	The	prevalence	of	
diseases	caused	by	lysosome-related	genes	in	a	cohort	of	undiagnosed	patients.	Mol	Genet	Metab	Rep.	
2017;13:46-51.	doi:	10.1016/j.ymgmr.2017.08.001.	PubMed	PMID:	28831385;	PubMed	Central	PMCID:	
PMCPMC5554961.	
32.	 Peake	RW,	Bodamer	OA.	Newborn	Screening	for	Lysosomal	Storage	Disorders.	J	Pediatr	Genet.	
2017;6(1):51-60.	doi:	10.1055/s-0036-1593843.	PubMed	PMID:	28180027;	PubMed	Central	PMCID:	
PMCPMC5288002.	
33.	 Matern	D,	Gavrilov	D,	Oglesbee	D,	Raymond	K,	Rinaldo	P,	Tortorelli	S.	Newborn	screening	for	
lysosomal	storage	disorders.	Semin	Perinatol.	2015;39(3):206-16.	doi:	10.1053/j.semperi.2015.03.005.	
PubMed	PMID:	25891428.	
34.	 Desnick	RJ,	Brady	R,	Barranger	J,	Collins	AJ,	Germain	DP,	Goldman	M,	et	al.	Fabry	disease,	an	
under-recognized	multisystemic	disorder:	expert	recommendations	for	diagnosis,	management,	and	
enzyme	replacement	therapy.	Ann	Intern	Med.	2003;138(4):338-46.	Epub	2003/02/15.	doi:	200302180-
00014	[pii].	PubMed	PMID:	12585833.	
35.	 Schiffmann	R,	Warnock	DG,	Banikazemi	M,	Bultas	J,	Linthorst	GE,	Packman	S,	et	al.	Fabry	
disease:	progression	of	nephropathy,	and	prevalence	of	cardiac	and	cerebrovascular	events	before	
enzyme	replacement	therapy.	Nephrol	Dial	Transplant.	2009;24(7):2102-11.	Epub	2009/02/17.	doi:	
10.1093/ndt/gfp031.	PubMed	PMID:	19218538;	PubMed	Central	PMCID:	PMC2698092.	
36.	 Wilcox	WR,	Banikazemi	M,	Guffon	N,	Waldek	S,	Lee	P,	Linthorst	GE,	et	al.	Long-term	safety	and	
efficacy	of	enzyme	replacement	therapy	for	Fabry	disease.	Am	J	Hum	Genet.	2004;75(1):65-74.	Epub	
2004/05/22.	doi:	10.1086/422366	
S0002-9297(07)61994-6	[pii].	PubMed	PMID:	15154115;	PubMed	Central	PMCID:	PMC1182009.	
37.	 Banikazemi	M,	Bultas	J,	Waldek	S,	Wilcox	WR,	Whitley	CB,	McDonald	M,	et	al.	Agalsidase-beta	
therapy	for	advanced	Fabry	disease:	a	randomized	trial.	Ann	Intern	Med.	2007;146(2):77-86.	PubMed	
PMID:	17179052.	
38.	 Germain	DP.	Fabry	disease.	Orphanet	J	Rare	Dis.	2010;5:30.	Epub	2010/11/26.	doi:	
10.1186/1750-1172-5-30.	PubMed	PMID:	21092187;	PubMed	Central	PMCID:	PMC3009617.	
39.	 Spada	M,	Pagliardini	S,	Yasuda	M,	Tukel	T,	Thiagarajan	G,	Sakuraba	H,	et	al.	High	incidence	of	
later-onset	fabry	disease	revealed	by	newborn	screening.	American	journal	of	human	genetics.	
2006;79(1):31-40.	Epub	2006/06/15.	doi:	10.1086/504601.	PubMed	PMID:	16773563;	PubMed	Central	
PMCID:	PMC1474133.	
40.	 Nelson	DL.	Lehninger	principles	of	biochemistry.	7th	edition.	ed.	New	York,	NY:	W.	H.	Freeman;	
2016.	pages	cm	p.	
41.	 Ioannou	YA,	Zeidner	KM,	Grace	ME,	Desnick	RJ.	Human	alpha-galactosidase	A:	glycosylation	site	
3	is	essential	for	enzyme	solubility.	Biochem	J.	1998;332	(	Pt	3):789-97.	PubMed	PMID:	9620884;	
PubMed	Central	PMCID:	PMCPMC1219542.	
42.	 Garman	SC.	Structure-function	relationships	in	alpha-galactosidase	A.	Acta	Paediatr.	
2007;96(455):6-16.	doi:	10.1111/j.1651-2227.2007.00198.x.	PubMed	PMID:	17391432;	PubMed	Central	
PMCID:	PMCPMC3065945.	
M a r i a m 	 M e g h d a r i 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
113	
43.	 Baehner	F,	Kampmann	C,	Whybra	C,	Miebach	E,	Wiethoff	CM,	Beck	M.	Enzyme	replacement	
therapy	in	heterozygous	females	with	Fabry	disease:	results	of	a	phase	IIIB	study.	J	Inherit	Metab	Dis.	
2003;26(7):617-27.	Epub	2004/01/07.	doi:	5254756	[pii].	PubMed	PMID:	14707510.	
44.	 Christensen	EI,	Zhou	Q,	Sorensen	SS,	Rasmussen	AK,	Jacobsen	C,	Feldt-Rasmussen	U,	et	al.	
Distribution	of	alpha-galactosidase	A	in	normal	human	kidney	and	renal	accumulation	and	distribution	
of	recombinant	alpha-galactosidase	A	in	Fabry	mice.	J	Am	Soc	Nephrol.	2007;18(3):698-706.	Epub	
2007/02/09.	doi:	10.1681/ASN.2006080822.	PubMed	PMID:	17287429.	
45.	 Prabakaran	T,	Nielsen	R,	Larsen	JV,	Sorensen	SS,	Feldt-Rasmussen	U,	Saleem	MA,	et	al.	
Receptor-mediated	endocytosis	of	alpha-galactosidase	A	in	human	podocytes	in	Fabry	disease.	PLoS	
One.	2011;6(9):e25065.	Epub	2011/09/29.	doi:	10.1371/journal.pone.0025065.	PubMed	PMID:	
21949853;	PubMed	Central	PMCID:	PMC3176300.	
46.	 Kampmann	C,	Baehner	F,	Whybra	C,	Martin	C,	Wiethoff	CM,	Ries	M,	et	al.	Cardiac	
manifestations	of	Anderson-Fabry	disease	in	heterozygous	females.	J	Am	Coll	Cardiol.	2002;40(9):1668-
74.	PubMed	PMID:	12427421.	
47.	 MacDermot	KD,	Holmes	A,	Miners	AH.	Anderson-Fabry	disease:	clinical	manifestations	and	
impact	of	disease	in	a	cohort	of	98	hemizygous	males.	J	Med	Genet.	2001;38(11):750-60.	PubMed	PMID:	
11694547.	
48.	 Ries	M,	Gupta	S,	Moore	DF,	Sachdev	V,	Quirk	JM,	Murray	GJ,	et	al.	Pediatric	Fabry	disease.	
Pediatrics.	2005;115(3):e344-55.	Epub	2005/02/17.	doi:	peds.2004-1678	[pii]	
10.1542/peds.2004-1678.	PubMed	PMID:	15713906.	
49.	 Clarke	JT,	West	ML,	Bultas	J,	Schiffmann	R.	The	pharmacology	of	multiple	regimens	of	agalsidase	
alfa	enzyme	replacement	therapy	for	Fabry	disease.	Genet	Med.	2007;9(8):504-9.	Epub	2007/08/21.	doi:	
10.1097GIM.0b013e318133fb1b.	PubMed	PMID:	17700388.	
50.	 Eng	CM,	Guffon	N,	Wilcox	WR,	Germain	DP,	Lee	P,	Waldek	S,	et	al.	Safety	and	efficacy	of	
recombinant	human	alpha-galactosidase	A--replacement	therapy	in	Fabry's	disease.	N	Engl	J	Med.	
2001;345(1):9-16.	Epub	2001/07/07.	doi:	10.1056/NEJM200107053450102.	PubMed	PMID:	11439963.	
51.	 Schiffmann	R,	Kopp	JB,	Austin	HA,	3rd,	Sabnis	S,	Moore	DF,	Weibel	T,	et	al.	Enzyme	replacement	
therapy	in	Fabry	disease:	a	randomized	controlled	trial.	JAMA.	2001;285(21):2743-9.	Epub	2001/06/21.	
doi:	joc10278	[pii].	PubMed	PMID:	11386930.	
52.	 Maier	EM,	Osterrieder	S,	Whybra	C,	Ries	M,	Gal	A,	Beck	M,	et	al.	Disease	manifestations	and	X	
inactivation	in	heterozygous	females	with	Fabry	disease.	Acta	Paediatr	Suppl.	2006;95(451):30-8.	Epub	
2006/05/25.	doi:	10.1080/08035320600618809.	PubMed	PMID:	16720462.	
53.	 Schiffmann	R,	Ries	M,	Timmons	M,	Flaherty	JT,	Brady	RO.	Long-term	therapy	with	agalsidase	alfa	
for	Fabry	disease:	safety	and	effects	on	renal	function	in	a	home	infusion	setting.	Nephrol	Dial	
Transplant.	2006;21(2):345-54.	Epub	2005/10/06.	doi:	10.1093/ndt/gfi152.	PubMed	PMID:	16204287.	
54.	 Ohashi	T,	Sakuma	M,	Kitagawa	T,	Suzuki	K,	Ishige	N,	Eto	Y.	Influence	of	antibody	formation	on	
reduction	of	globotriaosylceramide	(GL-3)	in	urine	from	Fabry	patients	during	agalsidase	beta	therapy.	
Mol	Genet	Metab.	2007;92(3):271-3.	Epub	2007/08/11.	doi:	10.1016/j.ymgme.2007.06.013.	PubMed	
PMID:	17689998.	
55.	 Deegan	PB.	Fabry	disease,	enzyme	replacement	therapy	and	the	significance	of	antibody	
responses.	J	Inherit	Metab	Dis.	2012;35(2):227-43.	Epub	2011/11/01.	doi:	10.1007/s10545-011-9400-y.	
PubMed	PMID:	22037707.	
56.	 Desnick	RJ,	Schuchman	EH.	Enzyme	replacement	and	enhancement	therapies:	lessons	from	
lysosomal	disorders.	Nat	Rev	Genet.	2002;3(12):954-66.	Epub	2002/12/03.	doi:	10.1038/nrg963	
nrg963	[pii].	PubMed	PMID:	12459725.	
M a r i a m 	 M e g h d a r i 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
114	
57.	 Moore	DF,	Ries	M,	Forget	EL,	Schiffmann	R.	Enzyme	replacement	therapy	in	orphan	and	ultra-
orphan	diseases:	the	limitations	of	standard	economic	metrics	as	exemplified	by	Fabry-Anderson	
disease.	Pharmacoeconomics.	2007;25(3):201-8.	Epub	2007/03/06.	PubMed	PMID:	17335306.	
58.	 Brady	RO,	Schiffmann,	R.	Possible	future	therapies	for	Fabry	disease.	In:	Mehta	A,	Beck,	M.,	
Sunder-Plassmann,	editor.	Fabry	Disease	2007	Book2007.	p.	Section	43.	
59.	 Ohashi	T.	Enzyme	replacement	therapy	for	lysosomal	storage	diseases.	Pediatr	Endocrinol	Rev.	
2012;10	Suppl	1:26-34.	Epub	2013/01/22.	PubMed	PMID:	23330243.	
60.	 Ziegler	RJ,	Cherry	M,	Barbon	CM,	Li	C,	Bercury	SD,	Armentano	D,	et	al.	Correction	of	the	
biochemical	and	functional	deficits	in	fabry	mice	following	AAV8-mediated	hepatic	expression	of	alpha-
galactosidase	A.	Mol	Ther.	2007;15(3):492-500.	PubMed	PMID:	17191071.	
61.	 Ziegler	RJ,	Lonning	SM,	Armentano	D,	Li	C,	Souza	DW,	Cherry	M,	et	al.	AAV2	vector	harboring	a	
liver-restricted	promoter	facilitates	sustained	expression	of	therapeutic	levels	of	alpha-galactosidase	A	
and	the	induction	of	immune	tolerance	in	Fabry	mice.	Mol	Ther.	2004;9(2):231-40.	PubMed	PMID:	
14759807.	
62.	 Przybylska	M,	Wu	IH,	Zhao	H,	Ziegler	RJ,	Tousignant	JD,	Desnick	RJ,	et	al.	Partial	correction	of	the	
alpha-galactosidase	A	deficiency	and	reduction	of	glycolipid	storage	in	Fabry	mice	using	synthetic	
vectors.	J	Gene	Med.	2004;6(1):85-92.	PubMed	PMID:	14716680.	
63.	 Ziegler	RJ,	Li	C,	Cherry	M,	Zhu	Y,	Hempel	D,	van	Rooijen	N,	et	al.	Correction	of	the	nonlinear	dose	
response	improves	the	viability	of	adenoviral	vectors	for	gene	therapy	of	Fabry	disease.	Hum	Gene	Ther.	
2002;13(8):935-45.	PubMed	PMID:	12031126.	
64.	 Li	C,	Ziegler	RJ,	Cherry	M,	Lukason	M,	Desnick	RJ,	Yew	NS,	et	al.	Adenovirus-transduced	lung	as	a	
portal	for	delivering	alpha-galactosidase	A	into	systemic	circulation	for	Fabry	disease.	Mol	Ther.	
2002;5(6):745-54.	PubMed	PMID:	12027559.	
65.	 Ziegler	RJ,	Yew	NS,	Li	C,	Cherry	M,	Berthelette	P,	Romanczuk	H,	et	al.	Correction	of	enzymatic	
and	lysosomal	storage	defects	in	Fabry	mice	by	adenovirus-mediated	gene	transfer.	Hum	Gene	Ther.	
1999;10(10):1667-82.	PubMed	PMID:	10428212.	
66.	 Kim	EY,	Hong	YB,	Lai	Z,	Kim	HJ,	Cho	YH,	Brady	RO,	et	al.	Expression	and	secretion	of	human	
glucocerebrosidase	mediated	by	recombinant	lentivirus	vectors	in	vitro	and	in	vivo:	implications	for	
gene	therapy	of	Gaucher	disease.	Biochem	Biophys	Res	Commun.	2004;318(2):381-90.	PubMed	PMID:	
15120612.	
67.	 Yoshimitsu	M,	Higuchi	K,	Ramsubir	S,	Nonaka	T,	Rasaiah	VI,	Siatskas	C,	et	al.	Efficient	correction	
of	Fabry	mice	and	patient	cells	mediated	by	lentiviral	transduction	of	hematopoietic	stem/progenitor	
cells.	Gene	Ther.	2007;14(3):256-65.	PubMed	PMID:	16929352.	
68.	 Boyd	RE,	Lee	G,	Rybczynski	P,	Benjamin	ER,	Khanna	R,	Wustman	BA,	et	al.	Pharmacological	
Chaperones	as	Therapeutics	for	Lysosomal	Storage	Diseases.	J	Med	Chem.	2013.	Epub	2013/02/01.	doi:	
10.1021/jm301557k.	PubMed	PMID:	23363020.	
69.	 Bethencourt	V.	Virus	stalls	Genzyme	plant.	Nat	Biotechnol.	2009;27(8):681.	doi:	
10.1038/nbt0809-681a	
.	
70.	 Kizhner	T,	Azulay	Y,	Hainrichson	M,	Tekoah	Y,	Arvatz	G,	Shulman	A,	et	al.	Characterization	of	a	
chemically	modified	plant	cell	culture	expressed	human	alpha-Galactosidase-A	enzyme	for	treatment	of	
Fabry	disease.	Mol	Genet	Metab.	2015;114(2):259-67.	doi:	10.1016/j.ymgme.2014.08.002.	PubMed	
PMID:	25155442.	
71.	 Chiba	Y,	Sakuraba	H,	Kotani	M,	Kase	R,	Kobayashi	K,	Takeuchi	M,	et	al.	Production	in	yeast	of	
alpha-galactosidase	A,	a	lysosomal	enzyme	applicable	to	enzyme	replacement	therapy	for	Fabry	disease.	
Glycobiology.	2002;12(12):821-8.	Epub	2002/12/25.	PubMed	PMID:	12499404.	
M a r i a m 	 M e g h d a r i 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
115	
72.	 Goldstein	JL,	Ho	YK,	Basu	SK,	Brown	MS.	Binding	site	on	macrophages	that	mediates	uptake	and	
degradation	of	acetylated	low	density	lipoprotein,	producing	massive	cholesterol	deposition.	Proc	Natl	
Acad	Sci	U	S	A.	1979;76(1):333-7.	Epub	1979/01/01.	PubMed	PMID:	218198;	PubMed	Central	PMCID:	
PMC382933.	
73.	 Grabowski	GA.	Gaucher	disease	and	other	storage	disorders.	Hematology	Am	Soc	Hematol	Educ	
Program.	2012;2012:13-8.	Epub	2012/12/13.	doi:	10.1182/asheducation-2012.1.13.	PubMed	PMID:	
23233555.	
74.	 Desnick	R,	Ioannou,YA,	Eng,CM.	a-Galactosidase	A	defiency:	Fabry	disease.	In:	Scriver	CB,	AL	
Sly,WS	Valle,D,	editor.	The	Metabolic	Basis	of	Inherited	Disease.	New	York:	McGraw-Hill;	1995.	p.	2741-
84.	
75.	 Deduve	C.	From	Cytases	to	Lysosomes.	Fed	Proc.	1964;23:1045-9.	PubMed	PMID:	14209796.	
76.	 Barton	NW,	Brady	RO,	Dambrosia	JM,	Di	Bisceglie	AM,	Doppelt	SH,	Hill	SC,	et	al.	Replacement	
therapy	for	inherited	enzyme	deficiency--macrophage-targeted	glucocerebrosidase	for	Gaucher's	
disease.	N	Engl	J	Med.	1991;324(21):1464-70.	doi:	10.1056/NEJM199105233242104.	PubMed	PMID:	
2023606.	
77.	 Barton	NW,	Furbish	FS,	Murray	GJ,	Garfield	M,	Brady	RO.	Therapeutic	response	to	intravenous	
infusions	of	glucocerebrosidase	in	a	patient	with	Gaucher	disease.	Proc	Natl	Acad	Sci	U	S	A.	
1990;87(5):1913-6.	PubMed	PMID:	2308952;	PubMed	Central	PMCID:	PMCPMC53594.	
78.	 Beutler	E.	Gaucher's	disease.	N	Engl	J	Med.	1991;325(19):1354-60.	doi:	
10.1056/NEJM199111073251906.	PubMed	PMID:	1922238.	
79.	 Beutler	E,	Kay	A,	Saven	A,	Garver	P,	Thurston	D,	Dawson	A,	et	al.	Enzyme	replacement	therapy	
for	Gaucher	disease.	Blood.	1991;78(5):1183-9.	PubMed	PMID:	1878585.	
80.	 Grace	ME,	Balwani	M,	Nazarenko	I,	Prakash-Cheng	A,	Desnick	RJ.	Type	1	Gaucher	disease:	null	
and	hypomorphic	novel	chitotriosidase	mutations-implications	for	diagnosis	and	therapeutic	monitoring.	
Hum	Mutat.	2007;28(9):866-73.	doi:	10.1002/humu.20524.	PubMed	PMID:	17464953.	
81.	 Germain	DP,	Waldek	S,	Banikazemi	M,	Bushinsky	DA,	Charrow	J,	Desnick	RJ,	et	al.	Sustained,	
long-term	renal	stabilization	after	54	months	of	agalsidase	beta	therapy	in	patients	with	Fabry	disease.	J	
Am	Soc	Nephrol.	2007;18(5):1547-57.	doi:	10.1681/ASN.2006080816.	PubMed	PMID:	17409312.	
82.	 Whybra	C,	Schwarting	A,	Kriegsmann	J,	Gal	A,	Mengel	E,	Kampmann	C,	et	al.	IgA	nephropathy	in	
two	adolescent	sisters	heterozygous	for	Fabry	disease.	Pediatr	Nephrol.	2006;21(9):1251-6.	doi:	
10.1007/s00467-006-0176-5.	PubMed	PMID:	16838183.	
83.	 Pintos-Morell	G,	Beck	M.	Fabry	disease	in	children	and	the	effects	of	enzyme	replacement	
treatment.	Eur	J	Pediatr.	2009;168(11):1355-63.	doi:	10.1007/s00431-009-0937-9.	PubMed	PMID:	
19242721;	PubMed	Central	PMCID:	PMCPMC2745529.	
84.	 Schiffmann	R,	Martin	RA,	Reimschisel	T,	Johnson	K,	Castaneda	V,	Lien	YH,	et	al.	Four-year	
prospective	clinical	trial	of	agalsidase	alfa	in	children	with	Fabry	disease.	J	Pediatr.	2010;156(5):832-7,	7	
e1.	doi:	10.1016/j.jpeds.2009.11.007.	PubMed	PMID:	20097359.	
85.	 Nakao	S,	Kodama	C,	Takenaka	T,	Tanaka	A,	Yasumoto	Y,	Yoshida	A,	et	al.	Fabry	disease:	
detection	of	undiagnosed	hemodialysis	patients	and	identification	of	a	"renal	variant"	phenotype.	
Kidney	Int.	2003;64(3):801-7.	doi:	10.1046/j.1523-1755.2003.00160.x.	PubMed	PMID:	12911529.	
86.	 Matsuura	F,	Ohta	M,	Ioannou	YA,	Desnick	RJ.	Human	alpha-galactosidase	A:	characterization	of	
the	N-linked	oligosaccharides	on	the	intracellular	and	secreted	glycoforms	overexpressed	by	Chinese	
hamster	ovary	cells.	Glycobiology.	1998;8(4):329-39.	PubMed	PMID:	9499380.	
87.	 Bekri	S.	Importance	of	glycosylation	in	enzyme	replacement	therapy.	In:	Mehta	A,	Beck	M,	
Sunder-Plassmann	G,	editors.	Fabry	Disease:	Perspectives	from	5	Years	of	FOS.	Oxford2006.	
88.	 Brady	RO,	Schiffmann	R.	Possible	future	therapies	for	Fabry	disease.	In:	Mehta	A,	Beck	M,	
Sunder-Plassmann	G,	editors.	Fabry	Disease:	Perspectives	from	5	Years	of	FOS.	Oxford2006.	
M a r i a m 	 M e g h d a r i 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
116	
89.	 Motabar	O,	Sidransky	E,	Goldin	E,	Zheng	W.	Fabry	disease	-	current	treatment	and	new	drug	
development.	Curr	Chem	Genomics.	2010;4:50-6.	doi:	10.2174/1875397301004010050.	PubMed	PMID:	
21127742;	PubMed	Central	PMCID:	PMCPMC2995157.	
90.	 Ruiz	de	Garibay	AP,	Solinis	MA,	Rodriguez-Gascon	A.	Gene	therapy	for	fabry	disease:	a	review	of	
the	literature.	BioDrugs.	2013;27(3):237-46.	doi:	10.1007/s40259-013-0032-7.	PubMed	PMID:	
23575647.	
91.	 Frustaci	A,	Chimenti	C,	Ricci	R,	Natale	L,	Russo	MA,	Pieroni	M,	et	al.	Improvement	in	cardiac	
function	in	the	cardiac	variant	of	Fabry's	disease	with	galactose-infusion	therapy.	N	Engl	J	Med.	
2001;345(1):25-32.	doi:	10.1056/NEJM200107053450104.	PubMed	PMID:	11439944.	
92.	 Shin	SH,	Murray	GJ,	Kluepfel-Stahl	S,	Cooney	AM,	Quirk	JM,	Schiffmann	R,	et	al.	Screening	for	
pharmacological	chaperones	in	Fabry	disease.	Biochem	Biophys	Res	Commun.	2007;359(1):168-73.	doi:	
10.1016/j.bbrc.2007.05.082.	PubMed	PMID:	17532296;	PubMed	Central	PMCID:	PMCPMC2729584.	
93.	 Suzuki	Y.	Chaperone	therapy	update:	Fabry	disease,	GM1-gangliosidosis	and	Gaucher	disease.	
Brain	Dev.	2013;35(6):515-23.	doi:	10.1016/j.braindev.2012.12.002.	PubMed	PMID:	23290321.	
94.	 Marshall	J,	Ashe	KM,	Bangari	D,	McEachern	K,	Chuang	WL,	Pacheco	J,	et	al.	Substrate	reduction	
augments	the	efficacy	of	enzyme	therapy	in	a	mouse	model	of	Fabry	disease.	PLoS	One.	
2010;5(11):e15033.	doi:	10.1371/journal.pone.0015033.	PubMed	PMID:	21124789;	PubMed	Central	
PMCID:	PMCPMC2991350.	
95.	 Boustany	RM.	Lysosomal	storage	diseases--the	horizon	expands.	Nat	Rev	Neurol.	
2013;9(10):583-98.	doi:	10.1038/nrneurol.2013.163.	PubMed	PMID:	23938739.	
96.	 Brady	RO,	Schiffmann	R.	Enzyme-replacement	therapy	for	metabolic	storage	disorders.	Lancet	
Neurol.	2004;3(12):752-6.	doi:	10.1016/S1474-4422(04)00938-X.	PubMed	PMID:	15556808.	
97.	 Desnick	RJ.	Enzyme	replacement	and	enhancement	therapies	for	lysosomal	diseases.	J	Inherit	
Metab	Dis.	2004;27(3):385-410.	doi:	10.1023/B:BOLI.0000031101.12838.c6.	PubMed	PMID:	15190196.	
98.	 Desnick	RJ,	Schuchman	EH.	Enzyme	replacement	therapy	for	lysosomal	diseases:	lessons	from	
20	years	of	experience	and	remaining	challenges.	Annu	Rev	Genomics	Hum	Genet.	2012;13:307-35.	doi:	
10.1146/annurev-genom-090711-163739.	PubMed	PMID:	22970722.	
99.	 Schiffmann	R,	Brady	RO.	New	prospects	for	the	treatment	of	lysosomal	storage	diseases.	Drugs.	
2002;62(5):733-42.	PubMed	PMID:	11929328.	
100.	 Ioannou	YA,	Bishop	DF,	Desnick	RJ.	Overexpression	of	human	alpha-galactosidase	A	results	in	its	
intracellular	aggregation,	crystallization	in	lysosomes,	and	selective	secretion.	J	Cell	Biol.	
1992;119(5):1137-50.	PubMed	PMID:	1332979;	PubMed	Central	PMCID:	PMCPMC2289730.	
101.	 Schiffmann	R,	Murray	GJ,	Treco	D,	Daniel	P,	Sellos-Moura	M,	Myers	M,	et	al.	Infusion	of	alpha-
galactosidase	A	reduces	tissue	globotriaosylceramide	storage	in	patients	with	Fabry	disease.	Proc	Natl	
Acad	Sci	U	S	A.	2000;97(1):365-70.	PubMed	PMID:	10618424;	PubMed	Central	PMCID:	PMCPMC26669.	
102.	 Sakuraba	H,	Chiba	Y,	Kotani	M,	Kawashima	I,	Ohsawa	M,	Tajima	Y,	et	al.	Corrective	effect	on	
Fabry	mice	of	yeast	recombinant	human	alpha-galactosidase	with	N-linked	sugar	chains	suitable	for	
lysosomal	delivery.	J	Hum	Genet.	2006;51(4):341-52.	doi:	10.1007/s10038-006-0369-6.	PubMed	PMID:	
16532254.	
103.	 Cereghino	GP,	Cereghino	JL,	Ilgen	C,	Cregg	JM.	Production	of	recombinant	proteins	in	fermenter	
cultures	of	the	yeast	Pichia	pastoris.	Curr	Opin	Biotechnol.	2002;13(4):329-32.	PubMed	PMID:	
12323354.	
104.	 Macauley-Patrick	S,	Fazenda	ML,	McNeil	B,	Harvey	LM.	Heterologous	protein	production	using	
the	Pichia	pastoris	expression	system.	Yeast.	2005;22(4):249-70.	doi:	10.1002/yea.1208.	PubMed	PMID:	
15704221.	
105.	 Daly	R,	Hearn	MT.	Expression	of	heterologous	proteins	in	Pichia	pastoris:	a	useful	experimental	
tool	in	protein	engineering	and	production.	J	Mol	Recognit.	2005;18(2):119-38.	doi:	10.1002/jmr.687.	
PubMed	PMID:	15565717.	
M a r i a m 	 M e g h d a r i 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
117	
106.	 Lodish	H,	Berk	A,	Zipursky	S,	Matsudaira	P,	Baltimore	D,	Darnell	J.	Molecular	Cell	Biology:	New	
York:	W.	H.	Freeman;	2000.	
107.	 Montesino	R,	Garcia	R,	Quintero	O,	Cremata	JA.	Variation	in	N-linked	oligosaccharide	structures	
on	heterologous	proteins	secreted	by	the	methylotrophic	yeast	Pichia	pastoris.	Protein	Expr	Purif.	
1998;14(2):197-207.	PubMed	PMID:	9790882.	
108.	 Alegra	T,	Vairo	F,	de	Souza	MV,	Krug	BC,	Schwartz	IV.	Enzyme	replacement	therapy	for	Fabry	
disease:	A	systematic	review	and	meta-analysis.	Genet	Mol	Biol.	2012;35(4	(suppl)):947-54.	PubMed	
PMID:	23413206;	PubMed	Central	PMCID:	PMCPMC3571424.	
109.	 Zhang	W,	Inan	M,	Meagher	M.	Fermentation	strategies	for	recombinant	protein	expression	in	
the	methylotrophic	yeastPichia	pastoris.	Biotechnol	Bioprocess	Eng.	2000;5(4):275-87.	doi:	
10.1007/bf02942184.	
110.	 Yasuda	K,	Chang	HH,	Wu	HL,	Ishii	S,	Fan	JQ.	Efficient	and	rapid	purification	of	recombinant	
human	alpha-galactosidase	A	by	affinity	column	chromatography.	Protein	expression	and	purification.	
2004;37(2):499-506.	Epub	2004/09/11.	doi:	10.1016/j.pep.2004.07.005.	PubMed	PMID:	15358377.	
111.	 Soper	AS,	Aird	SD.	Elution	of	tightly	bound	solutes	from	concanavalin	A	Sepharose.	Factors	
affecting	the	desorption	of	cottonmouth	venom	glycoproteins.	J	Chromatogr	A.	2007;1154(1-2):308-18.	
doi:	10.1016/j.chroma.2007.03.126.	PubMed	PMID:	17449042;	PubMed	Central	PMCID:	
PMCPMC2040237.	
112.	 Wong	C,	Sridhara	S,	Bardwell	JC,	Jakob	U.	Heating	greatly	speeds	Coomassie	blue	staining	and	
destaining.	Biotechniques.	2000;28(3):426-8,	30,	32.	PubMed	PMID:	10723553.	
113.	 Lorenzen	A,	Kennedy	SW.	A	fluorescence-based	protein	assay	for	use	with	a	microplate	reader.	
Anal	Biochem.	1993;214(1):346-8.	doi:	10.1006/abio.1993.1504.	PubMed	PMID:	8250247.	
114.	 Guce	AI,	Clark	NE,	Rogich	JJ,	Garman	SC.	The	molecular	basis	of	pharmacological	chaperoning	in	
human	alpha-galactosidase.	Chem	Biol.	2011;18(12):1521-6.	doi:	10.1016/j.chembiol.2011.10.012.	
PubMed	PMID:	22195554;	PubMed	Central	PMCID:	PMCPMC3246215.	
115.	 Gomori	G.	Preparation	of	buffers	for	use	in	enzyme	studies.	Methods	Enzymol1955.	
116.	 Chaudhury	S,	Lyskov	S,	Gray	JJ.	PyRosetta:	a	script-based	interface	for	implementing	molecular	
modeling	algorithms	using	Rosetta.	Bioinformatics.	2010;26(5):689-91.	doi:	
10.1093/bioinformatics/btq007.	PubMed	PMID:	20061306;	PubMed	Central	PMCID:	PMCPMC2828115.	
117.	 The	PyMOL	molecular	graphics	system	[Internet].	2010.	
118.	 Kelley	LA,	Sternberg	MJ.	Protein	structure	prediction	on	the	Web:	a	case	study	using	the	Phyre	
server.	Nat	Protoc.	2009;4(3):363-71.	doi:	10.1038/nprot.2009.2.	PubMed	PMID:	19247286.	
119.	 Calhoun	DH,	Bishop	DF,	Bernstein	HS,	Quinn	M,	Hantzopoulos	P,	Desnick	RJ.	Fabry	disease:	
isolation	of	a	cDNA	clone	encoding	human	alpha-galactosidase	A.	Proc	Natl	Acad	Sci	U	S	A.	
1985;82(21):7364-8.	PubMed	PMID:	2997789.	
120.	 Kase	R,	Bierfreund	U,	Klein	A,	Kolter	T,	Utsumi	K,	Itoha	K,	et	al.	Characterization	of	two	alpha-
galactosidase	mutants	(Q279E	and	R301Q)	found	in	an	atypical	variant	of	Fabry	disease.	Biochim	
Biophys	Acta.	2000;1501(2-3):227-35.	PubMed	PMID:	10838196.	
121.	 Beutler	E,	Kuhl	W.	Purification	and	properties	of	human	alpha-galactosidases.	J	Biol	Chem.	
1972;247(22):7195-200.	PubMed	PMID:	4629399.	
122.	 Lieberman	RL,	D'Aquino	J	A,	Ringe	D,	Petsko	GA.	Effects	of	pH	and	iminosugar	pharmacological	
chaperones	on	lysosomal	glycosidase	structure	and	stability.	Biochemistry.	2009;48(22):4816-27.	doi:	
10.1021/bi9002265.	PubMed	PMID:	19374450;	PubMed	Central	PMCID:	PMCPMC2699628.	
123.	 Vedder	AC,	Breunig	F,	Donker-Koopman	WE,	Mills	K,	Young	E,	Winchester	B,	et	al.	Treatment	of	
Fabry	disease	with	different	dosing	regimens	of	agalsidase:	effects	on	antibody	formation	and	GL-3.	Mol	
Genet	Metab.	2008;94(3):319-25.	doi:	10.1016/j.ymgme.2008.03.003.	PubMed	PMID:	18424138.	
M a r i a m 	 M e g h d a r i 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
118	
124.	 Smid	BE,	Hoogendijk	SL,	Wijburg	FA,	Hollak	CE,	Linthorst	GE.	A	revised	home	treatment	
algorithm	for	Fabry	disease:	influence	of	antibody	formation.	Mol	Genet	Metab.	2013;108(2):132-7.	doi:	
10.1016/j.ymgme.2012.12.005.	PubMed	PMID:	23332169.	
125.	 Linthorst	GE,	Hollak	CE,	Donker-Koopman	WE,	Strijland	A,	Aerts	JM.	Enzyme	therapy	for	Fabry	
disease:	neutralizing	antibodies	toward	agalsidase	alpha	and	beta.	Kidney	Int.	2004;66(4):1589-95.	doi:	
10.1111/j.1523-1755.2004.00924.x.	PubMed	PMID:	15458455.	
126.	 Ohashi	T,	Iizuka	S,	Ida	H,	Eto	Y.	Reduced	alpha-Gal	A	enzyme	activity	in	Fabry	fibroblast	cells	and	
Fabry	mice	tissues	induced	by	serum	from	antibody	positive	patients	with	Fabry	disease.	Mol	Genet	
Metab.	2008;94(3):313-8.	doi:	10.1016/j.ymgme.2008.03.008.	PubMed	PMID:	18456533.	
127.	 Ohshima	T,	Murray	GJ,	Swaim	WD,	Longenecker	G,	Quirk	JM,	Cardarelli	CO,	et	al.	alpha-
Galactosidase	A	deficient	mice:	a	model	of	Fabry	disease.	Proc	Natl	Acad	Sci	U	S	A.	1997;94(6):2540-4.	
PubMed	PMID:	9122231;	PubMed	Central	PMCID:	PMCPMC20124.	
128.	 Taguchi	A,	Maruyama	H,	Nameta	M,	Yamamoto	T,	Matsuda	J,	Kulkarni	AB,	et	al.	A	symptomatic	
Fabry	disease	mouse	model	generated	by	inducing	globotriaosylceramide	synthesis.	Biochem	J.	
2013;456(3):373-83.	doi:	10.1042/BJ20130825.	PubMed	PMID:	24094090;	PubMed	Central	PMCID:	
PMCPMC4160053.	
129.	 Albery	WJ,	Knowles	JR.	Evolution	of	enzyme	function	and	the	development	of	catalytic	
efficiency.	Biochemistry.	1976;15(25):5631-40.	PubMed	PMID:	999839.	
130.	 Maranville	E,	Zhu	A.	The	carboxyl	terminus	of	coffee	bean	alpha-galactosidase	is	critical	for	
enzyme	activity.	Arch	Biochem	Biophys.	2000;373(1):225-30.	doi:	10.1006/abbi.1999.1532.	PubMed	
PMID:	10620342.	
131.	 Mohammed	KD,	Topper	MB,	Muesing	MA.	Sequential	deletion	of	the	integrase	(Gag-Pol)	
carboxyl	terminus	reveals	distinct	phenotypic	classes	of	defective	HIV-1.	J	Virol.	2011;85(10):4654-66.	
doi:	10.1128/JVI.02374-10.	PubMed	PMID:	21367893;	PubMed	Central	PMCID:	PMCPMC3126176.	
132.	 Hsu	TY,	Liu	MW,	Chang	YR,	Pai	CY,	Liu	MY,	Yang	CS,	et	al.	Functional	analysis	of	C-terminal	
deletion	mutants	of	Epstein-Barr	virus	thymidine	kinase.	J	Gen	Virol.	1996;77	(	Pt	8):1893-9.	doi:	
10.1099/0022-1317-77-8-1893.	PubMed	PMID:	8760441.	
133.	 Lin	HH,	Pan	YJ,	Hsu	SH,	Van	RC,	Hsiao	YY,	Chen	JH,	et	al.	Deletion	mutation	analysis	on	C-
terminal	domain	of	plant	vacuolar	H(+)-pyrophosphatase.	Arch	Biochem	Biophys.	2005;442(2):206-13.	
doi:	10.1016/j.abb.2005.08.010.	PubMed	PMID:	16185650.	
134.	 Passonneau	JV,	Lowry	OH.	The	role	of	phosphofructokinase	in	metabolic	regulation.	Adv	Enzyme	
Regul.	1964;2:265-74.	PubMed	PMID:	4222062.	
135.	 Sola-Penna	M,	Da	Silva	D,	Coelho	WS,	Marinho-Carvalho	MM,	Zancan	P.	Regulation	of	
mammalian	muscle	type	6-phosphofructo-1-kinase	and	its	implication	for	the	control	of	the	metabolism.	
IUBMB	Life.	2010;62(11):791-6.	doi:	10.1002/iub.393.	PubMed	PMID:	21117169.	
136.	 Benkovic	SJ,	Hammes-Schiffer	S.	A	perspective	on	enzyme	catalysis.	Science.	
2003;301(5637):1196-202.	doi:	10.1126/science.1085515.	PubMed	PMID:	12947189.	
137.	 Sikorski	RS,	Wang	L,	Markham	KA,	Rajagopalan	PT,	Benkovic	SJ,	Kohen	A.	Tunneling	and	coupled	
motion	in	the	Escherichia	coli	dihydrofolate	reductase	catalysis.	J	Am	Chem	Soc.	2004;126(15):4778-9.	
doi:	10.1021/ja031683w.	PubMed	PMID:	15080672.	
138.	 Wang	L,	Goodey	NM,	Benkovic	SJ,	Kohen	A.	Coordinated	effects	of	distal	mutations	on	
environmentally	coupled	tunneling	in	dihydrofolate	reductase.	Proc	Natl	Acad	Sci	U	S	A.	
2006;103(43):15753-8.	doi:	10.1073/pnas.0606976103.	PubMed	PMID:	17032759;	PubMed	Central	
PMCID:	PMCPMC1635075.	
139.	 Wang	L,	Goodey	NM,	Benkovic	SJ,	Kohen	A.	The	role	of	enzyme	dynamics	and	tunnelling	in	
catalysing	hydride	transfer:	studies	of	distal	mutants	of	dihydrofolate	reductase.	Philos	Trans	R	Soc	Lond	
B	Biol	Sci.	2006;361(1472):1307-15.	doi:	10.1098/rstb.2006.1871.	PubMed	PMID:	16873118;	PubMed	
Central	PMCID:	PMCPMC1647312.	
M a r i a m 	 M e g h d a r i 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
119	
140.	 Wang	L,	Tharp	S,	Selzer	T,	Benkovic	SJ,	Kohen	A.	Effects	of	a	distal	mutation	on	active	site	
chemistry.	Biochemistry.	2006;45(5):1383-92.	doi:	10.1021/bi0518242.	PubMed	PMID:	16445280;	
PubMed	Central	PMCID:	PMCPMC2553318.	
141.	 Murray	GJ,	Anver	MR,	Kennedy	MA,	Quirk	JM,	Schiffmann	R.	Cellular	and	tissue	distribution	of	
intravenously	administered	agalsidase	alfa.	Mol	Genet	Metab.	2007;90(3):307-12.	Epub	2006/12/26.	
doi:	10.1016/j.ymgme.2006.11.008.	PubMed	PMID:	17188539;	PubMed	Central	PMCID:	PMC1839873.	
142.	 Brady	RO.	Enzyme	replacement	for	lysosomal	diseases.	Annu	Rev	Med.	2006;57:283-96.	doi:	
10.1146/annurev.med.57.110104.115650.	PubMed	PMID:	16409150.	
143.	 Hasholt	L,	Wandall	A,	Sorensen	SA.	Enzyme	replacement	in	Fabry	endothelial	cells	and	
fibroblasts:	uptake	experiments	and	electron	microscopical	studies.	Clin	Genet.	1988;33(5):360-71.	
PubMed	PMID:	2837353.	
144.	 Urayama	A,	Grubb	JH,	Sly	WS,	Banks	WA.	Mannose	6-phosphate	receptor-mediated	transport	of	
sulfamidase	across	the	blood-brain	barrier	in	the	newborn	mouse.	Mol	Ther.	2008;16(7):1261-6.	doi:	
10.1038/mt.2008.84.	PubMed	PMID:	18443601;	PubMed	Central	PMCID:	PMCPMC2908959.	
145.	 Urayama	A,	Grubb	JH,	Banks	WA,	Sly	WS.	Epinephrine	enhances	lysosomal	enzyme	delivery	
across	the	blood	brain	barrier	by	up-regulation	of	the	mannose	6-phosphate	receptor.	Proc	Natl	Acad	Sci	
U	S	A.	2007;104(31):12873-8.	doi:	10.1073/pnas.0705611104.	PubMed	PMID:	17646643;	PubMed	
Central	PMCID:	PMCPMC1937559.	
146.	 Vogler	C,	Levy	B,	Grubb	JH,	Galvin	N,	Tan	Y,	Kakkis	E,	et	al.	Overcoming	the	blood-brain	barrier	
with	high-dose	enzyme	replacement	therapy	in	murine	mucopolysaccharidosis	VII.	Proc	Natl	Acad	Sci	U	
S	A.	2005;102(41):14777-82.	doi:	10.1073/pnas.0506892102.	PubMed	PMID:	16162667;	PubMed	Central	
PMCID:	PMCPMC1253584.	
147.	 Urayama	A,	Grubb	JH,	Sly	WS,	Banks	WA.	Pharmacologic	manipulation	of	lysosomal	enzyme	
transport	across	the	blood-brain	barrier.	J	Cereb	Blood	Flow	Metab.	2016;36(3):476-86.	doi:	
10.1177/0271678X15614589.	PubMed	PMID:	26661222;	PubMed	Central	PMCID:	PMCPMC4794098.	
148.	 Ashe	KM,	Budman	E,	Bangari	DS,	Siegel	CS,	Nietupski	JB,	Wang	B,	et	al.	Efficacy	of	Enzyme	and	
Substrate	Reduction	Therapy	with	a	Novel	Antagonist	of	Glucosylceramide	Synthase	for	Fabry	Disease.	
Mol	Med.	2015;21:389-99.	doi:	10.2119/molmed.2015.00088.	PubMed	PMID:	25938659;	PubMed	
Central	PMCID:	PMCPMC4559530.	
149.	 Schiffmann	R,	Rapkiewicz	A,	Abu-Asab	M,	Ries	M,	Askari	H,	Tsokos	M,	et	al.	Pathological	findings	
in	a	patient	with	Fabry	disease	who	died	after	2.5	years	of	enzyme	replacement.	Virchows	Arch.	
2006;448(3):337-43.	doi:	10.1007/s00428-005-0089-x.	PubMed	PMID:	16315019;	PubMed	Central	
PMCID:	PMCPMC2288734.	
150.	 Tsuji	A,	Omura	K,	Suzuki	Y.	I-cell	disease:	evidence	for	a	mannose	6-phosphate	independent	
pathway	for	translocation	of	lysosomal	enzymes	in	lymphoblastoid	cells.	Clin	Chim	Acta.	
1988;176(1):115-21.	PubMed	PMID:	2971480.	
151.	 Owada	M,	Neufeld	EF.	Is	there	a	mechanism	for	introducing	acid	hydrolases	into	liver	lysosomes	
that	is	independent	of	mannose	6-phosphate	recognition?	Evidence	from	I-cell	disease.	Biochem	
Biophys	Res	Commun.	1982;105(3):814-20.	PubMed	PMID:	6807313.	
152.	 Sarrias	MR,	Gronlund	J,	Padilla	O,	Madsen	J,	Holmskov	U,	Lozano	F.	The	Scavenger	Receptor	
Cysteine-Rich	(SRCR)	domain:	an	ancient	and	highly	conserved	protein	module	of	the	innate	immune	
system.	Crit	Rev	Immunol.	2004;24(1):1-37.	PubMed	PMID:	14995912.	
153.	 Wilkinson	K,	El	Khoury	J.	Microglial	scavenger	receptors	and	their	roles	in	the	pathogenesis	of	
Alzheimer's	disease.	Int	J	Alzheimers	Dis.	2012;2012:489456.	Epub	2012/06/06.	doi:	
10.1155/2012/489456.	PubMed	PMID:	22666621;	PubMed	Central	PMCID:	PMC3362056.	
154.	 Stephen	SL,	Freestone	K,	Dunn	S,	Twigg	MW,	Homer-Vanniasinkam	S,	Walker	JH,	et	al.	
Scavenger	receptors	and	their	potential	as	therapeutic	targets	in	the	treatment	of	cardiovascular	
M a r i a m 	 M e g h d a r i 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
120	
disease.	Int	J	Hypertens.	2010;2010:646929.	Epub	2010/10/29.	doi:	10.4061/2010/646929.	PubMed	
PMID:	20981357;	PubMed	Central	PMCID:	PMC2958427.	
155.	 Terpstra	V,	van	Amersfoort	ES,	van	Velzen	AG,	Kuiper	J,	van	Berkel	TJ.	Hepatic	and	extrahepatic	
scavenger	receptors:	function	in	relation	to	disease.	Arterioscler	Thromb	Vasc	Biol.	2000;20(8):1860-72.	
PubMed	PMID:	10938005.	
156.	 Yabe	Y,	Nishikawa	M,	Tamada	A,	Takakura	Y,	Hashida	M.	Targeted	delivery	and	improved	
therapeutic	potential	of	catalase	by	chemical	modification:	combination	with	superoxide	dismutase	
derivatives.	J	Pharmacol	Exp	Ther.	1999;289(2):1176-84.	PubMed	PMID:	10215702.	
157.	 Mukhopadhyay	A,	Mukhopadhyay	B,	Srivastava	RK,	Basu	SK.	Scavenger-receptor-mediated	
delivery	of	daunomycin	elicits	selective	toxicity	towards	neoplastic	cells	of	macrophage	lineage.	Biochem	
J.	1992;284	(	Pt	1):237-41.	PubMed	PMID:	1599401;	PubMed	Central	PMCID:	PMCPMC1132722.	
158.	 Mukhopadhyay	A,	Mukhopadhyay	B,	Basu	SK.	Circumvention	of	multidrug	resistance	in	
neoplastic	cells	through	scavenger	receptor	mediated	drug	delivery.	FEBS	Lett.	1995;376(1-2):95-8.	
PubMed	PMID:	8521976.	
159.	 Basu	S,	Mukhopadhyay	B,	Basu	SK,	Mukhopadhyay	A.	Enhanced	intracellular	delivery	of	
doxorubicin	by	scavenger	receptor-mediated	endocytosis	for	preferential	killing	of	histiocytic	lymphoma	
cells	in	culture.	FEBS	Lett.	1994;342(3):249-54.	PubMed	PMID:	8150079.	
160.	 Nagae	T,	Louie	AY,	Aizawa	K,	Ishimaru	S,	Wilson	SE.	Selective	targeting	and	photodynamic	
destruction	of	intimal	hyperplasia	by	scavenger-receptor	mediated	protein-chlorin	e6	conjugates.	J	
Cardiovasc	Surg	(Torino).	1998;39(6):709-15.	PubMed	PMID:	9972886.	
161.	 Srividya	S,	Roy	RP,	Basu	SK,	Mukhopadhyay	A.	Scavenger	receptor-mediated	delivery	of	
muramyl	dipeptide	activates	antitumor	efficacy	of	macrophages	by	enhanced	secretion	of	tumor-
suppressive	cytokines.	J	Leukoc	Biol.	2000;67(5):683-90.	PubMed	PMID:	10811009.	
162.	 Srividya	S,	Roy	RP,	Basu	SK,	Mukhopadhyay	A.	Selective	activation	of	antitumor	activity	of	
macrophages	by	the	delivery	of	muramyl	dipeptide	using	a	novel	polynucleotide-based	carrier	
recognized	by	scavenger	receptors.	Biochem	Biophys	Res	Commun.	2000;268(3):772-7.	doi:	
10.1006/bbrc.2000.2216.	PubMed	PMID:	10679281.	
163.	 Ahmad	I,	Allen	TM.	Antibody-mediated	specific	binding	and	cytotoxicity	of	liposome-entrapped	
doxorubicin	to	lung	cancer	cells	in	vitro.	Cancer	Res.	1992;52(17):4817-20.	Epub	1992/09/01.	PubMed	
PMID:	1511445.	
164.	 Kamps	JA,	Morselt	HW,	Swart	PJ,	Meijer	DK,	Scherphof	GL.	Massive	targeting	of	liposomes,	
surface-modified	with	anionized	albumins,	to	hepatic	endothelial	cells.	Proc	Natl	Acad	Sci	U	S	A.	
1997;94(21):11681-5.	Epub	1997/10/23.	PubMed	PMID:	9326670;	PubMed	Central	PMCID:	PMC23586.	
165.	 Jansen	RW,	Molema	G,	Harms	G,	Kruijt	JK,	van	Berkel	TJ,	Hardonk	MJ,	et	al.	Formaldehyde	
treated	albumin	contains	monomeric	and	polymeric	forms	that	are	differently	cleared	by	endothelial	
and	Kupffer	cells	of	the	liver:	evidence	for	scavenger	receptor	heterogeneity.	Biochem	Biophys	Res	
Commun.	1991;180(1):23-32.	Epub	1991/10/15.	doi:	S0006-291X(05)81249-5	[pii].	PubMed	PMID:	
1656967.	
166.	 Van	Berkel	TJ,	De	Rijke	YB,	Kruijt	JK.	Different	fate	in	vivo	of	oxidatively	modified	low	density	
lipoprotein	and	acetylated	low	density	lipoprotein	in	rats.	Recognition	by	various	scavenger	receptors	on	
Kupffer	and	endothelial	liver	cells.	J	Biol	Chem.	1991;266(4):2282-9.	Epub	1991/02/05.	PubMed	PMID:	
1989982.	
167.	 Yamasaki	Y,	Hisazumi	J,	Yamaoka	K,	Takakura	Y.	Efficient	scavenger	receptor-mediated	hepatic	
targeting	of	proteins	by	introduction	of	negative	charges	on	the	proteins	by	aconitylation:	the	influence	
of	charge	density	and	size	of	the	proteins	molecules.	Eur	J	Pharm	Sci.	2003;18(5):305-12.	Epub	
2003/04/16.	PubMed	PMID:	12694882.	
M a r i a m 	 M e g h d a r i 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
121	
168.	 de	Boer	AG,	van	der	Sandt	ICJ,	Gaillard	PJ.	THE	ROLE	OF	DRUG	TRANSPORTERS	AT	THE	BLOOD-
BRAIN	BARRIER.	Annual	Review	of	Pharmacology	and	Toxicology.	2003;43(1):629-56.	doi:	
doi:10.1146/annurev.pharmtox.43.100901.140204.	PubMed	PMID:	12415123.	
169.	 Angin	Y,	Steinbusch	LK,	Simons	PJ,	Greulich	S,	Hoebers	NT,	Douma	K,	et	al.	CD36	inhibition	
prevents	lipid	accumulation	and	contractile	dysfunction	in	rat	cardiomyocytes.	Biochem	J.	
2012;448(1):43-53.	doi:	10.1042/BJ20120060.	PubMed	PMID:	22780108.	
170.	 Bonen	A,	Campbell	SE,	Benton	CR,	Chabowski	A,	Coort	SL,	Han	XX,	et	al.	Regulation	of	fatty	acid	
transport	by	fatty	acid	translocase/CD36.	Proc	Nutr	Soc.	2004;63(2):245-9.	doi:	10.1079/PNS2004331.	
PubMed	PMID:	15294038.	
171.	 Wilcox	WR,	Banikazemi	M,	Guffon	N,	Waldek	S,	Lee	P,	Linthorst	GE,	et	al.	Long-term	safety	and	
efficacy	of	enzyme	replacement	therapy	for	Fabry	disease.	Am	J	Hum	Genet.	2004;75(1):65-74.	doi:	
10.1086/422366.	PubMed	PMID:	15154115;	PubMed	Central	PMCID:	PMCPMC1182009.	
172.	 Grubb	JH,	Vogler	C,	Levy	B,	Galvin	N,	Tan	Y,	Sly	WS.	Chemically	modified	beta-glucuronidase	
crosses	blood-brain	barrier	and	clears	neuronal	storage	in	murine	mucopolysaccharidosis	VII.	Proc	Natl	
Acad	Sci	U	S	A.	2008;105(7):2616-21.	Epub	2008/02/13.	doi:	10.1073/pnas.0712147105.	PubMed	PMID:	
18268347;	PubMed	Central	PMCID:	PMC2268185.	
173.	 Biegstraaten	M,	Arngrimsson	R,	Barbey	F,	Boks	L,	Cecchi	F,	Deegan	PB,	et	al.	Recommendations	
for	initiation	and	cessation	of	enzyme	replacement	therapy	in	patients	with	Fabry	disease:	the	European	
Fabry	Working	Group	consensus	document.	Orphanet	J	Rare	Dis.	2015;10:36.	doi:	10.1186/s13023-015-
0253-6.	PubMed	PMID:	25885911;	PubMed	Central	PMCID:	PMCPMC4383065.	
174.	 Gill	SC,	von	Hippel	PH.	Calculation	of	protein	extinction	coefficients	from	amino	acid	sequence	
data.	Anal	Biochem.	1989;182(2):319-26.	PubMed	PMID:	2610349.	
175.	 Shen	JS,	Meng	XL,	Schiffmann	R,	Brady	RO,	Kaneski	CR.	Establishment	and	characterization	of	
Fabry	disease	endothelial	cells	with	an	extended	lifespan.	Mol	Genet	Metab.	2007;92(1-2):137-44.	Epub	
2007/07/24.	doi:	10.1016/j.ymgme.2007.06.003.	PubMed	PMID:	17644384;	PubMed	Central	PMCID:	
PMC2063578.	
176.	 Kuipers	ME,	Swart	PJ,	Schutten	M,	Smit	C,	Proost	JH,	Osterhaus	AD,	et	al.	Pharmacokinetics	and	
anti-HIV-1	efficacy	of	negatively	charged	human	serum	albumins	in	mice.	Antiviral	Res.	1997;33(2):99-
108.	Epub	1997/01/01.	PubMed	PMID:	9021051.	
177.	 Stocks	SJ,	Jones	AJ,	Ramey	CW,	Brooks	DE.	A	fluorometric	assay	of	the	degree	of	modification	of	
protein	primary	amines	with	polyethylene	glycol.	Anal	Biochem.	1986;154(1):232-4.	PubMed	PMID:	
3706727.	
178.	 Kamps	JA,	Swart	PJ,	Morselt	HW,	Pauwels	R,	De	Bethune	MP,	De	Clercq	E,	et	al.	Preparation	and	
characterization	of	conjugates	of	(modified)	human	serum	albumin	and	liposomes:	drug	carriers	with	an	
intrinsic	anti-HIV	activity.	Biochim	Biophys	Acta.	1996;1278(2):183-90.	Epub	1996/01/31.	PubMed	PMID:	
8593275.	
179.	 Majumdar	A,	Capetillo-Zarate	E,	Cruz	D,	Gouras	GK,	Maxfield	FR.	Degradation	of	Alzheimer's	
amyloid	fibrils	by	microglia	requires	delivery	of	ClC-7	to	lysosomes.	Mol	Biol	Cell.	2011;22(10):1664-76.	
doi:	10.1091/mbc.E10-09-0745.	PubMed	PMID:	21441306;	PubMed	Central	PMCID:	PMCPMC3093319.	
180.	 Ahmad	S,	Gromiha	M,	Fawareh	H,	Sarai	A.	ASAView:	database	and	tool	for	solvent	accessibility	
representation	in	proteins.	BMC	Bioinformatics.	2004;5:51.	Epub	2004/05/04.	doi:	10.1186/1471-2105-
5-51.	PubMed	PMID:	15119964;	PubMed	Central	PMCID:	PMC420234.	
181.	 Fraczkiewicz	R,	BRAUN	W.	Exact	and	Efficient	Analytical	Calculation	of	the	Accessible	Surface	
Areas	and	Their	Gradients	for	Macromolecules.	Journal	of	Computational	Chemistry.	1998;19:319-33.	
182.	 Goodwin	JF,	Choi	SY.	Quantification	of	protein	solutions	with	trinitrobenzenesulfonic	acid.	
Clinical	chemistry.	1970;16(1):24-31.	Epub	1970/01/01.	PubMed	PMID:	5414117.	
M a r i a m 	 M e g h d a r i 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
122	
183.	 Wen	X,	Wang	N,	Zhang	F,	Dong	C.	Overexpression	of	SCARA5	inhibits	tumor	proliferation	and	
invasion	in	osteosarcoma	via	suppression	of	the	FAK	signaling	pathway.	Mol	Med	Rep.	2016;13(3):2885-
91.	doi:	10.3892/mmr.2016.4857.	PubMed	PMID:	26847210.	
 
